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Abstract 
 
Topoisomerase II (TOP2) poisons are effective anti-cancer agents used to treat a wide 
range of neoplasms. However, TOP2 poisons are subjected to enzymatic conversion 
which leads to metabolites with altered DNA damaging properties. Myeloperoxidase, 
present exclusively within developing myeloid progenitors and granulocytes, is capable 
of the biotransformation of TOP2 poisons to metabolites that are potentially more 
genotoxic in nature. Whilst TOP2 poisons are valuable chemotherapeutic agents, their 
use is associated with myelosuppression and with the risk of developing therapy related 
acute myeloid leukaemia. The reason that myeloid progenitor cells are particularly 
susceptible to TOP2 poison associated genotoxicity is unclear, however the presence of 
myeloperoxidase could potentially make myeloid progenitor cells more vulnerable to 
TOP2 poison mediated damage. This lead to the hypothesis that myeloperoxidase 
inhibition could protect developing hematopoietic cells from TOP2 poison associated 
genotoxic and/or cytotoxic damage. Data generated in this thesis supports the proposed 
hypothesis as expression of myeloperoxidase significantly enhanced the accumulation 
of TOP2 poison induced TOP2-DNA covalent complexes and the level of DNA breaks 
within myeloid cell lines. The use of two potential clinically relevant inhibitors of 
myeloperoxidase showed that reduction in myeloperoxidase activity reduced the 
abundance of TOP2 poison stabilised TOP2-DNA complexes and DNA breaks. 
Furthermore, depletion of glutathione to mimic conditions experienced during 
chemotherapy, resulted in a myeloperoxidase dependent increase in TOP2 poison 
mediated DNA damage. Taken together these results show inhibition of 
myeloperoxidase could protect developing hematopoietic cells from TOP2 poison 
mediated damage without compromising the effectiveness of these drugs as anti- 
neoplastic agents.  
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Chapter 1. Introduction 
1.1 Topoisomerase II (TOP2) 
 
Topoisomerases are critical cellular enzymes present in all domains of life. Their 
function is to relieve DNA topological stress allowing normal DNA processes such as 
transcription, replication and chromosome segregation to occur efficiently. Humans 
encode six topoisomerases (TOP) known as TOP1, TOP1mt (mitochondria specific), 
TOP2A, TOP2B, TOP3A and TOP3B. Topoisomerases catalytic mechanism involves 
the cleavage of a DNA segment followed by either a DNA strand passage (TOP2 and 
TOP3) or a controlled DNA rotation event (TOP1) and the subsequent re-ligation of 
the cleaved DNA molecule. Due to topoisomerases being essential nuclear enzymes 
functioning in processes such as cell proliferation and their ability to catalyse DNA 
strand breaks, human topoisomerases are targeted in chemotherapy regimens. The 
focus of this thesis will be on human topoisomerase II (TOP2) and will be discussed 
in detail herein.  
1.1.1 TOP2 isoforms and cellular roles  
 
Humans express two isoforms of TOP2 known as Topoisomerase II alpha (TOP2A) 
and Topoisomerase II beta (TOP2B) (EC 5.99.1.3) that are encoded on separate 
genes and differentially regulated in cells (TOP2A 17q21-22; TOP2B 3q24) (Tsai-
Pflugfelder et al., 1988; Chung et al., 1989; Drake et al., 1989; Austin and Fisher, 
1990; Jenkins et al., 1992). The isoforms share an overall 68% amino acid identity. 
The N-terminal region and catalytic portions share 78% amino acid identity, whereas 
the C-terminal region shares only 34% identity between the two isoforms (Austin et 
al., 1993).  
TOP2A (170kDa) is essential for the survival of proliferating cells and its expression 
(protein and mRNA) is tightly regulated during the cell cycle (Woessner et al., 1991; 
Pendleton et al., 2014). TOP2A protein expression is at its highest during the G2/M 
phase of the cell cycle and remains low in G1 to mid-S phase (Heck et al., 1988; 
Felix et al., 2006) (Figure 1.1.A). The cell cycle regulation of TOP2A protein 
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expression is due to key post-translational modifications and changes in mRNA 
stability with a 15-fold elevation in mRNA levels at late S-phase (Wells et al., 1995b; 
Goswami et al., 1996).  This also correlates with a peak in TOP2A activity at M-phase 
and activity is dependent on phosphorylation of residues within the C-terminus 
(Corbett et al., 1993; Chikamori et al., 2003; Li et al., 2008). Defects in 
phosphorylation of TOP2A or inhibition of TOP2A activity can result in S-phase arrest 
(Ishida et al., 1996; Li et al., 2008; Wu et al., 2016).  
 
Figure 1.1 (A) Cell cycle changes in TOP2A and TOP2B levels and (B) Switching of TOP2A and 
TOP2B expression in cell differentiation. (A) The cell cycle is divided into four phases; G1 (stage of 
metabolic changes to prepare cells for chromosome duplication), S phase (DNA replication to 
duplicate chromosomes), G2 (undergo metabolic changes to prepare the cell for mitosis and to check 
duplicated chromosomes), M phase (nuclear division followed by cell division by cytokinesis). During 
the cell cycle phases, TOP2 expression is dynamically regulated both at the mRNA level and by post-
translational modifications to regulate TOP2 activity and cellular distribution. 
 
 
In contrast, TOP2B (180kDa) levels remain constant once cells enter the cell cycle, 
after cell cycle exit TOP2B levels can drop by ~60% (Woessner et al., 1991; Meyer et 
al., 1997) (Figure 1.1.A). TOP2B is the predominant isoform in post-mitotic 
differentiated cells whereas; TOP2A expression is almost absent in quiescent and 
terminally differentiated cells (Woessner et al., 1991; Thakurela et al., 2013). 
However, in foetal tissues TOP2A is strongly associated at sites of proliferation 
compared to TOP2B, but TOP2A also present in foetal cells which have differentiated 
(Zandvliet et al., 1996).  
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TOP2B plays an essential role in transcriptional regulation and is required for proper 
neural and retinal development and in the transcriptional regulation of ligand 
inducible genes (Manville et al., 2015; Calderwood, 2016). Studies conducted using 
mouse embryonic stem cells induced to differentiate into post-mitotic glutamatergic 
neurons showed TOP2A and TOP2B expression can ‘switch’ during cell 
differentiation. This study showed TOP2A levels were high during the stem cell to 
neuronal progenitor stage. Once stem cells had differentiated into post-mitotic, 
neurons TOP2A levels were undetectable and this was accompanied by an increase 
in both TOP2B mRNA and protein expression (Tiwari et al., 2012) (Figure 1.1.B).  
Role of TOP2A in DNA replication, S-phase transcription and chromosome 
condensation and segregation.  
DNA replication  
DNA replication is initiated at multiple sites across chromosomes. Dynamic protein 
and DNA polymerase containing structures form around a DNA segment during 
replication and are termed replication forks. Replication forks consist of cellular 
machinery required to replicate DNA, including DNA helicases that use ATP to 
unwind the DNA helix, separating parental strands (Branzei and Foiani, 2010). 
Unwinding of the DNA duplex creates differences in the topology and conformation of 
the replicating DNA creating torsion stress. This results in positive supercoiling ahead 
of the replication fork and precatenanes (wrapping of two replicated strands) behind 
the replication fork (Peter et al., 1998) (Figure 1.2.A).  
DNA cannot resolve supercoiling stress by itself and the presence of chromatin 
structure (nucleosomes) prevents the diffusion of positive supercoils therefore, 
hindering the progression of replication (Mondal et al., 2003). The cleavage and 
religation activity of TOP1 and TOP2 can relax positive supercoiling ahead of the 
replication fork sustaining the progressive action of the replication machinery (Figure 
1.2.A). Precatenanes do not pose a major threat to replication machinery however as 
these structures form by winding of daughter chromosomes around each other, this 
would create a problem during chromosome segregation in mitosis.  
Precatenanes are substrates for TOP2A. Studies conducted in Xenopus egg extracts 
showed TOP2 is dispensable for plasmid DNA replication, but the plasmid is 
associated with increased positive helical stress. Furthermore, by mapping the TOP2 
cleavage site (using stabilisation of TOP2-DNA complexes by the TOP2 poison 
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etoposide) showed TOP2 predominantly acts behind the replication fork (Lucas et al., 
2001). 
 
Figure 1.2 Requirement of TOP2 to relieve positive supercoiling during different stages of 
replication. (A) During the progression of the replication fork (RF), the unwinding action of ATP-
dependent helicases creates positive supercoiling ahead of the replication fork and behind the 
replication fork precatenanes develop causing a problem for chromosome segregation. (B) At 
replication termination, the progression of two replication forks closes the gap separating the two forks 
creating positive supercoils, the merging of two replication forks at termination creates catenated sister 
chromatid junctions which are resolved by TOP2. (C) Replication forks colliding with transcription 
factories in S-phase can slow down replication and TOP1/TOP2 can create DNA looping to insulate 
the transcription machinery preventing collision with replication forks. TOP2 is labeled as Top2 and 
TOP1 as Top1 as the yeast nomenclature are used, the alternative dark red to off white colouring 
associated with Top2 or Top1 is used to show which topoisomerase is shown to function more 
predominantly in the different progresses of replication (red=major role; off white=minor role according 
to reported data). Figure adapted with permission from Branzei and Foiani 2010.  
 
 
Studies have suggested that TOP2A has a more predominant role at the final stages 
of DNA replication and this coincides with the high expression of TOP2A at late S-
phase (Figure 1.1). Earlier studies have shown that TOP2 (Top2) mutant yeast were 
defective at the stages of DNA replication termination but not in replication elongation 
(Brill et al., 1987). At replication termination, two replication forks fuse creating 
interlinked catenanes (interlocked DNA molecules) and require separation by TOP2 
prior to segregation (Sundin and Varshavsky, 1980; Sundin and Varshavsky, 1981) 
(Figure. 1.2.B). Experiments conducted using yeast TOP2 (Top2) showed that during 
S phase, Top2 is recruited to sites of chromosomal termination regions (TERs) to 
prevent chromosomal fragmentation during replication fork fusion. Top2 mutants 
displayed delayed replication termination, exhibited un-replicated regions and had 
chromosome entanglements resulting in chromosomal breakage during segregation 
(Wang, 2002; Fachinetti et al., 2010).   
Another role of TOP2A in S phase is to prevent collision of replication forks with 
transcription hubs. TOP2 solves this problem by binding to intragenic regions (DNA 
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located between genes) using the HMG protein Hmo1 (High mobility group of 
proteins).  TOP2 is thought to insulate transcription bubbles from replication forks in 
S phase by looping DNA to concentrate transcription machinery and to maintain 
chromosome stability (Bermejo et al., 2009) (Figure 1.2C). However, TOP1 may play 
a more predominant role over TOP2A in S-phase transcription (Tuduri et al., 2009). 
During the process of DNA replication, TOP2A has a role in relaxing DNA supercoils 
and but also maintaining genomic stability. Sites of replication termination and 
intragenic regions (region between genes) are fragile sites within chromosomes and 
are frequently associated with phosphorylated H2Ax sites (marker of DNA damage). 
The binding of TOP2A to these regions is suggested to protect DNA from aberrant 
breaks induced by torsion stress created by the movement of cellular machinery 
(Bermejo et al., 2009; Fachinetti et al., 2010).  
Chromosome segregation and condensation  
DNA replication has been reported to prime the accumulation of TOP2A to 
heterochromatin in late S phase, as failure of DNA replication results in loss of the 
tight association of TOP2A with chromosomes (Cuvier and Hirano, 2003; Gonzalez 
et al., 2011). The processes of chromosome segregation and condensation are 
dependent on TOP2A. At the concentrations expressed in cells, TOP2B cannot 
compensate for the loss of TOP2A protein expression. In the G2/M phase TOP2A is 
required to facilitate the untangling of catenations, condensation and segregation of 
chromosomes (Holm et al., 1985; Uemura and Tanagida, 1986; Adachi et al., 1992; 
Buchenau et al., 1993). TOP2A binds tightly to chromatin as studies showed that 
during S phase and metaphase TOP2A is harder to extract using sodium chloride 
(350mM) whereas the equivalent concentration of salt can extract more than 90% 
TOP2B but only 52% of TOP2A is extractable (Meyer et al., 1997).   
The recruitment of TOP2A to chromosomes is partly dependent on its interaction with 
the chromatin remodeller complex BAF (mSWI/SNF). Specificity the interaction of 
TOP2A is with BAF’s ATPase subunit, BAF250a (Dykhuizen et al., 2013). However, 
authors also identified regions of genome where TOP2A binds independently to BAF.  
TOP2A also is essential for anaphase sister chromatid separation. In Drosophila 
cells, depletion of Top2 resulted in 2.5 fold decrease in chromosome compaction and 
chromosomes were described to be morphologically abnormal (Chang et al., 2003). 
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During the M (mitotic) phase of the cell cycle, TOP2A dynamically associates with 
mitotic chromatin and remains associated until anaphase being highly concentrated 
at the centromeres where it has a structural role and causes chromatin hyper-
compaction. Disruption of TOP2A’s catalytic function results in deficient chromosome 
hyper-compaction slowing progression through the G2/M phase (Earnshaw and 
Heck, 1985; Tavormina et al., 2002). 
TOP2B is also reported to distribute weakly along chromosomes, contributing to the 
initial shortening of chromosomes (Taagepera et al., 1993; Christensen et al., 2002; 
Null et al., 2002; Farr et al., 2014). However, the mechanisms of TOP2B in the 
localisation and shortening of mitotic chromosomes are not yet fully understood. 
However, it could be that localisation of TOP2B across the arms of chromosomes 
causes initial compaction to aid in TOP2A-mediated chromatin hyper-compaction. 
Transcription  
Both isoforms of TOP2 play roles in transcription. TOP2A is involved in both 
transcription initiation and transcription elongation. TOP2B plays a predominant role 
in regulating transcription at signal-dependent promoter and regulatory regions of 
genes in response to ligands.    
Transcription elongation  
During transcription, the progression of DNA through RNA polymerase II generates 
positive supercoiling ahead of RNA polymerase II and negative supercoiling behind. 
This is referred as the ‘twin supercoiled domain’ generated during transcription (Liu 
and Wang, 1987; Wu et al., 1988). If positive supercoiling were not resolved then this 
would result in hyperwinding of the DNA structure upstream of the template, blocking 
transcription. The relaxation activity of TOP2A is reported to be required during 
transcription elongation by the association with RNA polymerase (Schultz et al., 
1992). 
Studies conducted in yeast showed, yeast deficient in Top2 or when Top2 activity 
was inhibited using etoposide or ICRF-193, transcription of nucleosome free DNA 
continued but transcription was inhibited for DNA wrapped in chromatin. This 
supports the hypothesis that in the presence of nucleosomes diffusion of positive 
supercoils is inhibited (Mondal and Parvin, 2001; Mondal et al., 2003). However, 
earlier studies conducted in yeast suggested that Top2 is crucial for termination of 
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DNA replication and chromosome segregation but is dispensable for transcription 
(Brill et al., 1987).  
Initiation of transcription 
A study conducted by Bunch and colleagues report that TOP2 may be required for 
the pause and release of RNA polymerase II at the transcription start site (Bunch et 
al., 2015). The pause and release activity of RNA polymerase II at the promoter-
proximal site before elongation is an important step in gene regulation and ‘primes’ 
genes for rapid induction. TOP2A and TOP2B mediated DSB seems to be an 
important step in pause-release activity of RNA polymerase II. As the catalytic 
inhibition of TOP2 resulted in retention of RNA polymerase II at transcription start 
sites and reduced the level of γH2Ax signal (marker of DNA damage). However, the 
level of retention of RNA polymerase II was greater for serum inducible genes. 
Additionally, TOP2A also plays a role in RNA polymerase Iβ transcription by inducing 
DSB in the promoter region to facilitate the assembly of the pre-initiation complex 
(Ray et al., 2013).  
The role of TOP2B in regulating transcription of ligand inducible genes 
TOP2B has been reported to play role in regulating the transcription of hormonally 
and developmentally regulated genes and gene networks (Ju et al., 2006b; Perillo et 
al., 2008; Li et al., 2014; Madabhushi et al., 2015). Binding of TOP2B at promoter 
regions is required for neural and retinal development and the survival of post-mitotic 
cells. Furthermore, deficiency of TOP2B in mouse models has shown to lead 
increased DNA damage and contributes to neurodegeneration (Heng et al., 2012).  
Studies have shown that TOP2B is recruited to promoter regions of ligand dependent 
genes where it may have a role in the regulation of transcription. Furthermore, Non-
homologous end joining (NHEJ) factors are associated with promoter regions 
indicating TOP2B may catalyse the formation of DNA break that requires repair. 
A study conducted by Ju and colleagues showed that in the absence of estrogen, 
TOP2B and Poly[ADP-ribose] polymerase 1 (PARP-1) are located in a co-repressor 
complex on the promoter region of pS2 (estrogen regulated gene). Other 
components of the co-repressor complex include histone deacetylase 3, nuclear 
receptor co-repressor, nucleolin, nucleophosmin and heat shock protein 70. 
However, stimulation with 17-β estradiol resulted in a dynamic and rapid recruitment 
of TOP2B, PARP1 and components of the NHEJ system (DNA-PK/Ku86/Ku70) to 
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promoter of pS2 together with RNA polymerase II and the eviction of components 
within the co-repressor complex (except TOP2B and PARP-1).  
TOP2B catalysed the formation of a DNA strand break between linker regions of 
nucleosomes and following this PARP-1 was activated to cause the exchange of 
nucleosomes to allow changes in chromatin architecture allowing nuclear receptor 
and transcription activation (Ju et al., 2006a). A further study evaluated the hormone 
dependent recruitment of TOP2B/PARP 1 to the pS2 gene requires the chromatin 
remodellers BAF (mSWI/SNF) (Trotter et al., 2015). Subsequent studies showed 
TOP2B DSB positively regulates androgen and glucocorticoid stimulated genes in 
response to ligand stimulation (Haffner et al., 2010; Trotter et al., 2015). However, 
TOP2B recruitment to the promoter of the RARA gene (retinoid nuclear receptors 
which regulate myeloid differentiation) is associated with transcriptional repression 
(McNamara et al., 2008). 
1.1.2.Structure of TOP2 
 
TOP2 functions as a dimeric enzyme with each monomeric unit consisting of three 
structural domains (Austin et al., 1995) (Figure 1.3). The N-terminal domain is the site 
of DNA entry and consists of ATPase domain that is sub-divided into a N-terminal 
nucleotide binding domain (a member of the GHKL superfamily) and a C-terminal 
transducer domain. The central domain is referred as to the breakage-reunion core 
comprising of DNA-binding and the catalytic centre and is target for anti-cancer 
TOP2 poisoning agents. The C-terminal domain is the site for nuclear localisation 
signals and post-translational modifications and but is also important in regulating 
catalysis (Austin et al., 1993; Wells et al., 1995a; Ishida et al., 1996; Cowell et al., 
2000; Kim et al., 2002; Lindsey et al., 2014; Yoshida et al., 2016). 
Separate protein structural determination of the breakage-reunion and ATPase units 
of Saccharomyces cerevisiae Top2, showed the dimeric enzyme has a two-fold 
symmetry (Berger et al., 1996b) (Figure 1.3). In addition, the quaternary assembly of 
TOP2 was shown to make three major interfaces/gates that work in a coordinated 
manner allowing DNA cleavage and gated strand passage. These interfaces at which 
the protomers of the dimeric enzyme contact each other are known as the N-gate (N-
terminal domain), DNA gate and C-gate (within breakage-reunion domain). 
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The N-gate is formed by the ATPase domains, as mentioned earlier this domain is 
sub-divided into nucleotide binding and transducer domains. The nucleotide-binding 
domain comprises of a GHKL ATP binding fold, which is also present in proteins 
such as gyrase B, Hsp90 and histidine kinases. The nucleotide binding and 
transducer domains form the ATP binding pocket (one ATP binds per monomer). 
Upon ATP binding, dimerisation occurs between the nucleotide GHKL domains of the 
two protomers, in particular an N-terminal coil region within the nucleotide domain, 
termed the N-terminal strap wraps around the symmetry axis to contact the 
neighbouring promoter. The C-terminal of the transducer domain is a key component 
consisting of an α/β fold and a conserved QTK loop, which forms a salt bridge and 
contacts the γ-phosphate of ATP. (Wigley et al., 1991; Classen et al., 2003; Wei et 
al., 2005).  
 
Figure 1.3 Domain arrangement and protein structure of Saccharomyces cerevisiae TOP2 (PDB 
ID 4GFH). One monomer of the TOP2 protein is coloured according the domain structure whilst the 
other monomer is coloured in grey. The DNA duplex is shown in yellow and the catalytic tyrosine is 
shown in green. Figure produced using CCP4MG version 2.9.0. 
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The DNA-gate consists of a TOpisomerase/PRIMase (TOPRIM) domain and a 
winged helix domain (WHD). The TOPRIM domain has a compact α/β fold of ~100 
amino acids conserved from archaea, bacteria to humans. In the C-terminal region of 
the TOPRIM domain comprises of a catalytic Mg2+ ion coordinated in an acidic triad 
(DxD motif) (Aravind et al., 1998). The DxD (IMTD(Q/A)DxD) is critical and site-
directed mutagenesis in this region results in an unstable protein that is rapidly 
degraded (West et al., 2000). Also residing the TOPRIM domain is a non-catalytic 
tyrosine (Tyr640 for TOP2A and Tyr656 for TOP2B) is crucial for efficient TOP2 
activity and mutations leads to resistance to TOP2 poisons (Kozuki et al., 2017). The 
TOPRIM domain connects to the WHD via a three-helix bundle. The catalytic tyrosine 
is located in the WHD. Adjacent to the WHD is a tower domain arranged in a α/β fold 
(also participates in DNA binding), from the tower domain a coiled-coil domain 
extends to make connections with the C-gate, the site for DNA exit. Structural studies 
reveal the ATPase domain once dimerised, contacts the TOPRIM domain of its 
partner subunit. Although the significance of this is unknown, this signifies that each 
protomer subunit makes contacts with the neighbouring promoter serving to 
communicate information for strand cleavage and passage (Schmidt et al., 2012). 
Two separate TOP2 Saccharomyces cerevisiae structures revealed the dynamic 
nature of the TOPRIM and WHD domains as differences in the separation distance 
between the TOPRIM and WHD were reported by two separate studies (Berger et 
al., 1996a; Fass et al., 1999). This lead to the proposal of the TOPRIM and WHD 
undergo conformational changes to position the divalent Mg2+ ion relative to tyrosine 
within WHD to allow DNA cleavage. Later studies showed the transition from the apo 
state (non DNA bound) to the DNA bound state, the TOPRIM domain would make an 
~80o movement to contact the WHD domain. There are two main consequences for 
this rotation; the first is to position the Mg2+ ion relative to the tyrosine to prime the 
DNA cleavage reaction and also to create a positively charged deep groove allowing 
channelling of the DNA into the cleavage core (breakage-reunion domain) (Dong and 
Berger, 2007) (see section 1.1.3). 
Structural determination of the human TOP2A bound non-covalently to DNA and 
TOP2B stabilised in a cleavage complex with DNA and etoposide revealed similar 
arrangements of domains and overall quaternary structure as that of Saccharomyces 
cerevisiae (Wu et al., 2011; Wendorff et al., 2012) (Figure 1.4.A TOP2A bound to 
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DNA). By comparing previously solved TOP2 protein structures, Wendorff and 
colleagues suggest binding of the first segment of DNA promotes movement in the 
WHD domains which allow clamping of TOPRIM and tower domains around the 
DNA. In addition, the movement of WHD domains in each promoter is suggested to 
control the movement of the C-gate and therefore the coiled-coil domain that connect 
the DNA-gate to the C-gate controlling the movement of DNA (Wu et al., 2011; 
Wendorff et al., 2012).   
Prior to solving the structure of breakage-reunion domain of TOP2, the structure of 
human TOP2A’s dimeric ATPase domain was solved bound to ADP or AMPPNP 
(non-hydrolysable analogue, this locks the N-gate in the dimerised position) (Figure 
1.4.B).  By comparing the two bound states of the domain, authors found that in the 
ADP bound state, the ATPase domain displays a relaxed confirmation, in which the 
transducer domain extends and retracts the lysine from the QTK loop away from the 
γ-phosphate. This movement seems to be crucial in accommodating the second DNA 
segment (T-segment) into the enzyme (Wei et al., 2005) (see section 1.1.3).  
 
Figure 1.4 (A) Structure of a fragment of human TOP2A bound non-covalently to DNA (residues 
431-1193) (PDB ID 4FM9). (B) Structure of human TOP2A ATPase domain in ADP bound state 
(PDB ID 1ZXN). DNA is coloured yellow. Figure produced using CCP4MG version 2.9.0.  
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However due to the structures of human TOP2A ATPase and DNA binding and 
cleavage core being solved separately the communication events between the two 
domains are not clear.  
The C-terminal region (residues 1242-1531 TOP2A and 1263-1621 TOP2B) is the 
main but not only site for post-translational modifications, such as phosphorylation for 
cell-cycle control, nuclear localisation and nuclear export signals determining the 
cellular distribution of the enzymes (Adachi et al., 1997; Cowell et al., 1998; Mirski et 
al., 1999; Mirski et al., 2003; Meczes et al., 2008). Studies conducted using chimeric 
TOP2A and TOP2B, which had exchange of C-terminal regions, showed the C-
terminal region is not required for basic cleavage activity but presence of C-terminal 
region confers isoform specific properties of the TOP2 isoforms and allows 
determination of DNA’s topological state (McClendon and Osheroff, 2006; 
McClendon et al., 2008; Lindsey et al., 2014).  
The post-translational modifications on the C-terminal are important in controlling 
TOP2 activity; an example is the phosphorylation of residue Thr1342 on TOP2A. 
Threonine 1342 is phosphorylated throughout the cell cycle and targeting with a 
specific Thr1343 antibody (PT1343-reacts with TOP2A phosphoThr1342) abolishes 
TOP2A activity suggesting this Thr1342 phosphorylation is key in controlling TOP2A 
activity (Ishida et al., 1996). Similarly, phosphorylation at Ser1337 and Ser1524 
during the cell cycle positively regulates TOP2A activity and defects in 
phosphorylation reduce TOP2A decatenation activity (Li et al., 2008). Furthermore, 
fusion of TOP2B’s C-terminal region with TOP2A resulted in a chimeric protein that 
was unable to support proliferation, and had lower enzymatic activity (Linka et al., 
2007; Meczes et al., 2008). Furthermore, deletion of the C-terminal region of TOP2A 
but retaining the nuclear localisation signal enhances etoposide (TOP2 poison) 
cytotoxicity (Kozuki et al., 2017). This further suggests that the C-terminal domain 
has an important role in controlling TOP2 activity. 
1.1.3 Catalytic cycle of TOP2 
 
TOP2A and TOP2B function to alter DNA topology using an ATP dependent strand 
passage event to relieve DNA torsion stress (supercoiling). Both isoforms require 
almost identical concentrations of ATP for their catalytic activities and display similar 
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kinetics for ATP hydrolysis (TOP2B kcat 2.25s-1 at 30oC and for TOP2A  kcat 2.17s-1   at 
37oC) (West et al., 2002).  
However, TOP2A and TOP2B have certain differences in enzymatic properties, 
which are in part due the heterogeneity in the C-terminal regions. For example, 
TOP2B requires a higher concentration of KCl for in vitro cleavage reactions and is 
less thermally stable compared to TOP2A in vitro (Drake et al., 1989). On the other 
hand, TOP2A can distinguish between different DNA geometries and can relax 
positively supercoiled DNA faster than negative helical twisted DNA (McClendon and 
Osheroff, 2006; McClendon et al., 2008; Fernández et al., 2014; Lindsey et al., 
2014). Both isoforms also display differences in DNA binding affinities, as TOP2B 
has a higher affinity for DNA compared to TOP2A and deletion of the C-terminal 
region of TOP2B greatly increases binding to DNA (KD 72.9 ±18.6 for full length 
TOP2B vs 17.8± 2.72 for C-terminal truncated TOP2B) (Gilroy and Austin, 2011). 
TOP2 works in a coordinated manner to alter the topological state of DNA by 
introducing two transient DNA nicks in one segment of DNA (G-segment) and 
allowing a second intact DNA molecule (T-segment) to pass unidirectionally from the 
N-gate to the C-gate, followed by the religation of the cleaved DNA (Cowell and 
Austin, 2012; Pendleton et al., 2014) (Figure 1.5).  
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Figure 1.5 Domain structure and catalytic cycle of TOP2. (1) DNA duplex (G-segment) enters into 
the TOP2 enzyme thought the N-gate. (2) Binding of two molecules of ATP and capture of second 
DNA duplex (T-segment) triggers structural rearrangements causing the dimerisation and closure of 
the N-gate (3). The T-segment translocates through the transiently formed TOP2-DNA bridged gate 
and exits through the C-gate (4). Hydrolysis of a second molecule of ATP begins during the transport 
of the T-segment, and opens the N-gates to ‘reset’ TOP2 for another catalytic cycle (1). 
Saccharomyces cerevisiae TOP2 structure is shown on the left (PDB ID 4GFH) was produced using 
CCP4MG v2.9.0. TOP2 catalytic cycle diagram is adapted with permission from Bates et al; 2011.  
 
TOP2 binds to helix-helix juxtapositions as in vitro studies showed TOP2 binds with 
greater affinity to four-way junction DNA compared to linear DNA (Zechiedrich and 
Osheroff, 1990; West and Austin, 1999). The TOP2 reaction begins with the transport 
of a DNA segment (G-segment) through the N-terminal gate and into the breakage-
reunion core (Figure 1.5 (1)). Binding of the G-segment promotes movements of the 
TOPRIM, WHD and tower domains to shift into an ‘engagement’ conformation 
allowing the enzyme to clamp around the DNA segment and cause bending of the 
DNA duplex (Wendorff et al., 2012; Laponogov et al., 2013).  
ATP loads onto the ATPase domain triggering structural rearrangements allowing 
capture of the T-segment and dimerisation of the N-terminal gate causing the closure 
of the gate. N-gate closure facilitates DNA deformation and enhances cleavage (Lee 
et al., 2012b). Determination of the DNA bound structure revealed that DNA is bent 
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sharply by up to 150o  (130o for human TOP2A) with each interface of TOP2 bending 
DNA by 75o . This deformation of DNA positions the DNA backbone near the catalytic 
tyrosine and Mg2+ ion, critical to prime the DNA cleavage reaction. The bent DNA is 
stabilised by the positive cavity created by the rotation of TOPRIM domain relative to 
the WHD domain (see section 1.1.2). 
Hydrolysis of one molecule of ATP allows the expansion of the upper cavity of the N-
terminal gate to allow movement of T-segment towards the lower cavity (Wei et al., 
2005). This closure of the N-terminal gate and passage of the T-segment triggers 
cleavage of the G-segment to generate a TOP2-bridged DNA gate which is termed 
the ‘cleavage complex’ (Corbett et al., 1992) (Figure 1.5 (2-3).  
Cleavage of the G-segment is initiated by the active site nucleophilic tyrosine that 
resides in the WHD of the breakage-reunion domain (Figure 1.3). The tyrosine 
residue (Tyr805 for TOP2A and Tyr821 for TOP2B) attacks the phosphate backbone 
of the scissile bond resulting in the formation of a 5’phosphotyrosyl linkage between 
DNA and TOP2 and a 3’-hydroxyl moiety that interacts with TOP2 non-covalently 
(Figure. 1.6). This nucleophilic reaction is coordinated by Mg2+ ions situated in the 
TOpisomerase/PRIMase (TOPRIM) domain (Deweese et al., 2009a; Deweese et al., 
2009b) (Figure 1.3). Each protomer subunit cleaves one strand of the DNA helix 
generating a DNA nick that is separated 4bp apart from a second DNA nick, forming 
a staggered DNA break. The covalent linkage of DNA with the active site tyrosine 
residue and interaction of the two promoter subunits maintains genomic integrity of 
DNA. In addition, there are two non-catalytic Mg2+ ions, which contact DNA bases up- 
stream and down-stream of the cleavage site and have a role in stabilising the 
transition state (Wu et al., 2011; Wendorff et al., 2012). 
After passage of the T-segment though the C-gate, the cleaved DNA molecule is re-
ligated. The 5’phosphotyrosyl linkage (TOP2-DNA linkage) is equivalent in energy to 
a phosphodiester bond and therefore the bond energy is preserved allowing the 
release of DNA from the enzyme by a nucleophilic attack from the 3’OH of the 
opposing strand (Figure. 1.5). Each subunit acts independently in strand re-ligation 
(Bromberg et al., 2004).  Hydrolysis of the second ATP molecule resets the enzyme 
to begin a new reaction cycle (Figure 1.5 (1)) (Deweese and Osheroff, 2009). 
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Figure 1.6 Chemical mechanism of DNA cleavage by TOP2. TOP2 utilises a nucleophilic tyrosine 
residue to attack the scissile phosphate resulting in the formation of a phosphotyrsoyl bond linking the 
protein to a newly generated 5’ termini of DNA (cleavage complex). Ligation occurs when 3’OH of 
DNA is deprotonated by a general acid followed by a nucleophilic attack on the 5’phosphotyrosyl bond 
to release DNA from TOP2. This reaction is dependent on the coordination by Mg2+ and DNA 
deformation mediated by the movements by the TOPRIM and WHD domains. 
 
1.1.4. Interference of TOP2’s catalytic cycle by TOP2 poisons  
 
There are various chemically distinct drugs available to inhibit TOP2’s catalytic cycle, 
one such class of drugs are known as TOP2 poisons and act by stabilising the 
transient cleavage complex. Drugs, which inhibit other steps of TOP2’s catalytic cycle 
are termed catalytic inhibitors and are discussed in chapter 6.  
TOP2 poisons such as etoposide, mitoxantrone, doxorubicin and epirubicin act by 
stabilising the TOP2-DNA cleavage complex to prevent the re-ligation of DNA (Figure 
1.5 and 1.7). In cells, TOP2 maintains a fine balance between enzyme-mediated 
DNA cleavage and re-ligation. In the presence of TOP2 poisons, this equilibrium is 
disrupted increasing the level of cleavage complexes within the cell, holding DNA in 
the cleaved state. TOP2 poisons are licensed for use in chemotherapy to treat a 
board spectrum of cancers (Table 1) however, TOP2 poison therapy is associated 
with a rare but serious side effect of the development of therapy related leukaemia. In 
this thesis, the focus will be on the TOP2 poisons; etoposide, mitoxantrone, 
doxorubicin and epirubicin and their roles as interfacial TOP2 poisons (Pendleton et 
al., 2014). The other class of TOP2 poisons are covalent TOP2 poisons, which 
covalently bind at a site distinct from the active site to increase the level of cleavage 
complexes; an example is etoposide quinone, which is discussed in section 1.3.1.  
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Figure. 1.7 Chemical structures of TOP2 poisons. 
 
TOP2 poison Use in clinics (UK) 
Etoposide Lung, testicular, ovarian and stomach cancer, 
leukaemia and non-Hodgkin lymphoma1,2 
Mitoxantrone Metastatic breast cancer, primary liver cancer 
non-Hodgkin lymphoma, leukaemia 1, 2 and  
Multiple Sclerosis (MS) (not licensed in the UK, 
but is used at some specialist centers)3  
Doxorubicin Used for treatment of a range of cancers 
including breast, bladder, thyroid, small cell lung 
cancer, advanced ovarian cancer, bladder 
cancer, Hodgkin’s disease, Ewing’s sarcoma, 
leukaemia and advanced neuroblastoma 4 
Epirubicin Breast, ovarian, stomach, lung, bowel cancer, 
myeloma, leukaemia and lymphoma1 
 
Table 1: The clinical use of selected TOP2 poisons in the UK. 1Information obtained from Cancer 
Research UK; 2Macmillan org.uk; 3Multiple Sclerosis Trust UK; 4electronic Medicines Compendium 
(eMC) UK. 
Etoposide  
Etoposide is a semi-synthetic derivative of podophyllotoxin, synthesised in 1966 and 
approved for clinical use in 1983 (Hande, 1998) (Figure 1.7). Etoposide was first 
described to cause both DNA single and double strand breaks that quickly reversed 
upon drug removal. However, the mechanism of etoposide induced DNA damage 
was unclear (Loike and Horwitz, 1976; Wozniak and Ross, 1983). Studies later 
revealed that etoposide interfered with the breakage-reunion reaction of TOP2 and 
was termed a TOP2 poison (Chen et al., 1984; Minocha and Long, 1984; Ross et al., 
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1984). Studies conducted using cell line models specificity showed that etoposide 
targets both isoforms of TOP2, and upon removal of etoposide from cell medium, 
stabilised TOP2-DNA complexes can reverse to background levels within 120min 
after drug removal (Willmore et al., 1998; Errington et al., 2004).  
A two-drug model for etoposide’s TOP2 poisoning action was proposed using gel-
based DNA cleavage and ligation assays. The two-drug model suggested that one 
molecule of etoposide intercalates into one scissile bond to physically block DNA 
religation (Figure 1.8 A). A second etoposide molecule independently intercalates 
into the neighbouring scissile bond (which is in the separate promoter unit of dimeric 
TOP2) stabilising the second DNA nick. Therefore, it was proposed that binding of 
one etoposide molecule at one active site of TOP2 does not affect the reactions 
occurring in the neighbouring active site and two molecules of etoposide per TOP2 
enzyme are required to stabilise a DNA DSB (Bromberg et al., 2003). Due to 
etoposide’s mode of action, it is referred an interfacial TOP2 poison. This refers to a 
drug that reversibly binds at a site created by the interaction/movement of two or 
more components (i.e. etoposide binds at the TOP2 bridged DNA gate) (Pommier 
and Marchand, 2012). This two-drug model was later confirmed by structural 
determination of the human TOP2B-DNA-etoposide ternary complex (residues 445-
1201 of TOP2B) (Wu et al., 2011; Wendorff et al., 2012) (Figure 1.8.B and 1.9). 
 
Figure 1.8 Intercalation of etoposide into the TOP2-DNA binary complex. (A) Etoposide (shown 
as green ovals) intercalates into the scissile bond using base stacking to physically block re-ligation of 
DNA, this is known as the two-drug model proposed by Bromberg and colleagues (Bromberg et al., 
2003). (B) Etoposide intercalation into the TOP2B-DNA complex. Diagram produced using CCP4MG 
v2.9.0 using the TOP2B-DNA-etoposide protein structure (PDB ID 3QX3).  
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Structural studies reveal that etoposide poisons TOP2 as predicted by the two-drug 
model. Etoposide intercalates into the TOP2-DNA binary complex with one molecule 
of etoposide per scissile bond (one etoposide at +1/+4 site and the other at -1/+5) 
requiring two molecules of etoposide to stabilise a DSB (Figure 1.8.B 1.9). The 
polycyclic ring of etoposide sits between base pairs acting as a physical block to 
disfavour re-ligation of DNA. This physical block induced by the presence of 
etoposide decouples the active site tyrosine and the catalytic Mg2+, disrupting the 
Mg2+ coordination required for re-ligation and shifts the nucleophilic 3’OH to a 
distance of 8.33Å away from the 5’-phosphotyrosyl bond preventing nucleophilic 
attack. This suggests that etoposide induces conformational changes in the TOP2B 
protein shifting the positions of the TOPRIM domain relative to the WHD domain 
resulting in displacement Mg2+ ion relative to the cleavage site (see section 1.1.2). 
The E-ring of etoposide is pointed towards the minor groove-binding pocket and 
causes local DNA deformation. However, the DNA deformation induced by one 
etoposide molecule does not extend to the neighbouring active site (Wu et al., 2011). 
This further supports the two-drug model that etoposide molecules act independently 
to each other (Bromberg et al., 2003).  
In addition to intercalating into the TOP2-DNA complex, etoposide makes hydrogen 
bonding and Val der Waals interactions with the TOP2 protein to stabilise its 
intercalation into the protein-DNA binary complex (Wu et al., 2011) (1.9 right panel). 
Etoposide’s A, B, C and D ring sit between base pairs, and rings A, B and D contact 
protein residues (Figure 1.9). Etoposide’s glycosidic moiety makes minimal contact 
with DNA but is involved in making drug-protein interactions (Wendorff et al., 2012). 
Superimposition of the TOP2B-DNA-etoposide structure onto the TOP2A-DNA 
structure revealed similar interactions of etoposide with DNA and TOP2 but point 
towards some differences in residues (Gln778 TOP2B to Met762 in TOP2A and 
Ser800 of TOP2A replacing Ala816 of TOP2B) between the isoforms that could be 
used to develop isoform specific drugs.  
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Figure 1.9 Structure of the DNA binding and cleavage core of TOP2B-DNA (3QX3) binary 
complex stabilised by etoposide. One monomer of the TOP2B dimeric structure is coloured 
according to the domain structure (shown above). Protein structure has been set to 0.74 opacity to 
show the etoposide intercalating into DNA (yellow) more clearly. Figure produced using CCP4MG 
2.9.0. The right hand panel shows the key residues of the TOP2B protein that etoposide contacts, 
figure adapted with permission from Wu et al., 2013.  
 
Before the availability of the protein structure, it was believed etoposide or any TOP2 
poison traps TOP2-DNA in the cleaved complex state in which the N- and C-gates 
are in the closed positions (Figure.1.3). However, the TOP2B structure revealed an 
open quaternary structure as opposed to closed conformation of the enzyme, which 
suggests that etoposide does trap the cleavage complex but is described to be a 
putative intermediate state between the closed pre-cleavage and open conformation 
(Wu et al., 2011). This putative intermediate state may be a result of etoposide 
binding and causing conformational changes to the TOPRIM and WHD domains that 
results in the shifting of the Mg2+ relative to the active site tyrosine. 
Mitoxantrone  
Mitoxantrone is a synthetic anthracenedione developed in the 1980s and approved 
for use in the treatment of acute myeloid leukaemia by the Food and Drug 
Administration (FDA) in 1987 (Faulds et al., 1991). Mitoxantrone was developed to 
improve the therapeutic potential of anthracyclines by maintaining a planar polycyclic 
  
 
21 
aromatic ring system for DNA intercalation but substituted the sugar moiety with 
hydroxylalkylamino side chain to reduce cardiotoxicity (Zee-Cheng and Cheng, 1978; 
Evison et al., 2015) (Figure 1.7). Mitoxantrone, like etoposide was predicted to 
intercalate into the TOP2-DNA binary complex however mitoxantrone induces more 
stable TOP2-DNA covalent complexes compared to that stabilised by etoposide in 
cellulo (Fox and Smith, 1990; Errington et al., 2004). Recent structural determination 
of the mitoxantrone-TOP2B-DNA ternary complex supports the interfacial TOP2 
poisoning action of mitoxantrone (Wu et al., 2013).   
The structure of mitoxantrone bound to TOP2B-DNA was prepared using post-
crystallisation drug replacement of etoposide with mitoxantrone (Wu et al., 2013). 
Like etoposide, mitoxantrone uses its polycyclic ring structure to intercalate between 
base pairs +1/+4 and -1/+5. This increases the distance between the catalytic 
tyrosine and Mg2+ and the distance between the nucleophilic 3’OH and electrophilic 
5’-phosphotyrosine by 8.81Å, disfavouring re-ligation (Figure 1.10 and 1.6).  
A key difference to etoposide is that in the presence of mitoxantrone the attacking 
3’OH nucleotide shifts position of its ribose moiety from the C3’-endo to the C2’-endo 
conformation (Wu et al., 2013). This positions the attacking oxygen out of alignment 
with 5’-phosphotyrosine further suppressing religation and this arrangement is also 
seen in metal free TOP2 structures (Schmidt et al., 2010).  
To stabilise its residence within the TOP2-DNA binary complex, mitoxantrone uses 
both its polycyclic ring and hydroxylalkylamino arms to make hydrogen bond contacts 
and van der Waals interactions with the protein (Figure 1.10). One 
hydroxylalkylamino arm points towards the minor groove of DNA and fits into a 
crevice situated between the TOP2B and DNA to make contacts with residues 
Glu522, Asn520 and Arg503. Whereas the opposing arm points towards the major 
groove which is more solvent exposed and is seen to make a single hydrogen bond 
contact with Gln778 (Wu et al., 2013). 
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Figure 1.10 Mitoxantrone intercalation into the TOP2B-DNA complex. Mitoxantrone uses its 
polycyclic aromatic dihydroxy-anthraquinone (polycyclic ring) moiety to intercalate between DNA base 
pairs, the hydroxylalkylamino arms project towards the DNA major and minor grooves forming 
hydrogen bonding interactions with the protein stabilising the ternary complex. Diagram was produced 
using CCP4MG v.2.9.0 by importing the TOP2B-DNA-mitoxantrone structural coordinates from PDB 
ID 4G0V and for simplicity the TOP2B protein was removed to show the interactions of mitoxantrone 
with DNA. Right panel shows the interactions mitoxantrone makes with residues of TOP2B protein, 
figure adapted with permission from Wu et al., 2013.  
 
In contrast to etoposide, studies using mitoxantrone suggest that mitoxantrone can 
also induce DNA damage independently to its TOP2 poisoning action. However the 
other roles of mitoxantrone induced DNA damage are described to be minor or weak 
functions of mitoxantrone and that TOP2 is important in mitoxantrone induced 
cytotoxicity (Evison et al., 2015). In support of this, studies have shown that reduction 
TOP2B levels or exclusion of TOP2A from nucleus leads to resistance to 
mitoxantrone (Harker et al., 1991; Harker et al., 1995a; Harker et al., 1995b; 
Errington et al., 1999). 
Nevertheless, mitoxantrone can directly interfere with mitosis by preventing the 
formation of microtubules by directly interacting with tubule monomers and 
preventing their polymerisation. Failure to assemble microtubules prevents 
chromosome segregation and therefore cell division (Ho et al., 1991). Therefore in 
proliferating cells mitoxantrone may utilise both the poising of TOP2A-DNA covalent 
complexes and binding to tubules to prevent cell division. Studies also suggest that 
mitoxantrone can directly bind to chromatin causing compaction and aggregation of 
chromatin structure which could potentially inhibit processes such as transcription 
and replication (Hajihassan and Rabbani-Chadegani, 2009). Additional studies 
showed that mitoxantrone inhibits DNA and RNA synthesis, which could be due to 
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mitoxantrone ability to intercalate in between base pairs or by direct binding to DNA 
and RNA. However a study conducted by Fox and colleagues showed the 
persistence of stabilised mitoxantrone TOP2-DNA complexes even after drug 
removable correlated with suppression of DNA synthesis (Johnson et al., 1979). 
Therefore the block on DNA synthesis could be a function dependent on 
mitoxantrone’s ability to poison TOP2-DNA complexes (Fox and Smith, 1990).    
Doxorubicin and epirubicin  
Doxorubicin and epirubicin belong to the anthracyclines class of drugs. The first 
isolated anthracyclines from Streptomyces peucetius were doxorubicin and 
dauorubicin. Epirubicin is a semi-synthetic derivate of doxorubicin that differs in the 
position of the C4 OH group in the daunosamine moiety (Figure 1.7). In epirubicin, 
the 4’OH is arranged in an equatorial configuration whereas for doxorubicin the 4’OH 
is arranged in an axial configuration. This epimerisation of the hydroxyl group 
introduces pharmacokinetic changes in drug properties whilst maintaining its 
cytotoxic function (Gewirtz, 1999a).  
Studies reported that described doxorubicin to induced both DNA single and double 
strand breaks, however purified DNA fragments were found to be covalently bound to 
proteins, which was later deduced to be TOP2. Therefore, the role of doxorubicin as 
a TOP2 poison was established (Tewey et al., 1984). Both doxorubicin and epirubicin 
induce TOP2 dependent DNA cleavage at lower drug concentrations with a 
preference for the nucleotide A at the -1 position relative to the cleavage site (in vitro 
drug concentrations 0.1-10µM) (Frederick et al., 1990; Cornarotti et al., 1996). At 
higher drug concentrations both drugs in vitro suppress TOP2-mediated DNA 
cleavage and inhibit the action of TOP2 poisons such as teniposide (podophyllotoxin 
derivative) and amsacrine (DNA intercalating TOP2 poison, drug class: acridines) 
(Capranico et al., 1990a; Capranico et al., 1990b). However, the TOP2 poisoning in 
cell lines has been difficult to detect (Montaudon et al., 1997; Willmore et al., 2002).  
This suggests a different cytotoxic mode of action for anthracyclines compared to 
mitoxantrone or etoposide. In addition to poisoning or inhibiting TOP2, doxorubicin 
and epirubicin can directly intercalate between DNA base pairs causing DNA cross-
linking which prevents the activity of DNA helicases and inhibits of macromolecular 
synthesis (Tuteja et al., 1997; Gewirtz, 1999b; Minotti et al., 2004). As both 
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doxorubicin and epirubicin can intercalate into DNA and poison TOP2 they are 
termed intercalative TOP2 poisons (Nitiss, 2009b). 
Structural studies using post-crystallisation drug replacement show that a single 
doxorubicin molecule intercalates asymmetrically into sites +1/+4 and +2/+3 
(between the cleavage site) of the TOP2B-DNA binary complex structure (Figure. 
1.11). This intercalation is suggested to disrupt the two-fold symmetry of the 
cleavage site moving the attacking 3’-OH by distance of 7.83Å from the 5’-
phosphotyrosine. Wu and colleagues reported that the binding of doxorubicin causes 
repositioning of adenine at +4 site and changes the ribose sugar orientation causing 
the formation of a non-canonical base pair (Wu et al., 2013) (Figure 1.11). Although 
the consequences of this repositioning induced by doxorubicin were not fully 
discussed, there is a possibility that the mis-alignment of bases up-stream from the 
cleavage site cause distortion of the 3’-OH and  
In addition, doxorubicin is reported to make only three contacts with the TOP2B 
protein (Lys456, Arg820 and Gln778) and relies mainly on hydrogen bonding with 
DNA to stabilise its interactions (Figure 1.11). However, it has been suggested that 
as the doxorubicin-TOP2B-DNA ternary complex structure was determined by 
soaking out etoposide and then subsequently soaking doxorubicin into the TOP2B-
DNA complex crystals, this may not be a true representative of how doxorubicin 
binds into the TOP2-DNA binary complex (Wu et al., 2013). 
Recent in vitro experimental studies using calf thymus DNA and doxorubicin have 
identified the potential reason behind the preference for A-T regions outside the 
intercalation site. Perez-Arnaiz and colleagues propose that doxorubicin uses A-T 
regions to bind into the minor groove of DNA (fast step) and then slowly intercalates 
between CpG sites (Perez-Arnaiz et al., 2014).  
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Figure 1.11 The intercalation of doxorubicin into the TOP2B-DNA complex (left panel) and the 
interactions doxorubicin makes with the TOP2B protein (right panel).  Figure adapted with 
permission from Wu et al., 2013. 
 
1.2 Myeloperoxidase  
 
Myeloperoxidase (MPO) (EC 1.11.2.2) is part of the heam peroxidase-
cyclooxygenase superfamily that utilises hydrogen peroxide to catalyse the oxidation 
of a range of halide ions, organic and inorganic substances.  Other members of this 
superfamily include; lactoperoxidase (LPO), eosinophil peroxidase (EPX) and thyroid 
peroxidase (TPO) which share 51%, 70% and 45% amino acid identify with MPO 
(Davies 2008). MPO is a homodimeric enzyme and has the unique ability to oxidise 
chloride at neutral pH generating hypochlorous acid-a strong oxidant. MPO is a key 
component of the azurophilic (primary) granules of neutrophils and functions in the 
innate immune response. In addition to MPO’s role in assisting the killing of 
pathogenic organisms, MPO has been implicated in a growing number of 
inflammatory diseases, such as atherosclerosis, neurodegenerative, lung and renal 
diseases. Furthermore, due to MPO’s strong oxidising potential, MPO can also 
mediate drug biotransformation leading to compounds with altered properties. 
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1.2.1 Transcription, Translation and Post-translational processing of MPO 
 
MPO synthesis is restricted to the promyelocytic stage of myeloid differentiation 
(Figure 1.12). MPO protein expression is found in the common myeloid progenitor 
(promyelocytic stage) (CMP), granulocyte-macrophage progenitor (GMP), monocytes 
and most abundantly in neutrophils (Hansson et al., 2006).  
The gene encoding MPO is located on chromosome 17q22. The MPO gene is 
transcribed and translated into a single product of 80kDa termed preproMPO that is 
processed through the endoplasmic reticulum (ER), Golgi and azurophilic granules to 
generate mature dimeric MPO of 140kDa. The stepwise processing of MPO was 
experimentally defined using radiolabel pulse chase and immunoprecipitation 
experiments predominantly conducted in HL60 cell lines. PreproMPO consists of 
signal peptide (45aa), pro-peptide (116aa), a heavy α subunit and light β subunit 
(Figure.1.13). The N-terminal signal peptide targets preproMPO to the ER, in the ER 
compartment preproMPO undergoes slow processing to generate enzymatically 
active proMPO via apoproMPO intermediate.  
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Figure 1.12. The protein expression of MPO in hematopoietic cells. The hematopoietic stem cell (HSC) 
sits at the top of hierarchy and can differentiate to over 10 distinct mature blood cells. HSC gives rise to the 
multipotential progenitor  which has the full lineage potential but loses the capacity of self-renewal. MPP gives 
rise to the oligopotent progenitors; common myeloid progenitors (CMP) and common lymphoid progenitors 
(CLP), both, which are lineage committed (Seita and Weissman, 2010). Protein expression of MPO is shown 
in green. HSC and multipotential progenitors are positive for MPO expression at the RNA level. MPO protein 
expression in humans is restricted to the myeloid linage of cells being most abundantly expressed in 
neutrophils. However, in disease states such as multiples sclerosis and Alzheimer’s disease MPO expression 
is reactivated in macrophages of the brain (Nagra et al., 1997; Reynolds et al., 1999). Information used to 
construct (Seita and Weissman 2010) (permission obtained for figure adaptions). 
 
The first steps in the biosynthesis of mature MPO are the conversion of the 80kDa 
preproMPO to a glycosylated 90kDa apoproMPO. This is achieved by the co-translational 
cleavage of the 45aa signal peptide and en-bloc N-linked glycosylation consisting of two N-
acetylglucosamine residues, nine mannoses and three glucoses (GlcNAc2Man9Glu3) at five 
asparagine residues followed by limited deglucosylation. ApoproMPO then acquires haem 
by the sequential association with the ER molecular chaperon’s calreticulin (CRT) and 
calnexin (CLN) (Nauseef et al., 1995; Nauseef et al., 1998).  
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CRT binds to apoproMPO and maintains apoproMPO in a conformation competent to 
allow the insertion of haem. Haem incorporation occurs at the stage of CLN binding 
to apoproMPO to form an enzymatically active proMPO. It is likely that limited 
deglucosylation also occurs after the insertion of haem to allow the release of MPO 
from CLN (van Leeuwen and Kearse, 1996). ProMPO then exits from the ER to 
undergo rapid processing in the Golgi or is constitutively secreted. The proMPO 
exported to the Golgi has the propeptide removed by the action of subtilisin-like 
proprotein convertases in the post-ER compartment to generate a 74kDa 
intermediate, whereas constitutively secreted proMPO retains the N-terminal 
propeptide (McCormick 2012). However, there is still speculation on the precise 
timing of the propeptide cleavage and the events that occur in the Golgi network. 
Through the passage across the Trans-Golgi-network, the short-lived 74kDa 
intermediate MPO acquires modifications to the carbohydrate chains and exits for 
final processing in granules. In the granules the 74kDa intermediate is proteolytically 
cleaved into two subunits; a heavy α subunit (59kDa) and a light β subunit (14.5kDa) 
by the excision of a hexapeptide sequence (ASFVTG positions 273-278) and 
removal of a terminal carboxyl-terminal serine residue. The heavy α and light β 
subunits are held together via covalent bonds associated with the prosthetic heam 
group. More recently, heterogeneity in the sequence length elimination between the 
heavy α and light β subunits has been identified using tryptic digestion and peptide 
analysis (Grishkovskaya et al., 2017). This study reported the excision between the 
two subunits can be achieved by either tetra (A273-S-F-V276), penta- (A273-S-F-V-
T277) or hexapeptide (A273-S-F-V-T-G278) excisions (Grishkovskaya et al., 2017). 
The final stage in the maturation of MPO is the dimerisation of two α heavy subunits 
resulting in a symmetric dimer with each half linked by a disulphide linkage at 
Cys319. 
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Figure 1.13. MPO biosynthesis. MPO is translated into an 80kDa preproMPO. In the ER, preproMPO 
undergoes cotranslational cleavage of the signal peptide (45 amino acids) and N-linked glycosylation 
(GlcNAc2Man9Glu3) resulting in a 92kDa intermediate that is rapidly cleaved by glucosidase I to a 
90kDa apoproMPO. ApoproMPO sequentially associates with the ER molecular chaperones, 
calreticulin (CRT) and calnexin (CLN) which assist in protein folding and insertion of haem to generate 
proMPO, which is enzymatically active and exits the ER. In the Trans-Golgi Network (TGN) rapid 
processing occurs with some complex oligosaccharide side chains being modified. Final proteolytic 
processing occurs in the primary granules to form mature dimeric MPO (Hansson et al., 2006). 
Information used to construct figure obtained from Hasson et al., 2006. 
 
1.2.2 Structure of MPO 
 
The crystal structure of human MPO (PDB ID 3F9P) reveals a secondary structure 
consisting largely of alpha helices with very few beta sheets. The interface between 
the two symmetry dimers is highly glycosylated to stabilise the two-protomeric 
subunits (Figure 1.14). Each symmetry dimer of MPO consists of a single haem 
group identified as a derivative of protoporphyrin IX and a single calcium binding site 
arranged in pentagonal bipyramidal coordination. The haem group is crucial for the 
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catalytic function of MPO, whereas the Ca2+ is important in maintaining the 
architecture of MPO.   
The prosthetic haem group is covalently attached to the protein via a ester linkage 
between the methyl group of pyrrole ring C (of the haem group) to the carboxyl group 
of Asp94 and a sulfonium ion linkage between Met243 and the β-carbon of the vinyl 
group on pyrrole A (Fiedler et al., 2000). A second ester linkage, previously reported 
to play a key role in the attachment of haem to the MPO heavy subunit forms 
between pyrrole ring A and Glu242. However, a more recent study has suggested this 
ester linkage is not always present in MPO structure (Carpena et al., 2009). 
 
Figure 1.14 Crystal structure of human MPO (PDB ID 3F9P). MPO is a homodimeric enzyme with 
each monomer attached by a disulphide bridge at C319. Each symmetry dimer consists of a heavy α 
subunit (shown in light blue and orange) and light β subunit (shown in blue and red), a single calcium 
binding site (calcium ion shown in grey) and one haem group (shown in green). Carbohydrate chains 
are shown in yellow. Figure constructed using CCP4 Molecular Graphics Software version 2.9.0. 
 
1.2.3 Isoforms of MPO  
 
Three isoforms of MPO have been purified from the azurophilic granules of 
neutrophils and are termed MPO form I, II and III (Yamada et al., 1981). The three 
isoforms have identical spectral properties and have the same molecular weights for 
their light β subunits with differences in the molecular weight for the heavy α 
subunits, (form I 63kDa, form II and III 57.5kDa). The consequence for the 
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differences in the molecular weights of the heavy subunit is unknown however, MPO 
I is reported to have distinct properties from MPO forms II and III.  
MPO form I is suggested to be a membrane bound protein whereas forms II and III 
are reported to be soluble proteins within the azurophilic granules (Pember et al., 
1983). In addition, MPO form I is reported to have a lower activity compared to MPO 
forms II and III. MPO form I has a lower content of charged amino acids compared to 
forms II and III (Lys+Arg residues I<II<III) and therefore a reduced surface charge 
and differences in amino acids sequences (Pember et al., 1982; Pember et al., 
1983). Although additional studies have not been published to further evaluate the 
role of the three isoforms, differences in surface charges between the three isoforms 
of MPO would affect the ability of MPO (cationic protein) to bind to surfaces of red 
blood cells (anionic surface), leukocyte and the endothelial membranes (Adam et al., 
2014).    
1.2.4 Normal function of MPO 
 
MPO is a key component of the neutrophils and accounts for up 5% of the total 
cellular protein distributed between the azurophilic granules and the nucleus (3.5µg 
per 106 nuclei). Traditionally, it has been accepted that during the activation of 
neutrophils, MPO is released from the azurophilic granules to generate hypochlorous 
acid (HOCl), however additional roles of MPO in the innate immune response have 
emerged.  
HOCl is a strong oxidant that causes oxidative protein unfolding and the aggregation 
of bacterial proteins in vitro (Winterbourn, 2002; Winter et al., 2008). The ability for 
MPO to produce HOCl is dependent on a source of hydrogen peroxide (H2O2) which 
is supplied by the action of NADPH-oxidase during the neutrophil’s respiratory burst 
(Dahlgren and Karlsson, 1999). However, the generated HOCl not only serves to kill 
microorganisms but can also activate intracellular pathways such as the mitogen-
activated protein (MAP) kinase that promotes cell survival under oxidative stress and 
can modulate the activity of matrix metalloproteinases (MMPs).  
MPO can also act as a autocrine and paracrine stimulator in neutrophils to up-
regulate the activity of NADPH-oxidase and signalling cascades required for 
neutrophil degranulation (Lau et al., 2005). More recently studies have suggested 
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that MPO has a crucial role in mediating the formation of neutrophil extracellular 
traps (NET) by promoting chromatin de-condensation (a function independent of 
MPO’s ability to oxidise substances) (Papayannopoulos et al., 2010; Metzler et al., 
2011; Metzler et al., 2014). NETs are mesh like structures consisting of de-
condensed chromatin and antimicrobial proteins, used to combat Candida albicans 
and patients deficient in MPO are unable to form NETs and are susceptible to 
Candida infections.  
1.2.5 Reaction cycle  
 
The oxidation of halides (chloride, bromide, iodide and pseudohalide thiocyanate) 
begins with the reaction of ferric-MPO [Fe(III) Por] (MPO3+) with H2O2 to generate the 
redox intermediate Compound I [Fe(IV)=O Por!+] (Figure 1.15) (Malle et al., 2007). 
Compound I is two oxidising equivalents above the native enzyme and has a high 
two-electron reduction potential of 1.16V, this enables the oxidation of halides ions 
(HOX) regenerating ferric MPO. This is termed the halogenation cycle (Figure 1.15, 
reaction 1).  
In the peroxidase cycle, compound I has an even greater reduction potential of 
1.36V and can withdraw a single electron from an organic or an inorganic substrate 
(including drugs) (depicted as AH2) (Figure 1.15, reaction 2). In the peroxidase cycle, 
compound I reduces to compound II [Fe(IV)=O Por]. Compound II is characterised by 
having a formal oxidation state of +4 with the absence of porphyrin π-cation radical 
and cannot react with halides (redox potential 0.97V). For Compound II to reduce to 
the native enzyme [Fe(III) Por] (MPO3+)  it catalyses the one-electron oxidation of a 
second substrate (Figure 1.15 reaction 3). In addition there a two redox intermediates 
of MPO termed compound III [Fe(III)-O2!-Por] and ferrous MPO [Fe(II) Por] which do 
not actively participate in the catalytic cycle (Figure 1.15 reactions 4-6).  
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Figure 1.15 Reaction cycle of MPO. MPO’s catalytic cycle begins with the production of compound I 
(halogenation cycle). Compound I is produced by the reaction of ferric MPO (native enzyme) with 
H2O2 (reaction 1). Compound I is characterised by oxoiron (IV) centre with a porphyrin -cation 
radical. The reaction of compound I with halides regenerates native MPO. Alternatively compound I 
can catalyse the one-electron oxidation of a peroxidase substrate (AH2) generating compound II that 
has a reduction potential of 0.97V (peroxidation cycle, reaction 2). Compound II can reduce to the 
native enzyme by a reaction with a second substrate (reaction 3). Compound III (ferrous-dioxy/ferric 
superoxide complex) can be formed by reaction of compound II with H2O2 (reaction 4). Compound III is 
unstable and can reduce to ferrous MPO with the release of oxygen or to the ferric native enzyme with 
the release of superoxide. Additionally, compound III can be produced by the reaction of ferric MPO 
(native enzyme) with superoxide or ferrous MPO with dioxygen. Diagram constructed using 
information from Malle et al., 2007 but has not been replicated from figures in this review article. 
 
1.2.6 Inhibition of MPO 
MPO derived oxidants are implicated in acute and chronic inflammatory diseases, 
therefore MPO is an important target for the treatment of inflammatory diseases. 
Studies have linked the MPO 463A"G polymorphism in the incidence of Alzheimer’s 
disease, multiple sclerosis (MS), diabetic nephropathy, AML and possibly some solid 
tumours such as lung, bladder, breast and pancreatic cancer (van der Veen et al., 
2009). The 463A/G allelic polymorphism is in the promoter region of MPO and 
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presence of the G nucleotide can up-regulate transcription of MPO by 25-fold 
(Piedrafita et al., 1996). 
Due to the prevalence of MPO activity in multiple diseases, new small direct 
molecular inhibitors have been developed to reduce the activity of MPO and are 
currently being tested in Phase I and Phase II clinical trials. The most successful 
MPO inhibitors to date have been the 2-thioxanthines; AZD5904 and AZD3241, and 
the 2-thiouracil based inhibitors PF1355 and PF-06282999 (Figure 1.16). In 
experimental systems 4-ABAH (a direct MPO inhibitor) and succinylacetone (SA) (a 
haem biosynthesis inhibitor) have been used to reduce MPO activity (Figure 1.16). 
The inhibitor action of MPO inhibitors used in experimental models and in phase I/II 
trials will be discussed below. 
 
Figure 1.16 Chemical structures of MPO inhibitors. 
Succinylacetone  
Succinylacetone (SA) is a potent inhibitor of haem biosynthesis, binding irreversibly 
to the active site of delta-aminolevulinate dehydratase (also known as 
porphobilinogen synthase), the second enzyme involved in haem synthesis (Tschudy 
et al., 1981; Giger and Meyer, 1983) (Figure 1.16). Haem is crucial for the catalytic 
function of MPO and the inability to incorporate haem during MPO biosynthesis, halts 
the processing of the protein (Figure 1.13). Experiments have shown the addition of 
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SA prevented the proteolytic processing of the MPO precursor, precluding its export 
from the ER resulting in the degradation of the preproprotein (Nauseef et al., 1992; 
Pinnix et al., 1994). To date SA has been a popular approach utilised to inhibit MPO 
in cell-based systems. 
4-ABAH 
4-aminobenzoic acid hydrazine (4-ABAH) is a specific mechanistic based inhibitor of 
MPO (Figure 1.16). Depending on the availability of oxygen 4-ABAH can either act as 
a reversible or irreversible inhibitor of MPO. The mechanism of inhibition involves the 
auto-catalytic oxidation of 4-ABAH to a radical intermediate (4-ABAHox), a process 
dependent on H2O2. 4-ABAHox reacts with the native ferric state MPO [Fe(III) Por] 
(MPO3+) reducing it to its ferrous state [Fe(II) Por] (MPO2+) (Figure 1.17). The ferrous 
state of MPO does not participate in either the halogenation or peroxidase cycles 
(Figure 1.15). The fate of MPO2+ is dependent on the availability of the substrates. 
The reaction of MPO2+ with H2O2 leads to the destruction of the haem group 
(irreversible inhibition) producing an inactive ferric MPO2+. However, in the presence 
of oxygen, MPO2+ can react with oxygen to produce compound III [Fe(III)-O2!-Por] 
(reversible inhibition), thus protecting the haem groups (Kettle et al., 1997; Burner et 
al., 1999) (Figure 1.17).  
 
Figure 1.17. Inhibition of MPO by 4-ABAH. 4-ABAH oxidises to a radical intermediate (auto 
oxidation or MPO mediated) which reacts with ferric MPO (MPO3+) to generate ferrous MPO (MPO2+). 
Depending on the availability of oxygen, MPO can be reversibly or irreversibility inhibited. Oxygen can 
rapidly react with ferrous MPO producing compound III (an inactive MPO) protecting MPO’s haem 
groups. However in the absence of oxygen, the haem group of the ferrous MPO can be destroyed 
leading to inactive MPO2+.  Information used to construct figure was obtained from Kettle et al., 1997. 
2-Thioxanthines 
The recent development of 2-thioxanthines (2-TX) for MPO inhibition has led to 
clinical interest for the treatment of Multiple System Atrophy, Parkinson’s disease 
(AZD3241) and for chronic obstructive pulmonary disease and Multiple Sclerosis 
(AZD5904) (Figure 1.16). The 2-TX class of compounds are mechanism-based 
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inactivators of MPO. 2-TX reacts with MPO’s redox intermediate compound I 
[Fe(IV)=O Por!+],  with a of rate constant 6.8 x 105M-1s-1, effectively competing with 
chloride (rate constant 2.5 x 105M-1s-1). The reaction of 2-TX with compound I results 
in the production of compound II [Fe(IV)=O Por] and a free radical species of 2-TX 
(2-TX!) (Figure 1.18). The free radical, 2-TX! remains in the active site of compound II 
and covalently attaches to the methyl atom of the haem pyrrole D ring via a sulfonium 
ion linkage, causing inactivation of compound II (Tiden et al., 2011; Ward et al., 
2013). 
 
Figure 1.18. 2-Thioxanthines inhibition reaction equation. 2-TX reacts with MPO compound I 
causing irreversible inactivation of compound II by covalent modification of the haem group. 
Information used to construct this figure was obtained from Tiden et al., 2011 and Ward et al., 2013 
 
 PF1355 (2-thiouracil inhibitor) 
The 2-thiouracil based inhibitors have also been of clinical interest for use in the 
treatment of small vessel vasculitis (PF1355) and acute coronary syndrome (PF-
06282999) (Figure 1.16) (Zheng et al., 2015; Dong et al., 2016). The biochemical 
mechanisms of MPO inhibition have not been clearly defined for the 2-thiouracils, 
however they are likely to have a similar mechanism to the 2-thioxanthines. The 
sulfur atom of the 2-thioxanthines is present on the 2-thiouracil substructure for both 
PF1355 and PF-06282999 (Figure 1.19) The MPO based inhibition for 2-
thioxanthines is predicated to occur by the sulfur atom covalently attaching to the 
haem group of MPO compound II. It is proposed that both PF1355 and PF-06282999 
react with compound I to generate a free radical that can subsequently adduct the 
haem group via a sulfonium ion linkage (Ruggeri et al., 2015). 
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Figure 1.19 A possible route into the inactivation of MPO haem group by PF1355.  
 
MPOi-II 
MPOi-II, is a 3-Alklindole derivative compound which is chemically distinct to the 2-
thioxanthines and 2-thiouracuil based inhibitors (Figure. 1.16). MPOi-II works by 
reducing compound I to the compound II state, causing the accumulation of 
compound II. It is not known what the consequence of this accumulation is, but  
authors speculate that MPOi-II would have a slow dissociation from the haem cavity 
leading to inactivation of compound II (Soubhye et al., 2010; Soubhye et al., 2013). 
This inhibitor has not been tested in humans but MPOi-II has been tested in rats. 
Data reported showed that rats administered with 1mg/kg-10mg/kg of MPOi-II did not 
show signs of toxicity nor were changes in morphological features of organs 
observed therefore this compound may be of potential clinical interest (Soubhye et 
al., 2013). 
1.3 Oxidation of TOP2 poisons by MPO 
 
As discussed in section 1.2.5, MPO’s redox intermediate, compound I has a relatively 
high one-electron reduction potential (1.36V) and can catalyse the oxidation of 
organic compounds that subsequently have altered properties (Figure 1.15). For over 
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30 years, studies have been conducted to evaluate the role of MPO in the oxidation 
of TOP2 poisons (mainly etoposide). The MPO-mediated oxidation of TOP2 poisons 
generally occurs via a two-step oxidation reaction leading to metabolites that have 
altered DNA damaging properties compared to the parent compound.  
There is still however speculation whether in vivo MPO directly catalyses the 
oxidation of TOP2 poisons or if this reaction is mediated via small species such as 
nitric oxide (NO2) or tyrosine (Vlasova et al., 2011; Sinha et al., 2013). The reason for 
this speculation is that the active site of MPO (heam group) is buried within a narrow 
crevice measuring approximately 15Å in depth and 10Å in diameter with the main 
substrate access channel of length 20.3Å containing a bottleneck radius of 0.97Å 
which would restrict substrate access (Malle et al., 2007; Grishkovskaya et al., 2017). 
However, in vitro studies show MPO is capable of directly catalysing the oxidation of 
TOP2 poisons (Kagan et al., 1999).  
1.3.1 MPO mediated oxidation of etoposide. 
 
Etoposide can be metabolised to a redox active etoposide quinone (defined by 
carbonyl groups at positions 3’ and 4’ of the E-ring also referred as etoposide ortho-
quinone) by MPO (Haim et al., 1987b; Fan et al., 2006) (Figure 1.20). The MPO 
catalysed reaction begins with the one-electron oxidation of etoposide to a phenoxyl 
radical species releasing a methyl radical. The generated methyl radical can alkylate 
DNA and lead to DNA strand scission (Riordan and Wei, 1994).The phenoxyl radical 
can then either undergo a further one-electron oxidation (by MPO) or 
disproportionate to form etoposide quinone.  
Additionally, etoposide catechol (defined by the replacement of 3’ methoxy group 
with hydroxyl moiety on the E-ring) can be oxidised by MPO to etoposide quinone via 
a two-step oxidation reaction (Figure 1.20). Etoposide catechol is an etoposide 
metabolite found in patient plasma, produced by the action of cytochrome P450 
isoforms CYP3A4 and/or CYP3A5 (Zheng et al., 2004; Zhuo et al., 2004). The 
oxidation of etoposide catechol by MPO produces a semi-quinone intermediate 
releasing superoxide or H2O2. Etoposide semi-quinone can subsequently 
disproportionate to etoposide quinone and to etoposide (Kalyanaraman et al., 1989)  
(Figure 1.20). 
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Figure 1.20 Oxidation of etoposide by MPO.  
In vitro studies report etoposide catechol behaves as a interfacial TOP2 poison 
similar to etoposide but is 2- to 3-fold more potent at inducing TOP2-mediated DNA 
cleavage (Jacob et al., 2013). The reason for the greater potency in TOP2 poisoning 
for etoposide catechol is likely due to additional hydrogen-bond interactions from the 
3’ hydroxyl moiety with the TOP2 protein compared to the 3’ methoxy moiety of 
etoposide (Wu et al., 2011). 
Etoposide quinone is however reported to be a superior TOP2 poison compared to 
both etoposide and etoposide catechol with a greater activity towards TOP2B in vitro 
(Gantchev and Hunting, 1998; Jacob et al., 2011; Jacob et al., 2013; Smith et al., 
2014b). Due to the presence of the ortho-quinone group, etoposide quinone confers 
additional properties of being able to covalently bind to proteins (including TOP2) and 
to DNA (Haim et al., 1987b; Haim et al., 1987a; van Maanen et al., 1988a; Mans et 
al., 1990). In studies conducted in cellulo using MCF-7 cells (breast cancer cell line) 
etoposide quinone was less cytotoxic than etoposide. However, due to etoposide 
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quinone being more polar compared to etoposide, there was reduced cellular uptake 
of etoposide quinone (Sinha et al., 1990).  
Dual mechanism model for etoposide quinone TOP2 targeting 
A recent study has suggested a dual-mechanism model for TOP2 poisoning by 
etoposide quinone in vitro (Gibson et al., 2016). In this model, etoposide quinone has 
been demonstrated to behave both as an interfacial TOP2 poison (as for etoposide 
and etoposide catechol) and as covalent/redox-dependent TOP2 poison- a function 
that is distinct from etoposide and etoposide catechol. However, it is likely that 
etoposide quinone is not constrained to two mechanisms for targeting TOP2 but may 
have additional mechanisms that allow TOP2-mediated DNA damage.  
The first mechanism proposed for etoposide quinone is its ability to act as a 
interfacial TOP2 poison due to its ability to reversibly stabilise TOP2-DNA covalent 
complexes and induce single strand DNA breaks (Gantchev and Hunting, 1998; 
Gibson et al., 2016). This suggests that like etoposide; etoposide quinone can non-
covalently interact with the TOP2-DNA binary complex to disrupt religation of DNA 
requiring one drug molecule to intercalate into each DNA break (similar to the two-
drug model for etoposide) (Lindsey et al., 2014) (see section 1.1.4). 
The unique property of etoposide quinone from its parent compound, is its ability to 
act as a covalent/redox-dependent TOP2 poison, a mechanism similar to 1,4 
benzoquinone (Bender et al., 2007). Etoposide quinone is reported to induce higher 
proportion of DNA DSBs, strongly inhibit DNA religation, inhibit ATP hydrolysis and 
stabilise the N-terminal clamp of TOP2 (Gibson et al., 2016) (see section 1.1.2 and 
1.1.3). As these properties of etoposide quinone are similar to 1,4-benzoquinone, this 
strongly suggests that the presence of ortho-quinone is responsible for the additional 
properties.  
The covalent/redox-dependent poisoning of TOP2 by etoposide quinone can occur 
via two or three possible routes. Firstly, studies have shown residues Cys392 and 
Cys405 situated on the N-terminal domain of TOP2A are important in mediating 
increased DNA cleavage by etoposide quinone and 1,4-benzoquinone compared to 
etoposide. The precise mechanism of the requirement of cysteine’s residues is still 
not clearly defined. However, it is predicted that etoposide quinone covalently binds 
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to cysteine residues via the thiol group that somehow prevent DNA re-ligation (Jacob 
et al., 2011).  
The second route involves closing TOP2’s N-terminal clamp by cross-linking the two 
protomer subunits of TOP2. This also inhibits ATP hydrolysis preventing DNA strand 
passage (Jacob et al., 2013; Gibson et al., 2016). The closing of the N-terminal 
clamp has two consequences, if DNA is bound to TOP2, this would trap the TOP2-
DNA in a non-covalent complex. The subsequent removal of trapped TOP2 from the 
DNA would cause a DNA DSB. However, if etoposide quinone stabilises the N-
terminal clamp prior to DNA binding, this would block the entry of DNA, leading to 
‘inactivation’ of the enzyme (Jacob et al., 2013). Interestingly, the function of blocking 
the N-terminal clamp does not seem to involve cysteine residues despite the cysteine 
residues residing in the N-terminal region of TOP2 (Bender et al., 2007).  
Gibson and colleagues suggest the inhibition of ATP hydrolysis by etoposide quinone 
is due to the stabilisation of the N-terminal clamp but earlier studies predict etoposide 
quinone covalently adducts charged residues (such as the amine group on arginine) 
on the carboxyl terminal of the ATPase domain preventing hydrolysis of ATP. If this 
were the case then this would count for an additional mechanism of covalent 
poisoning by etoposide quinone (Vyas et al., 1992; Gantchev and Hunting, 1998). In 
addition, etoposide quinone can covalently bind to DNA causing DNA damage. 
Moreover the presence of a covalent DNA adduct could potentially block the binding 
of TOP2 to DNA (Haim et al., 1986, Haim et al., 1987).   
1.3.2. Biotransformation of mitoxantrone by MPO  
Direct oxidation of mitoxantrone by MPO  
Mitoxantrone contains a semi-quinone and a quinone moiety in its structure (Figure 
1.21), therefore given the chemical reaction between MPO and etoposide it was 
predicted that MPO would catalyse the oxidation of the semi-quinone moiety on 
mitoxantrone to a quinone, resulting in a di-quinone species. However, in vitro 
analysis of the MPO catalysed oxidation of mitoxantrone by high performance liquid 
chromatography and mass spectroscopy revealed oxidation occurs at the 
phenylenediamine substructure of mitoxantrone (Kolodziejczyk et al., 1988; Blanz et 
al., 1991) (Figure 1.10).  
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The MPO-catalysed oxidation of mitoxantrone yields a naphthoquinoxaline initial 
metabolite which is further oxidised to a metabolite of unknown identity (Panousis et 
al., 1994; Panousis et al., 1997) (Figure 1.21). The peroxidase catalysed reaction to 
naphthoquinoxaline proceeds via two consecutive one-electron oxidations where the 
second electron extraction is likely to be peroxidase independent. The first oxidation 
reactions yields quinone-diimine, a high electrophilic compound that undergoes an 
intramolecular nucleophilic attack to generate the cyclised naphthoquinoxaline 
metabolite. Studies have shown that naphthoquinoxaline can covalently adduct DNA 
but its role in TOP2 poisoning has not been documented (Reszka et al., 1989; 
Panousis et al., 1997).   
 
Figure 1.21. Peroxidase-mediated biotransformation of mitoxantrone. Information used to 
construct figure obtained from Blanz et al., 1991, Mewes et al., 1993 and Bruck and Bruck, 2011. 
 
The peroxidase catalysed oxidation reaction of mitoxantrone to naphthoquinoxaline is 
identical for MPO, cytochrome P450, horseradish peroxidase, lactoperoxidase (LPO) 
and lignin peroxidase, however the product of the subsequent oxidation of 
naphthoquinoxaline is suggested to be dependent on the specific peroxidase 
(Reszka et al., 1986; Mewes et al., 1993; Bruck and Harvey, 2003; Bruck and Bruck, 
2011). Whereas the final oxidation product for the MPO-catalysed oxidation of 
mitoxantrone has not been identified, the chemical structures for the LPO-catalysed 
oxidation of mitoxantrone have been characterised. As LPO shares 51% amino acid 
identity with MPO, it may be the case that both these peroxidases share a similar end 
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product in the oxidation of mitoxantrone. However, in contrast to MPO, LPO is a 
monomeric enzyme and LPO’s redox intermediates have lower redox potentials 
compared to MPO (1.09V vs 1.36V for compound I) (Furtmuller et al., 2003; 
Furtmüller et al., 2006). 
In the presence of LPO, naphthoquinoxaline is oxidised to monocarboxylic 
mitoxantrone (MH2Oa*), which is further oxidised to dicarboxylic acid mitoxantrone 
(MH2O2*) metabolites via the generation of radical intermediates (Bruck and Bruck, 
2011) (Figure 1.21). There are no known published studies conducted to analyse the 
activity and cellular functions of these two carboxylic acids mitoxantrone metabolites.  
Formation of formaldehyde activated mitoxantrone DNA adducts-an indirect 
role of MPO.  
Mitoxantrone can be activated by formaldehyde to form DNA adducts. These 
formaldehyde activated heat liable adducts occur preferentially at CpA and CpG sites 
and adduct formation is enhanced by DNA methylation at CpG sites (Parker et al., 
1999) (Figure 1.22). Formaldehyde reacts with the side chain amino group of 
mitoxantrone to form activated-mitoxantrone which is defined by the presence of a 
Schiff base at a second nitrogen of the mitoxantrone side chain (Parker et al., 2004).  
The Schiff base can undergo a nucleophilic reaction with the exocyclic N2 of guanine 
generating a DNA-adduct in which mitoxantrone is covalently bound to one strand of 
DNA using a covalent methylene linkage and uses hydrogen bonds to interact with 
the opposing DNA strand forming a virtual cross-link (Figure 1.22). It is to be noted 
that the precise chemical reaction between formaldehyde and mitoxantrone has not 
yet been fully established (Evison et al., 2015).  
The consequence of the mitoxantrone-guanine adduct is to impair DNA strand 
separation, blocking the progression of RNA polymerase and resulting in truncated 
RNA transcripts (Parker et al., 2000). Methylation at the CpG sites is predicted to 
prevent the entry of mitoxantrone into the major groove and therefore favour the 
entry of the activated mitoxantrone through the minor groove which positions 
mitoxantrone adjacent to the N2 of guanine facilitating nucleophilic attack (Parker et 
al., 2004).  
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Figure 1.22 Formaldehyde activated mitoxantrone-guanine lesion. Mitoxantrone reacts with 
formaldehyde producing activated mitoxantrone -defined by the presence of an Schiff base at the 
second nitrogen of the amine side chain. The Schiff base is subject to nucleophilic attack by the 
exocyclic N2 amino group of guanine to form a covalent bond. Mitoxantrone therefore covalently links 
to one strand of DNA forming a mono-adduct whilst the second strand of DNA has hydrogen-bonding 
interactions with mitoxantrone to form a virtual cross-link (Fenick et al.,1997). Information to construct 
diagram Parker et at., 1999 and Evison et al., 2015. 
 
MPO could influence the level of formaldehyde-activated mitoxantrone DNA adducts. 
The reason for suggesting this is, MPO catalyses the oxidation of amino acids to 
aldehydes via MPO-H2O2-Cl system to generate HOCl which chlorinates the free 
alpha amino group of amino acids generating a liable mono chloramine which 
decomposes to a aldehyde (Hazen et al., 1998) (Zgliczynski et al., 1968). Generally 
myeloid cells contain high concentrations of formaldehyde and this could potentially 
be an effect of high MPO activity within these cells (Thorndike and Beck, 1977). 
1.3.3 Biotransformation of doxorubicin and epirubicin by MPO  
Direct oxidation of doxorubicin by MPO 
Like mitoxantrone, the anthracycline doxorubicin contains a hydroquinone and 
quinone moiety. Given the MPO-catalysed oxidation pathway of mitoxantrone one 
may predict, that peroxidase oxidation of doxorubicin may occur at a distinct site from 
the hydro-and quinone moieties. It was first speculated that the hydroquinone of 
doxorubicin would be protected from oxidation by the presence of the neighbouring 
electrophilic quinone species. However, experimental studies using the MPO/H2O2 
system showed that oxidation of doxorubicin and a structurally similar, daunorubicin 
occur at the hydroquinone moiety (Figure 1.23).  
MPO catalyses the oxidation of the hydroquinone moiety of doxorubicin yielding a 
semi-quinone species and MPO compound II. Only compound I is capable of the 
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oxidation of doxorubicin (Reszka et al., 2004). The semi-quinone disproportionates to 
the parent compound (reversible oxidation) and to a highly electrophilic di-quinone 
species (irreversible oxidation) (Reszka et al., 2001; Reszka et al., 2005) (Figure. 
1.23A). Nitric oxide (NO2) facilitates the MPO catalysed reaction of doxorubicin by 
two possible mechanisms. The first mechanism involves the role of nitric oxide in 
accelerating MPO’s catalytic turnover. As the oxidation of doxorubicin to the semi-
quinone species results in the formation of MPO compound II which has a lower 
reduction potential and therefore cannot oxidise doxorubicin, therefore nitric oxide 
can react with compound II reducing it back to MPO which can re-enter the catalytic 
cycle and oxidise more molecules of doxorubicin. Alternatively, nitric oxide is oxidised 
to a free radical species (!NO2) by MPO’s compound I or compound II, the free 
radical species can oxidise the hydroquinone moiety of doxorubicin (QH2) to a semi-
quinone species (Q! -) (Figure 1.23 B) (Reszka et al., 2005; Wagner et al., 2007).   
Studies predict doxorubicin di-quinone may further undergo oxidation however no 
oxidation products of the di-quinone have been reported. Such di-quinone species 
can potentially adduct DNA and protein causing oxidative damage to cells. Attempts 
to purify the products of doxorubicin oxidation from cells (HL60 cells-MPO positive) 
have reported doxorubicin di-quinone to degrade into two inactive compounds; 3-
methoxyphthalic acid (3-MePA) and 3-methoxysalicylic acid (3-MeSA). However, 
these degradation products have not been identified from in vitro reactions therefore 
this could suggest that doxorubicin di-quinone degrades during the process of 
purification from cells (Reszka et al., 2001; Reszka et al., 2005; Wagner et al., 2007). 
The degradation products, 3-MePA and 3-MeSA have also been purified from 
cardiomyocytes. The formation of 3-MePA and 3-MeSA was reported to be 
dependent on the pseudo-peroxidase action of myoglobin, however it is still not clear 
how degradation occurs (Cartoni et al., 2004; Menna et al., 2007).  Alternatively, as 
doxorubicin di-quinone is an unstable compound, failure to react quickly with protein 
or DNA (this would reduce the di-quinone to a quinone which is stable) may result in 
degradation of the tetracycline ring.   
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Figure 1.23 Oxidation of doxorubicin by MPO. (A) Reaction showing the formation of doxorubicin-
di-quinone.  MPO compound I catalyses the oxidation of doxorubicin to semi-quinone species that 
further disproportionates to doxorubicin di-quinone. (B) Nitric oxide facilitates the MPO-mediated 
oxidation of doxorubicin by two possible mechanisms. Information used to construct diagram obtained 
from Reszka et al., 2001, Resezka et al., 2005 and Wagner et al., 2007. 
 
Formation of doxoform and epiform. 
As previously stated MPO can catalyse the oxidation of amino acids to form active 
aldehydes via the formation of HOCl. Formaldehyde can react with either doxorubicin 
or epirubicin to form doxoform or epiform that covalently link to the guanine base of 
DNA. The reaction of either doxorubicin or epirubicin results in the conjugation of two 
drug molecules joined to each other via a methylene group(s) resulting in doxoform 
or epiform (Figure 1.24) (Fenick et al., 1997; Taatjes et al., 1998). Interestingly the 
corresponding drug-formaldehyde conjugate for doxorubicin and epirubicin differ in 
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structure, this is perhaps surprising as epirubicin differs from doxorubicin only at the 
position of the 4’ alcohol group on daunosamine (sugar) moiety.  
 
Figure 1.24 Chemical structures of formaldehyde activated doxorubicin and epirubicin. 
Chemical structure information obtained from Post et al., 2005, Fenick et al., 1997 and Taatjes et al., 
1998. 
 
Doxoform (bis(3’-N-3’-N,4’-O-methylenedoxorubicinyl)methane is characterised by 
two parent molecules bound by a single methylene group (Fenick et al., 1997; Post et 
al., 2005). Whereas epiform consists of two parent molecules attached via three 
methylene groups in a 1,6-diaza-4,9-dioxabicyclo[4.4.1]undecane ring system 
(Taatjes et al., 1998). However, epiform and doxoform cannot conjugate with DNA 
until hydrolysis occurs to form the monomeric forms of the formaldehyde conjugates. 
The resulting DNA adduct for the monomeric activated epiform and doxoform are 
identical in structure and have been confirmed using X-ray crystallography (dauo-
form-DNA adduct PDB ID 1D33, 2D34) and NMR. The DNA adduct is identified to 
occur at the exocylic N2 amino of guanine via a single covalent bond (N-C-N) from 
the 3’ amino of daunosamine with the central carbon derived from formaldehyde 
(Wang et al., 1991; Kato et al., 2000; Cutts et al., 2005) (Figure. 1.25). The opposing 
DNA strand has hydrogen-bonding interactions with the drug molecule therefore the 
doxoform-DNA adducts are classified as a virtual cross-link and occur at the minor 
groove. A similar feature of the formaldehyde-activated drug conjugates is that they 
occur with the exocylic N2 amino of guanine and are hydrolytically unstable due to 
the formation of a virtual cross-link. The term virtual cross-link has been used to 
describe the linkage as a covalent bond is made to one DNA strand only whereas the 
interactions made with the neighbouring strand are weak hydrogen bonding 
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interactions (Fenick et al., 1997). Despite the doxoform and epiform- DNA adducts 
being relatively weak in strength both doxoform and epiform are reported to be more 
cytotoxic than their respective parent molecules (Fenick et al., 1997; Taatjes et al., 
1998; Kato et al., 2000).  
 
Figure 1.25 Doxoform-DNA adduct. Formaldehyde reacts with doxorubicin to form doxoform (Figure. 
1.13) consisting of two doxorubicin molecules attached by a methylene group. At neutral pH, doxoform 
or epiform hydrolyse to generate monomeric and dimeric forms of doxorubicin- or epirubicin-
formaldehyde conjugates that can adduct DNA in the minor groove. The DNA adduct has been 
characterised by X-ray crystallography and NMR and is identical for doxorubicin, dauorubicin and 
epirubicin. The Doxoform-DNA adduct is characterised by covalent methylene bridge (red) between 
the N3’ of daunosamine (black) and N2 of guanine (blue). Information to construct diagram obtained 
from Cutts et al., 2005. 
 
1.4 Glutathione  
 
Glutathione is a tri-peptide (L-γ-glutamyl-L-cysteinyl-glycine) that has multiple 
important functions in living organisms including protection from foreign compounds 
containing electrophilic sites (Habig et al., 1974). Glutathione is present at high 
concentrations in cells ranging from 0.5mM to 10mM and is distributed in the 
cytoplasm, ER, nucleus and mitochondria (Lushchak, 2012).    
1.4.1 Biosynthesis of glutathione  
 
The biosynthesis of glutathione requires two enzymes; glutamate cysteine ligase (EC 
6.3.2.2) (γ-glutamylcysteine synthase) and glutathione synthase (EC 6.3.2.3). Both 
catalytic steps are dependent on ATP and magnesium (Deponte, 2013). The first 
step in glutathione biosynthesis is catalysed by glutamate cysteine ligase to generate 
a peptide bond between the γ-carboxyl of glutamate and the amino group of cysteine 
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to generate L-γ-glutamyl-L-cysteine (Snoke et al., 1953) (Figure 1.26A). This first 
enzymatic step proceeds via the generation of a phosphorylated glutamate 
intermediate termed γ-glutamylphosphate, which undergoes a nucleophilic attack by 
cysteine producing L-γ-glutamyl-L-cysteine. Following this glutathione synthase 
catalyses the condensation of the dipeptide, L-γ-glutamyl-L-cysteine with glycine to 
form glutathione (Figure 1.26A) (Minnich et al., 1971). The arrangement of the 
glutathione tripeptide protects glutathione from cleavage by common peptidases and 
by γ-glutamyl cyclotransferase restricting cleavage by hydrolases specific for 
glutathione such as γ-glutamyltransferase (E.C 2.3.2.2) (Figure 1.26B) (Lushchak, 
2012). 
 
Figure 1.26 Glutathione biosynthesis chemical equation (A) and the chemical structure of 
glutathione (B). (A) Glutathione is synthesised using two enzymes the first reaction is catalysed by 
glutamate cysteine ligase to generate L-γ-glutamyl-L-cysteine. L-γ-glutamyl-L-cysteine is then 
combined with glycine by glutathione synthase to form glutathione (GSH). (B) The N-terminal 
glutamate is linked to cysteine via a γ-carboxyl group of glutamate; this arrangement of glutathione 
protects cleavage by common peptidases resulting in a relatively stable compound. Information used 
to construct this figure was derived from (Minnich et al., 1971; Lushchak, 2012). 
 
1.4.2 Inhibition by glutathione synthesis by buthionine sulfoximine (BSO)  
 
BSO is a mechanistic-based inhibitor of glutamate cysteine ligase, this enzyme is 
involved in the first step of glutathione synthesis (section 1.4.1 and Figure 1.26A). 
BSO has been characterised as the most potent inhibitor of glutathione (Griffith and 
Meister, 1979; Griffith, 1982) (Figure 1.27). BSO works by binding to the active site of 
glutamate cysteine ligase and is phosphorylated by an ATP/Mg2+ dependent reaction 
forming a transition state analogue (similar to the attack by cysteine on the 
phosphorylated glutamate intermediate) (Griffith et al., 1979; Biterova and Barycki, 
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2010). Phosphorylated BSO binds tightly to the active site occupying both the 
glutamate and cysteine binding sites and has a slow dissociation constant making it a 
successful inhibitor for glutathione synthesis and for use in the treatment of 
neuroblastoma to reduce glutathione mediated drug resistance (Clinical Trial ID 
NCT00005835) (Villablanca et al., 2016). 
 
Figure 1.27 Chemical structure of BSO. (Information used to construct this figure was obtained from 
PubChem CID 2115 
 
1.5 The effect of glutathione on MPO-mediated oxidation of TOP2 poisons and 
formaldehyde. 
 
Metabolites generated by the MPO-mediated oxidation of etoposide, mitoxantrone, 
doxorubicin or epirubicin can be rendered inactive by the conjugation with 
glutathione. Glutathione reacts with electrophilic sites via the action of glutathione-S-
transferase or by spontaneously to form glutathione adducts, ultimately resulting in 
the excretion of the metabolite (Habig et al., 1974). Therefore, glutathione may play a 
major role in protecting cells from the effects of TOP2 poison metabolites generated 
by MPO. 
1.5.1 Etoposide  
 
As described in section 1.4.1, MPO can catalyse the one-electron oxidation of 
etoposide to a phenoxyl radical, which can further oxidise to etoposide quinone 
(Figure 1.20). In the presence of glutathione, the formation of etoposide quinone is 
reduced using two mechanisms. In the first mechanism, glutathione can reduce 
etoposide phenoxyl radical back to etoposide releasing a glutathione thiyl radical 
(Figure 1.28). Studies conducted in vitro using electron paramagnetic resonance had 
observed a lag-phase in the production of etoposide phenoxyl radical in the 
MPO/H2O2/etoposide system that diminished once glutathione was titrated out 
(Kagan et al., 1994; Kagan et al., 1999).  
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Secondly, glutathione can conjugate with etoposide quinone or etoposide semi-
quinone (reaction intermediate in etoposide catechol oxidation) producing etoposide-
OH-6’-SG (major product) and/or etoposide-OH-2’-SG (minor product) (Figure 1.28) 
(Zheng et al., 2006). The presence of etoposide-OH-6’-SG has been confirmed in 
HL60 cells (MPO positive cells) treated with etoposide and was shown to be 
dependent on MPO activity (Fan et al., 2006). It is predicted that etoposide-OH-6’-SG 
is further modified by the cleavage of the terminal glutamate and glycine residues of 
glutathione followed by the acetylation to produce an N-acetylcysteine conjugate 
(etoposide-OH-6’-NAc-Cys) via mercapturic acid biosynthesis allowing the excretion 
of etoposide quinone (Hinchman et al., 1991; Zheng et al., 2006) (Figure 1.28). Due 
to this detoxification pathway by glutathione it is hypothesised that MPO-mediated 
oxidation of etoposide to etoposide quinone may occur at a higher efficiency in the 
nucleus as the etoposide quinone will be in closer proximity to DNA and the chances 
of conjugation with nuclear glutathione may be reduced (Murao et al., 1988).  
 Figure 1.28 Oxidation pathway of etoposide and formation of glutathione conjugates. 
Information used to construct this diagram and numbering of the glutatathione conjuagtion sites was 
obtained from Zheng et al., 2006.  
1.5.2 Mitoxantrone 
The oxidation of mitoxantrone to naphthoquinoxaline involves the formation of an 
electrophilic quinone-diimine intermediate (Figure 1.21). Quinone-diimine is subject 
to conjugation with glutathione preventing completion of the peroxidase-mediated 
reaction. Studies had first confirmed the presence quinone-diimine glutathione 
conjugate using tandem mass spectrometry (MS/MS) but were not able to deduce 
the positioning of the glutathione conjugation and predicted the conjugation occurred 
at the phenylenediamine substructure (Blanz et al., 1991). Later studies deduced that 
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glutathione conjugates at the hydroquinone moiety, but conjugation only occurs in the 
presence of the peroxidase/H2O2 (Mewes et al., 1993) however no further published 
studies have confirmed this. Although the consequence of the conjugation was not 
stated, it is likely that the glutathione-mitoxantrone conjugate undergoes a similar 
process to that described for etoposide quinone by the formation of N-acetylcysteine 
conjugates described in section 1.6.1. 
 
1.5.3 Doxorubicin  
 
MPO and other peroxidases (lactoperoxidase) can oxidise the hydroquinone moiety 
of doxorubicin to a quinone forming doxorubicin di-quinone - a highly electrophilic 
compound (Figure 1.23). In the presence of glutathione a rapid decline in the 
peroxidase-mediated oxidation of daunorubicin (structurally similar to doxorubicin) is 
observed and the drug is reported to largely remain unchanged (i.e. no detection of 
di-quinone species). This suggests that glutathione prevents the formation the di-
quinone species, but perhaps not by conjugation. This may either occur via a 
reduction reaction of the semi-quinone species back to daunorubicin releasing a thiyl 
radical, a mechanism similar to the reduction of the etoposide phenoxyl radical to 
etoposide. However, glutathione can directly conjugate with doxorubicin and this may 
potentially protect doxorubicin from peroxidase-mediated oxidation (Askura et al 
;1997).  
1.5.4 Formaldehyde 
 
Formaldehyde is potentially dangerous to cells and metabolism using glutathione is a 
key response to effectively detoxify excess cellular generated formaldehyde.  
Increased formaldehyde levels have been reported in neurodegenerative diseases 
such as multiple sclerosis (MS) in which mitoxantrone is used as a single agent 
(Tulpule and Dringen, 2013). Therefore it is likely that treatment with mitoxantrone in 
MS may lead to higher levels of formaldehyde-activated mitoxantrone. As previously 
described in sections 1.4.2 and 1.4.3 formaldehyde can activate mitoxantrone, 
doxorubicin and epirubicin to species that form virtual cross-links with DNA (Figure 
1.22, 1.24 and 1.25).  
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Glutathione can spontaneously react with formaldehyde via its nucleophilic thiol 
group to form glutathione-formaldehyde conjugates. In humans the major conjugation 
product is S-(hydroxymethyl)glutathione which is further oxidised by alcohol 
dehydrogenase 5 and then hydrolysed to formate releasing glutathione (Hopkinson et 
al., 2010). Studies have reported the formation of S-(hydroxymethyl)glutathione could 
possibly be facilitated enzymatically, but no such enzymes have been identified in 
humans (Goenrich et al., 2002; Hopkinson et al., 2015) (Figure. 1.29). However more 
recent studies have reported addition products of the initial conjugation of glutathione 
with formaldehyde resulting in formation of cyclic conjugates with one of these 
products, BiGF2 (5R,10S)-5- (carboxymethylcarbamoyl) -7-oxo-3 - thia- 1,6- 
diazabicylo[4.4.1] undecane-10-carboxylic acid) being observed bound to human 
Carbonyl Reductase I (Bateman et al., 2007; Hopkinson et al., 2010) (Figure. 1.29).   
 
Figure 1.29 Products of the formaldehyde-glutathione conjugation reaction. Structure 
information taken from Hopkinson et al., 2010. Full chemical name of MGF (4S,9R)-9-
(carboxymethylcarbamoyl)- 7-oxo-1,3,8-thiadiazecane-4-carboxylic acid and PGF (S)-1-(((R)-2-amino-
3-(carboxymethylamino)-3- oxopropylthio)methyl)-5-oxopyrrolidine-2-carboxylic acid.   
1.6 Development of therapy related leukaemia following TOP2 poison treatment 
 
TOP2 poisons are effective anti-neoplastic agents used to treat a wide range of 
malignancies (Table 1), however a serious long-term side effect to TOP2 poison 
therapy is the risk of developing therapy related acute myeloid leukaemia (t-AML). 
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The development of t-AML is a serious complication following primary treatment for a 
wide range of neoplasias and is often associated with a poor prognosis especially in 
patients above the age of fifty (Santo et al., 2016). It is estimated that up to 15% of 
reported AML cases are t-AML with ~70% of reported t-AMLs arising from prior 
therapy of solid cancers with breast cancer being the highest frequency. 
Haematological malignancies account for ~28% cases with Non-Hodgkin lymphoma 
accounting for the highest incidence (Block et al., 2002; Huret, 2004). However, as 
survival rates improve and life expectancy following treatment of the primary cancer 
increases, the incidence of t-AML could potentially rise. Therefore, the understanding 
of how t-AML arises is crucial. 
The development of t-AML or therapy related acute promyelocytic leukaemia (t-APL) 
following TOP2 poison exposure has a mean latency period of 1 to 3 years (Leone et 
al., 2010; Cowell and Austin, 2012). TOP2 poison associated t-AML frequently 
involves chromosome translocations occurring at the MLL (KMT2A) gene at 11q23 
with partners AF9/MLLT3 (9q22), AF4/AFF1 (4q21) and less frequently with other 
translocations partners (66 partners reported). Other recurrent translocations include 
t(15,17)(PML-RARA), t(8,21)(RUNX1-RUNX1T1/ETO), and inv(16)(p13;q22)(CBFB-
MYH11). Alkylating agent therapy (cyclophosphamide, melphalan and procarbazine) 
and antimetabolite therapy (azathioprine, fludarabine, 6-thioguanine) are also 
associated with the risk of developing t-AML but are characterised by chromosome 
deletions, particularly involving chromosome 5 and/or 7 (Leone et al., 2007; Leone et 
al., 2010). Therefore, a model of t-AML arising from TOP2 poison exposure involves 
the illegitimate recombination between DNA repair intermediates, resulting in 
leukaemogenic chromosome translocations, blocking differentiation of progenitor 
hematopoietic cells.  
MLL locus 
 
The Mixed linage leukaemia (MLL) gene is located on chromosome 11q23.3 and is 
frequently associated with etoposide related t-AML, it is estimated that 5-10% of MLL 
associated leukaemia’s are therapy related (Leone 2010). In addition, mitoxantrone, 
epirubicin and doxorubicin therapies are also associated with MLL translocations  
(Anderson 2001 and Ng 2005).   
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In the non-leukaemia state, the MLL protein forms a multicomponent complex 
(consisting of more than 30 proteins) to regulate transcription of a number of genes 
involved in haematopoiesis through the induction of chromatin modifications and 
remodeling (Slany, 2009; Yip and So, 2013).  To date, 66 translocation partners for 
MLL have been reported with 85 recurrent translocations (information obtained from 
http://atlasgeneticsoncology.org/Genes/MLLID13.html). The resulting translocations 
disrupt hematopoietic gene regulation (Slany, 2009).  
MLL translocation breakpoints identified in acute leukaemia cases occur in a 8.3Kb 
region located between exons 5 and 12 (Super et al., 1993). Breaks in this region for 
t-AML and neonatal leukaemia are clustered towards the telomeric 1Kb end (also 
known as SCII) of this region whereas in de novo leukaemia the breakpoints tend to 
cluster within the centromeric region (SCI) of the breakpoint cluster (bcr) (Cowell and 
Austin 2012) (Figure 1.30). The telomeric subcluster contains a DNAseI 
hypersensitive region colocalising with CTCF binding and is also reported to possess 
cryptic promoter activity (Scharf et al., 2006; Cowell et al., 2012).  Furthermore, in 
vitro studies showed that etoposide quinone, a metabolite generated by the MPO 
mediated oxidation of etoposide, induces strong heat stable cleavage at the MLL 
locus (study conducted outside of hotspot region for t-AML). (Lovett et al., 2001a; 
Lovett et al., 2001b). This suggests a role of peroxidase-mediated oxidation of TOP2 
poisons to reactive metabolites that may have increased potential of causing DNA 
damage (see section 1.1.4).  
 
Figure 1.30 MLL breakpoint cluster region. Exons are shown as boxes and intron regions are black 
lines. Information used to construct diagram obtained from Cowell and Austin 2012.  
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PML/RARA 
The PML/RARA (t15;17)(q24;21) translocation is a hallmark of t-APL (a sub-type of t-
AML). The resultant fusion protein suppresses transcription of retinoic acid regulated 
genes resulting in a block to myeloid differentiation. The PML/RARA translocation is 
commonly found in patients who have previously received mitoxantrone, doxorubicin 
or epirubicin therapy and less commonly with etoposide. Three APL-associated 
BCRs have been identified, and t-APL breakpoints cluster in BCR 1 (Fig 1.31). An 
8bp region within intron 6 (bcr 1) is a strong site for mitoxantrone-mediated cleavage 
in vitro but not for epirubicin and is a preferred site for mitoxantrone-induced 
translocation breakpoints (Mistry et al., 2005; Hasan et al., 2008; Hasan et al., 2010; 
Mays et al., 2010). Additionally doxorubicin and etoposide induce cleavage at all 
breakpoint cluster sites as well as etoposide quinone (Mistry et al., 2005).  
 
Figure 1.31 PML and RARA breakpoint regions. Information used to construct diagram obtained 
from Hasan et al., 2010. 
 
For the RARA the majority of breakpoint clusters are located intron 2 with high 
clustering of drug (mitoxantrone, doxorubicin, epirubicin and etoposide) induced 
TOP2 mediated cleavage at two main regions, which are breakpoint cluster 1 
(nucleotide positions 6000-9800) and breakpoint cluster 2 (nucleotide positions 
11500 to 15600) (Figure 1.31). However, etoposide quinone induces heat stable 
TOP2 mediated cleavage at bcr2 of RARA locus with cleavage centred at nucleotide 
16089 (Mistry et al., 2005). Further suggesting that peroxidase-mediated oxidation of 
TOP2 poisons may play a role in TOP2 poison development of t-AML. 
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TOP2B transcription and the mechanism of TOP2 poison induced 
chromosomal translocations 
 
TOP2 poisons effectively stabilise TOP2-DNA complexes for both TOP2A and 
TOP2B, however recent studies provide evidence for a greater role for TOP2B in 
TOP2 poison mediated genotoxicity. The current understanding is that TOP2B may 
induce DNA breaks in genes during the process of transcription which can be 
stabilised by TOP2 poisons such as etoposide (see section 1.1.1).  However, for a 
translocation to occur breaks must be stabilised in different chromosome segments 
that are in sufficiently close proximity for erroneous repair to occur.  
Studies conducted in cell lines using RNA-FISH have shown that 2-3% of actively 
transcribing MLL genes are in close proximity or overlapping with common 
translocations partners AF4, AF9 and 4-6% of transcribing MLL transcripts were 
within a 1µm distance to either AF4 or AF9 (Cowell et al., 2012). This was also 
shown to be true for RUNX1 and its translocation partner RUNX1T1 (using DNA-
FISH), (Smith et al., 2014a). Additionally the frequency of this close proximity 
between observed between RUNX1 and its partner gene was partly TOP2B 
dependent. Taken together these studies suggest a role of TOP2B in mediating 
TOP2 poison associated t-AML. 
Despite the risk associated with TOP2 poison therapy, these drugs are central to the 
treatment for a wide range of adult and paediatric cancers and hematologic 
malignancies and to some extent for multiple sclerosis. Therefore, interventions to 
protect developing hematopoietic progenitors from genotoxic damage caused by 
TOP2 poison would be of clinical benefit. MPO expression is restricted to myeloid 
cells and is capable of mediating the biotransformation of TOP2 poisons to potentially 
more genotoxic compounds. The inhibition of MPO could potentially reduce excess 
DNA damage in myeloid precursors reducing the chances of t-AML.  
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Aims 
 
The aim of the work presented is to: 
• To investigate the role of MPO expression in TOP2 poison induced TOP2-
DNA covalent complex stabilisation and γH2Ax (marker for DNA damage) 
formation 
• To investigate the combined effect of glutathione depletion and MPO inhibition 
TOP2 poison induced DNA damage   
• To test the whether anthracycline and mitoxantrone behave as TOP2 catalytic 
inhibitors  
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Chapter 2. Materials and Methods 
 
2.1 Drugs and Chemicals 
 
All chemicals and reagents were purchased from Sigma-Aldrich (Dorset, UK) unless 
otherwise specified. All tissue culture plasticware was purchased from Greiner bio-
one (Gloucestershire, UK) unless otherwise stated.  
2.1.1. Preparation of drugs and chemicals 
 
Doxorubicin, epirubicin and mitoxantrone were dissolved in dH2O to a stock 
concentration of 25mM, 5mM and 10mM respectively. Etoposide was dissolved in 
filter sterilised DMSO to a concentration of 10mM. All prepared drug stocks were 
stored in small aliquots at -20oC. 
Etoposide quinone and etoposide catechol were either synthesised by (i) Caymen 
Chemicals (Michigan, USA) or (ii) by Angelica Mariani in Dr. Raphael Rodriguez 
Laboratory (Toldo et al.) (see Appendix Figures i-iii for data on compounds 
synthesised by A.Mariani). The source of etoposide quinone and catechol used to 
conduct each experiment are specified in the figure legends. On the day of the 
experiment, etoposide quinone or catechol were prepared in filter sterilised DMSO to 
a concentration of 10mM and used on the day of preparation.  
Succinylacetone (SA) (4,6-Dioxoheptanoic acid) and DL-Buthionine sulfoximine 
(BSO) were prepared to 100mM in dH2O and stored in small aliquots at -20oC.  
The MPO inhibitors; PF1355 and MPOi-II (Merck-Millipore, Watford, UK) were 
dissolved in filter sterilised DMSO to a concentration of 5mM and 10mM respectively 
and stored at  -20oC in small aliquots.  
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2.2. Cell culture 
 
Cells were cultured at 37oC in a humidified atmosphere containing 5% CO2. Cell 
culture was performed under aseptic conditions in BIOAIR Safe Flow 1.2 hoods.  
2.2.1 Cell lines 
 
HL60 cell line (DSMZ no. ACC-3): a neutrophilic promyelocyte AML cell line that 
harbours the MYC gene amplification derived from a 35-year-old female (Gallagher 
et al., 2005). 
K562 cell line (ATCC CCL-243):  a CML cell line derived from a 53-year-old female 
and is characterised by having a Philadelphia (Ph1) chromosome (Lozzio and Lozzio, 
1975).  
Kasumi-1 cell line (ATCC CRL-2724; kindly provided by Dr. Olaf Heidenreich, 
Northern Institute for Cancer Research, UK): an AML cell line containing the t(8;21) 
fusion gene, derived from a 7 year old male patient (Asou et al., 1991). 
KG1 cell line (ATCC CCL-246): were derived from a 59-year-old male whom had 
developed AML following erythroleukaemia (Koeffler and Golder, 1978).  
NB4 cell line (DSMZ no. ACC-207): an APL cell line derived from a 23-year-old 
female whom had a second relapse and contains the t(15:17) PML-RARA fusion 
gene (Lanotte et al., 1991).  
The table shown below has the full set of chromosomal aberrations identified in each 
cell line (Table 2.1).  
 
 
 
 
 
 
  
 
62 
Cell line Primary aberration  Full set of aberrations identified  
HL60 amp (8)(q24) del(1)(p31p13),del(4)(q25),del(5)(q21), 
    del(7)(q35q36),amp(8)(q24),-9p, 
    del(10)(p14p11),del(11)(q13),del(12)(q13), 
    del(12)(q14.1),del(12)(q14.3),-17p, 
K562  t(9;22)(q34;11) del(3)(q27),del(9)(p21),amp(9)(q34), 
    del(18)(p11q21),gain(22)(q11) 
Kasumi-1  t(8;21)(q22;22) amp(4)(q12),gain(7)(q22qter),gain(8)(q24), 
    del(9)(p24p21),gain(10)(q21),gain(10)(q24), 
    del(13)(q14),del(16)(p13p11),del(17)(p13) 
KG1  
  
  
  
del(1)(p31p13),del(5)(q21),del(7)(q34q36), 
del(8)(p22),+8(p11q11),-12,-17p,del(18)(q21) 
NB4  t(15;17)(q22;q11–12.1) 1,+2,-3,-5q,+7,amp(8)(q24),gain(9)(p24p22), 
    amp(9)(p24),del(9)(p21),+10q,gain(11)(q22qter), 
    +12,amp(12)(p12),gain(13)(q14),del(17)(p13), 
    amp(19)(p13),amp(19)(q13),+20 
   
 
Table 2.1. Cell line karyotype. Table information obtained from (Rucker et al., 2006). 
Abbreviations used in table amp= amplification, del=deletion. 
2.2.2 Cell culture  
 
K562, Kasumi-1 and NB4 cell lines were maintained in RPMI 1640 medium 
supplemented with 10%(v/v) Fetal Bovine Serum (FBS) and 1%(v/v) penicillin and 
streptomycin (Thermo Fisher Scientific, Massachusetts, USA). The K562 derived 
MPO expressing cells were maintained as per K562 cells with the addition of 750 
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µg/mL or 500µg/mL G418 selection antibiotic. The HL60 cells were cultured as K562 
and NB4 cells but the cell medium was supplemented with 15% (v/v) FBS.  
KG1 cells were maintained in IDMEM medium supplemented with 20% (v/v) FBS and 
1% (v/v) penicillin and streptomycin (Thermo Fisher Scientific, Massachusetts, USA). 
For routine subculture, cells were grown to 1x106 cells/mL and diluted 1:5-10 in fresh 
medium every 2-3 days.  
Cells were cultured for up to 35 passages after which a fresh low passage cell stock 
was removed from the liquid nitrogen stores. 
2.2.3 Cryopreservation of cell lines 
 
Exponentially growing cells were pelleted by centrifugation at 1000xg for 5 minutes 
(Harrier 15/80 MSE). Cell pellets were re-suspended in half the final volume of the 
appropriate pre-warmed medium, to this an equal volume of medium containing 20% 
of DMSO (sterile filtered through 0.2µm filter) was added and mixed. The cell 
suspension was transferred to a 1.5mL labelled cryogenic vial. The vials were placed 
in a polystyrene box at -80oC for 24 hours, for gradual freezing, after which the vials 
were transferred to liquid nitrogen for long term storage.  
To recover cells, vials were rapidly thawed at 37oC and pelleted by centrifugation at 
1000xg for 5 minutes. Pelleted cells were re-suspended in 5mL of the appropriate 
complete growth medium and cultured appropriately. 
 2.2.4 Cell counting  
 
All cell counts were performed using the TC20 automated cell counter (Bio-Rad, UK) 
by placing 10µL of cell suspension into the cell counting slides provided (Bio-Rad, 
UK). To assess the cell viability, the cell suspension was mixed with trypan blue 
solution in a 1:1 ratio and counted using the cell counter.   
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2.3. Whole cell extract preparation for SDS-PAGE  
 
This method for the preparation of whole cell extracts was derived from Mirski et al; 
1993 and is described below. 
Cells were pelleted and washed in ice-cold PBS at 1000xg for 5 minutes. Pelleted 
cells were re-suspended in 4 pellet volumes of ice-cold extraction buffer (10mg/mL 
MgCl2, 50mM Tris-HCl, pH 7.4, 4mM DTT, 0.05% of protease inhibitor cocktail 
(Melford, Suffolk, UK)). To this suspension, SDS was added to 0.25% v/v and mixed. 
Then, DNase I was added to the mixture at a concentration of 50µg/mL and 
incubated on ice for 10 to 30 minutes, until the suspension was no longer viscous. 
Then an equal volume of solubilisation buffer (2% SDS, 20% glycerol, 5% β- 
mercaptoethanol, 0.6M Tris-HCl, pH 7.2) was added to the suspension and heated at 
68oC for 10 minutes (Stuart Scientific test tube heater SHT 2D). Samples were 
allowed to cool down prior to protein estimation or stored in aliquots at -80oC.  
2.3.1 Estimation of protein concentration  
 
The protein concentration of the prepared WCE was estimated using the Bradford 
assay in 96 well plates alongside a dH2O blank. Protein samples were serially diluted 
1:2 in dH2O across the plate. Bovine serum albumin (BSA) was used as the 
standard, this was firstly diluted 1:2 in solubilisation buffer (used to prepare WCE) 
and then serially diluted to a concentration ranging from 2mg/mL to 0.125mg/mL. To 
all wells an equal volume of Quick Start Bradford 1x Dye reagent (Bio-Rad, UK) was 
mixed and incubated for 10 minutes at room temperature. Absorbance readings were 
measured at 595nm using the Bio-Rad Microplate reader 550. The background value 
from dH2O blank was subtracted from all the readings obtained. A BSA standard 
curve of the background corrected absorbance at 595nm vs protein concentration 
(mg/mL) was plotted and the linear region of the curve was used to estimate the 
protein concentration of samples tested.  
2.4. SDS poly-acrylamide gel electrophoresis  
 
Protein samples (preparation stated in section 2.3) were mixed with 5x SDS loading 
buffer (30% Glycerol, 30% TRIS, 10% SDS; NuSep, Germany) and heated at 72oC 
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for 4 minutes (Stuart Scientific test tube heater SHT 2D). Samples were resolved on 
precast 4-20% SDS-polyacrylamide gels (NuSep, Germany) at 100V for 1 hour 
(Consort BIOBLOCK E455) using 1x Tris-HEPES running buffer supplied (60% 
HEPES, 35% TRIS, 5% SDS). Novex pre-stained markers (Thermo Fischer 
Scientific, UK) or WesternSure pre-stained chemiluminescent (Li-Cor, Cambridge, 
UK) protein ladders were used to determine the molecular weight of the protein 
bands. 
2.5 Western blotting 
 
After electrophoresis, SDS-polyacrylamide gels were transferred onto a nitrocellulose 
membrane (45µM, Hybond ECL, GE healthcare, UK) surrounded by filter paper and 
fibre pads. Western transfer was conducted in a cooled transfer chamber at 100V for 
1hour using cold western transfer buffer (25mM Tris, 192mM glycine, 20% v/v 
methanol). The membrane was then blocked in blocking buffer (5% w/v non-fat milk 
powder in Tris-buffered saline (TBS prepared using 20mM Tris-HCL pH 7.5 and 
150mM NaCl) and 0.1% Tween 20 (TBS-T)) at room temperature for 1 hour. 
Membranes were then incubated with the desired primary antibody diluted at 1:2000 
(unless otherwise stated, see table 2.2) in blocking buffer for 1 hour at room 
temperature. Membranes were washed using TBS-T firstly for 15 minutes and then 
twice for 5 minutes, followed by the incubation with the secondary antibody diluted 
1:20000 for 1 hour (anti-mouse horseradish peroxidase or anti-rabbit IgG horseradish 
peroxidase, GE healthcare). TBS-T washes were repeated as described above. 
The membrane peroxidase activity was detected using the Clarity Western ECL 
substrate (Bio-Rad, UK). ECL reagents were mixed in a 1:1 ratio and membranes 
were covered in the prepared ECL solution for 3 minutes, excess ECL solution was 
removed before conducting detection. Protein band detection was conducted by 
autoradiography in a dark room using Amersham Hyperfilm ECL film (GE healthcare) 
and processed using a Konica SRX-101A X-ray film developer or a C-Digit blot 
scanner (Li-Cor, UK).  
When necessary, membranes were stripped using mild stripping conditions and re-
probed with the desired antibody. For this membranes were washed with TBS-T for 
15 minutes and immersed in Restore Western Blot Stripping Buffer (Thermo Fisher 
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Scientific, Massachusetts, USA) for 15 minutes at room temperature. TBST washes 
were repeated and the membrane was blocked in blocking buffer for 1 hour before 
re-probing. 
 
Antibody  Catalogue 
number  
Host  Raised to  Supplier Antibody 
dilution used 
in western 
blotting   
Anti-
TOP2A  
4566 Rabbit 
(polyclonal)  
Full CTD Human 
TOP2A-GST fusion 
(residues 1244-1531) 
In house 1:2000 
Anti-
TOP2B  
4555 Rabbit 
(polyclonal) 
Full CTD Human 
TOP2B-GST fusion 
(residues 1263-1621) 
In house 1:2000 
Anti-β-
actin  
ab3280 Mouse 
(monoclonal) 
Humanactin (residues 
1-100) 
Abcam, UK 1:2000 
Anti-
MPO  
ab134132 Rabbit 
(monoclonal) 
Recognises both MPO 
(85-90kDa) and heavy 
chain (60kDa) 
Abcam, UK 1:2000 
Anti-
MPO 
Ab109116 Rabbit 
(polyclonal) 
Recognises both MPO 
(85-90kDa) and a 
possible cleavage 
fragment of the light 
chain (15kDa) 
Abcam, UK 1:2000 
Anti-
MPO 
P733 Rabbit 
(monoclonal) 
Recognises both MPO 
(85-90kDa) and heavy 
chain (60kDa) 
Cell Signaling 
Technology, 
UK  
1:1000 
Anti-
MPO 
07-496 Rabbit 
(polyclonal) 
Recognises both MPO 
(85-90kDa) and heavy 
chain (60kDa) 
Merck 
Millipore, UK 
1:1000 
 
Table 2.2. List of antibodies used for Western Blotting.
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2.5.1 Western Quantification  
  
Films that were processed using autoradiography were scanned and band intensities 
were quantified by densitometry using Image Lab Version 5.2.1 (Bio-Rad). 
Membranes that had been scanned using Li-Cor were quantified using Image Studio 
5.0 (Li-Cor). Band intensities were used to estimate the relative protein levels in cells.  
2.6 siRNA knockdown  
 
Cells were cultured in large T175 flasks to 50% confluency. The required cell density 
was adjusted by centrifugation at 1000xg for 5 minutes and re-suspended in the 
appropriate pre-warmed medium. To the electroporation cuvette (gap 4mm, 
Eurogentec, Belgium) 300µL of cell suspension (cell density 2.5 to 5.0 x 107 cells/mL) 
was added with the required concentration of siRNA (300nM to 1.0µM). 
Electroporation was performed at 330mV, 10mS pulse using a Fischer EPI2500 
electroporator. Electroporated cells were incubated at room temperature for 15 
minutes before transferring cells to small T25 cell culture flasks. Mock control siRNA 
transfection was performed for all experiments using the ON-TARGETplus Non-
targeting pool of siRNA (Thermo Fisher, catalogue number D-001810-10-20) used at 
an equivalent concentration to the target siRNA (target siRNA listed in Table 2.3). 
The control siRNA consists of four siRNAs that are stated to have minimal targeting 
to human, mouse or rat genes. All siRNA experiments were preformed using 
DNase/RNase free equipment.  
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2.7 MPO activity assay  
 
MPO activity was measured using a colorimetric assay purchased from Abcam, UK 
(ab105136). The assay was conducted according to the manufacture protocol with 
the following method conducted for sample preparation. Cells were pelleted and 
washed with ice-cold PBS at 1000xg for 5 minutes. Cell pellets were re-suspended in 
4 pellet volumes of ice cold MPO assay buffer provided and lysed using sonication at 
conditions of 17V, pulse 5, for 2 cycles on ice (Bandelin Sonopuls HD 2070). 
Sonicated samples were centrifuged at 14000xg for 10 minutes at 4oC (Sigma 1-16 
microfuge) to remove insoluble material. To ensure an equal protein concentration 
was used for all samples in the assay, the protein concentration was estimated using 
the Bradford assay described in section 2.3.2. MPO activity was determined by 
measuring the absorbance of a TNB-2 probe at 415nm. To ensure the assay was 
working, a positive control supplied in the kit was used in all experiments (kit 
components listed in Table 2.4). 
Component Volume supplied 
DTNB Probe 50µL 
MPO assay buffer 25mL 
MPO positive control (lyophilised) 1 vial 
MPO substrate stock 50µL 
Stop Mix (lyophilised) 20µL 
Tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP) (50mM) 
50µL 
 
Table 2.4 MPO assay kit components (ab105136 Abcam, UK) 
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2.8 XTT assay  
 
The Cell Proliferation Kit II (XTT) (Roche, Switzerland) was used to evaluate 
mitochondrial activity. The XTT assay was conducted according to the 
manufacturer's instructions. Briefly, NB4 cells were seeded at a cell density of 3.0 x 
104 cells per 100µL into 96 well plates and incubated at 37oC. On the day of the XTT 
experiment, the XTT labelling reagent and electron coupling reagent were thawed to 
room temperature and mixed in a ratio of 1:50 respectively. From this mixture, 50µL 
(XTT concentration 0.3mg/mL) was added to the plates and incubated for 4 hours at 
37oC. The plates were read using the Bio-Rad Microplate reader 550, at 450nm. 
Absorbance values were corrected for background using medium only control values 
and data was analysed using GraphPad Prism 4.0.  
2.9 Seahorse assay  
 
Seahorse XF96 cell energy phenotype test was used to measure real-time oxygen 
consumption (OCR) and extracellular acidification rate (ECAR). The XF96 plate was 
pre-coated with poly-L-lysine onto which 2x105 cells/well NB4 cells in seahorse assay 
medium (DMEM without NaHCO3 supplemented with 10mM glucose, 1mM pyruvate 
and 2mM glutamine pH 7.4) were seeded and equilibrated for 1 hour in a non-CO2 
incubator. The stressor mix was composed of the mitochondrial inhibitors; oligomycin 
(2µM) to inhibit complex V and FCCP (1µM) to uncouple the proton gradient. The 
XF96 phenotype test was conducted under manufacturer guidelines. OCR and ECAR 
were measured under basal conditions followed by sequential additions of oligomycin 
and FCCP, reading were determined using the Seahorse XF96 Flux analyser on 
Wave Desktop 2.3 and data analysis was conducted using GraphPad Prism 7.0. 
2.10. Stable transfection of MPO cDNA into K562 cells  
 
K562 cells were transfected with plasmid RC216029 containing the coding sequence 
for full-length human MPO with a C-terminal MYC-DDK tag encoded in the pCMV6-
Entry vector (Origene, Rockville USA) (Figure 2.1 and Appendix Figure iv for insert 
sequence). This vector also contains the gene encoding for neomycin-kanamycin 
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phosphortransferase type II enzyme that gives resistance to G418 to allow selection 
of cells which have taken up the plasmid.  
 
Figure 2.1 MPO cDNA construct, diagram obtained from Origene.  
A volume of 200µL of exponentially growing K562 cells were seeded into 24 well 
plates at a cell density of 5x105 cells/mL and incubated at 37oC for 1 hour prior to 
transfection. During this period the transfection mastermix was prepared (shown 
below), under DNase/RNase free conditions. The master mix was incubated for 20 
minutes at room temperature to allow the plasmid and Dharmafect Duo (Dharmacon, 
UK) to form a DNA-liposomal complex, prior to transfection. To the mastermix, 200µL 
of antibiotic free medium (normal K562 growth medium without 1% v/v penicillin and 
streptomycin see section 2.2.2) was mixed and added drop-wise to K562 cells. For a 
non-transfected control, 300µL of antibiotic free medium was added to separate K562 
cells.  
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Mastermix preparation for K562 cell transfection  
Transfected cells were incubated overnight at 37oC. The following day cell viability 
was assessed using trypan blue (2.2.4) and for selection, 750µg/mL of G418 was 
added. When cells became confluent in 24 well plates, cells were transferred to 6 
well plates and grown in the presence of 500µg/mL of G418 and tested for MPO 
expression by immunofluorescence (section 2.11). In all cases the population of 
K562 cells with positive MPO expression was low and to achieve a single colony of 
MPO expressing K562 cell line, cells were isolated by limited dilution.   
2.10.1 Cloning by limited dilution  
 
To isolate single colonies of MPO expressing cells the ‘Cell Cloning by Serial Dilution 
in 96 Well Plates Protocol’ method by John A Ryan (Corning Incorporated, New 
York) was used. Briefly, all wells of a 96 well plate expect well A1 were filled with 
100µL of K562 cell medium and 500µg/mL of G418 (Figure. 2.2). In well A1, 200µL of 
2.0x104 cells/mL of transfected K562 cells were seeded. Then 100µL of cell 
suspension from well A1 was transferred to well B1 and mixed gently, this series of 
1:2 dilutions was repeated down the entire column (C1-H1). An additional 100µL of 
medium was added to columns A1-H1. Then 100µL of cell suspension was 
transferred from the first columns (A1-H1) to the second columns (A2-H2), these 1:2 
dilutions were repeated across the entire plate. The final volume of each well was 
brought to 200µL with the addition of 100µL of K562 cell medium and 500µg/mL 
G418. Single clones in the well were visible down a light microscope after 3 weeks of 
plating. When clones became sufficiently confluent, they were pipetted from the 
selected well and transferred into 24 well plates and tested for MPO expression by 
immunofluorescence (see section 2.11). 
Component Volume (µL) 
Serum free RPMI 1640 medium 80 
Expression plasmid (stock 100µg/mL) 10 (MPO stock 1µg/mL) 
Dharmafect Duo (stock 200µg/mL in 
serum free medium) 
10 
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Figure 2.2 Limited dilution method. 
2.11 Immunofluorescence analysis of γH2Ax and MPO   
2.11.1 Fixation and permeabilisation of cells  
 
Cells were pelleted at 1000xg for 5 minutes and re-suspended in 50µL PBS. This 
suspension was applied onto pre-coated poly-L-lysine slides and cells were allowed 
to adhere onto slides for 10 minutes. Cells were fixed in 4% paraformaldehyde in 
PBS for 10 minutes and permeabilised using KCM+T buffer (120mM KCl, 20mM 
NaCl, 10mM Tris-HCl pH 8.0, 1mM EDTA, 0.1% Triton-X-100) for 15 minutes at room 
temperature. Slides were blocked in blocking buffer (2% (w/v) BSA, 10% (w/v) non-
fat milk powder in KCM+T) for 1 hour at room temperature.  
2.11.2 Staining  
 
The desired primary antibody (see Table 2.5) was incubated onto the slides at a 
concentration of 1:100 or 1:400 diluted in blocking buffer for 1.5 hours at room 
temperature. To remove the unbound antibody, slides were washed thrice in KCM+T 
buffer, each wash for 10 minutes, and then incubated with the appropriate 
fluorescent secondary antibody diluted 1:250 in blocking buffer (Alexa-488 anti rabbit 
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λex = 490 nm, λem = 525 nm or Alexa-594 anti-mouse λex = 590 nm, λem = 617 nm) 
for 1.5 hours, protected from light. KCM+T washes were then repeated.  
Slides were mounted using mounting medium containing DAPI (Vector Labs, CA) 
and secured with sealant. Slides were either immediately viewed under the 
microscope or stored at 4oC for a maximum of three days before viewing.  
 
Table 2.5 List of primary antibodies used for immunofluorescence (IF). 
2.11.3 Microscopy 
 
Images of blue (Hoechst-stained DNA) fluorescence (λex = 361nm, λem =497 nm) 
and green (FITC 488 fluorescence) (λex = 490nm, λem = 525nm) or red (Texas Red 
594) (λex = 590nm, λem = 617nm) were captured separately using an 
epifluorescence microscope (Olympus IX-81, 10x objective) fitted with an Orca-AG 
camera (Hamamatsu) and suitable narrow band filter sets. Images were taken to give 
at least 2000 cells per treatment. For background correction, images were taken 
Antibody  Catalogue number Host  Raised to  Supplier Application  Dilution  
Anti-
TOP2 4882 
Rabbit 
(polyclonal) 
N-terminal 
40kDa calf 
thymus In house  TARDIS   1:100  
Anti-
TOP2A 4566 
Rabbit 
(polyclonal) 
Full CTD 
Human 
TOP2A-GST 
fusion 
(residues 
1244-1531) In house  TARDIS and IF  1:400 
Anti-
TOP2B 4555 
Rabbit 
(polyclonal) 
Full CTD 
Human 
TOP2B-GST 
fusion 
(residues 
1263-1621) In house  TARDIS and IF  1:400 
Anti-
MPO ab9535 
Rabbit 
(polyclonal) 
Raised to MPO 
isolated from 
human 
granulocytes. 
Abcam, 
UK  IF  1:100 
γH2Ax 05-636 
Mouse 
(monoclonal
) 
Recognises 
Histone H2A.X 
phosphorylated 
at Ser139. 
Merck 
Millipore, 
UK IF 1:400 
 75 
using a blank slide (dark shade correction) and a fluorescence green slide (for FITC) 
or an orange slide (for Texas Red) for bright shade correction.  
Image analysis was conducted using Volocity 6.3 (PerkinElmer Inc.). For quantitative 
immunofluorescence (for γH2Ax), the integrated fluorescence obtained for 594 
background-subtracted values per cell, per treatment was used to conduct analysis. 
2.12 Glutathione colorimetric assay  
The glutathione assay separately measures the concentration of total and reduced 
glutathione in cells. The principle of the assay is based on the glutathione recycling 
system, in which reduced glutathione (GSH) can react with a DTNB probe 
(colourless) to generate glutathione disulfide (GSSG) and TNB (yellow). The level of 
TNB produced can be assayed spectrophotometrically. Therefore, the level of TNB 
produced is dependent on the amount of GSH present in cells. The generated GSSG 
can be reduced back to GSH by the action of glutathione reductase (provided in 
assay kit) that in turn generates more molecules of GSH to react with DTNB, 
improving the sensitivity of the assay. To measure the levels of reduced glutathione 
the enzyme glutathione reductase is omitted from the reaction (see Table 2.6), 
separating the levels of reduced glutathione and oxidised forms of glutathione in the 
mixture.  
The assay was conducted using the manufacturer’s guidelines (KA0797, Abnova, 
Taiwan). The following method was used for sample preparation. NB4 cells (cell 
density 2 x 106 cells/mL) were treated with various concentrations of BSO for 4.5 
hours, after this cells were pelleted (1000xg, 5 min) and washed in ice cold PBS. 
Cells were lysed in 4 pellet volumes of ice-cold glutathione assay buffer provided. 
Levels of total glutathione (GSH and GSSG) were determined by measuring the 
absorbance of the TNB chromophore at 490nm. To measure the levels of reduced 
glutathione, the enzyme glutathione reductase (see Table 2.6) was omitted from the 
reaction mixture and the absorbance of the TNB chromophore was measured at 
405nm. The level of TNB absorbance measured from this reaction (glutathione 
reductase omitted) is the measure of the level of reduced glutathione in the cell 
sample and not a contribution of the oxidised glutathione (GSSG) being reduced in 
the system to generate glutathione. The levels of total and reduced glutathione were 
calculated from a glutathione standard curve, prepared using glutathione standards 
provided (kit components listed in Table 2.6).  
 
Component Volume 
Glutathione Reaction Buffer 100mL 
Glutathione Substrate DTNB (lyophilised)  2 vials 
NADPH Generation Mix (lyophilised) 2 vials 
Glutathione Reductase (lyophilised) 50µL 
5-Sulfosalicylic acid (SSA)  1 gram 
GSH Standard (lypohilised, MW 307) 2mg 
 
Table 2.6. Components supplied in glutathione colorimetric assay kit  (KA0797, Abnova, Taiwan)  
2.13 Trapped in agarose DNA immunostaining (TARDIS) assay 
 
The TARDIS assay enables the detection and quantification of TOP2 enzyme 
covalently bound to nuclear DNA, in situ, for an individual cell (Figure.2.3). This 
method is described in Willmore et al; (1998). 
 
Figure 2.3 Schematic representation of the TARDIS assay.  
2.13.1 Drug incubations  
Exponentially growing cells (2-5 x 105 cells/mL) were seeded into 6 well plates and 
treated with the desired drug or a solvent control for 1 hour, unless otherwise 
specified. Cells were pelleted by centrifugation (1000xg, 5mins) and washed in ice-
cold PBS at 1000xg for 5 minutes. The supernatant was removed and cell pellets 
were re-suspended in 50µL PBS. 
2.13.2 Slide preparation and SDS-salt extraction  
 
The suspension consisting of cell pellet mixed with 50µL PBS was warmed at 37oC 
for 30 seconds and mixed with an equal volume of low melting point 2% agarose 
(Seaprep ultra-low gelling, FMC Bioproducts, Rockland, USA, prepared in PBS and 
pre-warmed to 37oC prior to use). This mixture was spread evenly onto 0.5% 
agarose coated microscope slides and placed onto ice to allow rapid solidification of 
agarose.  
Agarose-embedded cells were placed in lysis buffer (1% (w/v) sodium dodecyl 
sulfate, 20mM sodium phosphate (pH 6.5), 10mM EDTA plus 0.25% v/v of protease 
inhibitor cocktail, (Melford, Suffolk, UK)) for 30 minutes at room temperature. This 
disrupted the cell membrane and allowed the release of soluble proteins. Following 
this, slides were placed in 1M NaCl plus 0.1% v/v of protease inhibitor cocktail for 30 
minutes at room temperature. This procedure removed non-covalently nuclear 
proteins bound to cellular DNA. After this slides were washed three times with PBS 
for 5 minutes, the last wash of PBS had the addition of 0.05% of protease inhibitor 
cocktail. 
2.13.3 Staining of slides 
 
Following lysis, TOP2 covalent complexes were detected by immunofluorescence. 
Anti-topo II rabbit polyclonal antibodies (4566 for TOP2A, 4555 for TOP2B or 4882 
for TOP2 only see Table 2.5) were used at a 1:400 or 1:100 dilution in PBS 
containing 0.1% (v/v) Tween 20 (PBST) and 1% (w/v) bovine serum albumin (1% 
BSA-PBST) unless otherwise specified. The slides were incubated with the primary 
antibody for 1.5 hours at room temperature and then washed three times in PBST 
containing 0.05% protease inhibitor cocktail. From this point onwards all procedures 
were conducted in subdued light. Slides were incubated with Alexa488-conjugated 
secondary antibody (A11008 Alexa Fluor 488 goat anti-rabbit IgG, Life Technologies, 
1:250 diluted in 1% BSA-PBST) for 1.5 hours at room temperature. Washes were 
performed twice with PBST for 5 minutes and then with PBS for 20 minutes at room 
temperature. At this point, slides could be stored in PBS plus 0.05% protease 
inhibitor cocktail overnight at 4oC or processed immediately.   
Slides were counterstained with Hoechst 33258 (Invitrogen, diluted 2µg/ml in PBS) 
for 5 minutes to allow detection of DNA and mounted using Vectashield (Vector 
Laboratories, Peterborough, UK), coverslips were applied and secured with a 
sealant. At this stage slides were ready for viewing under the microscope or 
alternatively slides could be stored at 4oC for up to 3 days before conducting 
microscopy. 
2.13.4 Microscopy 
 
Images of blue (Hoechst-stained DNA) fluorescence (λex = 361 nm, λem = 497 nm) 
and green (FITC-stained drug-stabilised TOP2) fluorescence (λex = 490 nm, λem = 
525 nm) were captured separately using an epifluorescence microscope (Olympus 
IX-81, 10x objective) fitted with an Orca-AG camera (Hamamatsu) and suitable 
narrow band filter sets. Minimum of five images were taken per slide to give at least 
300 cells per treatment. In addition, background correction images were taken. A 
dark correction image was taken using a slide prepared in an analogous way as the 
sample slides but containing no cells. The bright correction slides were taken using a 
fluorescence green slide.  
Fluorescence images were processed as described in Cowell et al., 2011. 
Background correction and analysis of images was conducted using Volocity 6.3 
(PerkinElmer Inc.) The integrated fluorescence FITC background subtracted value 
per cell, per treatment was used to conduct analysis. 
Part of the microscopy used to generate the results in chapter 6 was conducted using 
a DMLB microscope (Leica, 10x objective) fitted with a Coolsnap HQ2 camera V1.0.0 
(Photometrics). Images were captured for both blue (Hoechst-stained DNA) and 
green (FITC-stained drug-stabilised TOP2) and background correction was 
conducted as previously stated. Images taken were manually imported into Volocity 
6.3 (PerkinElmer Inc.) for image analysis.   
 2.13.5 Variations to the standard TARDIS assay  
 
The TARDIS assay can be modified at the stage of drug incubations (2.13.1) to 
determine (i) the longevity of drug-stabilised complexes after the removal of the drug 
from cell medium, this is known as the TARDIS Reversal assay, (ii) if a certain 
drug/compound behaves as an inhibitor of TOP2, this is termed as the TARDIS 
inhibitor assay. The assays are described in detail below. 
2.13.6 TARDIS Reversal assay  
 
Exponentially growing cells (2-5 x 105 cells/mL) were seeded into 6 well plates and 
treated with the desired drug or a solvent control for 1 hour, unless otherwise stated. 
Cells were pelleted by centrifugation at 1000xg for 5 minutes to remove the drug 
containing medium. The supernatant was removed and cell pellets were re-
suspended in drug free cell medium and then returned to the incubator for the 
desired length of time. At the specified time points (e.g. 30, 60, 120min) the cells 
were removed from the incubator and pelleted (1000xg for 5 minutes). The 
supernatant was removed and cell pellets are mixed with ice-cold 50µL PBS. From 
this the point onwards the procedure stated in sections 2.13.2 to 2.13.5 were 
followed.  
2.13.7 TARDIS inhibitor assay 
 
Exponentially growing cells (2-5 x 105 cells/mL) were seeded into 6 well plates and 
treated with the proposed catalytic inhibitor for 1 hour. Following this a TOP2 poison, 
such as etoposide, was added for 1 hour. Cells were then pelleted (1000xg, 5mins) 
and mixed with ice-cold 50µL PBS and procedures stated in sections 2.13.3 to 2.13.5 
were followed. If a particular drug behaves as catalytic inhibitor of TOP2, then a 
decline in the level of etoposide (or any TOP2 poison) stabilised TOP2-DNA 
complexes is seen compared to etoposide only treated cells. 
 
 
 
2.14. Normalisation to combine biological replicates  
Data obtained from individual quantitative immunofluorescence experiments 
(including TARDIS) were combined using the following method described below 
(Figure 2.4).  
1. For each individual experiment the median values obtained for the highest 
drug treatment were taken and averaged out e.g. an example this 
normalisation step is shown below. For 100µM etoposide in each experiment 
the average median value for n=1 was 14800; n=2 13870 and n=3 14560 
these are referred to as the experimental average  
2. An average value of the all the experimental averages is then calculated i.e. 
for the example above the average value is 14410 
3. The average value is then divided by the experimental average i.e. for n=1 
14800/14410 =1.027, this value is referred to the normalisation factor and is 
specific to each experiment (normalisation factor for n=2 0.963 and n=3 1.010) 
4. All values in one individual experiment were divided by the normalisation 
factor (values in experiment n=1 will be divided by 1.027) to give a normalised 
values for each experiment 
5. The normalised values for each experiment were all combined together into 
one data set 
6. The normalised values were then calculated as a percentage of the positive 
control (e.g. 100µM etoposide) and expressed as histogram to conduct 
statistical analysis.  
2.15 Statistical analysis  
Data were organised and analysed using Microsoft Excel 2011 and GraphPad Prism 
4.0. Data were plotted using mean ± standard error of means (SEM) unless 
otherwise stated. For statistical analysis an unpaired Students t-test was used to 
compare differences between two sample means; or a one-way ANOVA with post 
analysis conducted using the Tukey test was used for multiple comparisons. The 
two-way ANOVA was used to analyse the interaction of two independent variables on 
one dependent variable with multiple comparisons conducted using the Bonferroni 
multiple comparison test; p-values of <0.05 were considered statistically significant.  
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Figure 2.4. Normalisation of data.   
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Chapter 3. Quantification and manipulation of TOP2 and MPO 
expression in myeloid cells and depletion of glutathione.  
3.1 Introduction 
 
This chapter aims to demonstrate how the tools required to answer the questions 
addressed in this thesis have been generated. Throughout this study, myeloid 
leukaemia cell lines have been used to study the effects of MPO. The selected cell 
lines are likely to have originated from the early myeloid precursor/progenitor cells 
(MacLeod and Drexler, 2008; Inoue et al., 2014; Jensen et al., 2015). A characteristic 
of myeloid progenitor cells is their potential to express MPO. The cell lines NB4, 
HL60 and Kasumi-1 express MPO protein whereas K562 and KG1 do not express 
MPO protein. The K562 cell line is a chronic myelogenous leukaemia (CML)-derived 
erythroleukaemia cell line. They originate from the erythroid lineage, which is MPO 
negative (Psaila et al., 2016). However, K562 cells can be engineered to successfully 
produce functional MPO protein when transfected with an MPO expression construct 
(Nauseef et al., 1996). KG1 cells are an acute myeloid leukaemia (Lee et al.) 
myoblast cell line that are reported to be positive for MPO at the RNA level but do not 
synthesise the MPO protein (Hu et al., 1993).  
The key aim for the work presented in this chapter, was to establish a cell-based 
system in which MPO can be effectively down regulated. This will allow the 
determination whether MPO has a role in TOP2 poison induced DNA damage.  A 
literature search was conducted to determine the methods that have been employed 
to inhibit MPO activity or protein production in cell-based systems. The most common 
method to inhibit MPO activity was to use succinylacetone (SA), a heam biosynthesis 
inhibitor (Figure. 3.1) (Kagan et al., 1999; Kagan et al., 2001; Fan et al., 2006; 
Nakazato et al., 2007; Vlasova et al., 2011). SA indirectly inhibits MPO by preventing 
mature protein synthesis via the depletion of heam pools but SA does not alter cell 
morphology or proliferation (Giger and Meyer, 1983).  
The effectiveness of SA to supress MPO activity in NB4 cells was determined. Three 
direct MPO inhibitors; 4-ABAH and the recent commercially available inhibitors, 
PF1355 and MPOi-II were also used (Figure.3.1). The three direct inhibitors act as 
suicide substrates for MPO causing the inactivation of different MPO redox 
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intermediates (Kettle et al., 1997; Soubhye et al., 2010; Zheng et al., 2015) (see 
section 1.2.5). In addition to chemical inhibitors, the conditions for MPO targeted 
knockdown using siRNA and the transfection of a MPO expression construct into 
K562 cells were also tested.  
                               
Figure 3.1.Chemical structure of MPO inhibitors. 
The effects of MPO mediated oxidation of TOP2 poisons can be limited by 
glutathione (Kagan et al., 1999; Kagan et al., 2001; Vlasova et al., 2011) (see section 
1.4). Therefore, to allow the determination of glutathione depletion and MPO 
inhibition on TOP2 poison induced DNA damage; the conditions to reduce cellular 
levels of glutathione were also established. 
3.2 Aims:  
 
• To quantify the relative levels of TOP2 protein in the myeloid cell lines; HL60, 
K562, KG1 and NB4.   
• To determine the conditions required to knockdown TOP2 and MPO using 
siRNA and whether siRNA knockdown of MPO was a suitable approach for 
these studies.  
• To optimise inhibitor concentrations required to chemically inhibit the 
enzymatic activity of MPO.  
• To test the conditions required to reduce cellular glutathione levels using 
buthionine sulfoximine (BSO).  
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3.3. Results 
3.3.1 Level of TOP2 protein in selected myeloid cell lines  
 
The expression of TOP2A and TOP2B were determined at the protein level in K562, 
KG1, HL60 and NB4 cell lines using western blotting (method described in section 
2.3. to 2.5). Whole cell extracts were prepared from cells growing in mid-log phase 
and western blots were probed using rabbit polyclonal antibodies specific to TOP2A 
(4566 anti-sera) or TOP2B (4555 anti-sera) (antibody details listed in Table 2.2). 
Protein band intensities were quantified and compared relative to K562 cells. 
Western blot analysis indicated all cell lines tested contain similar levels of both 
TOP2A and TOP2B protein (Figure.3.2.A-D).  
 
Figure 3.2. TOP2A and TOP2B protein expression levels in K562, KG1, HL60 and NB4 cell lines. 
Representative blots show the level of TOP2A (A) and TOP2B (B) protein in the specified cell lines 
with β-actin used as a loading control. Protein band intensities were quantified using densitometry for 
TOP2A (C) and TOP2B (D) and levels were compared to the mean value obtained for K562 cells. 
Band intensities were quantified for two separate protein loadings per blot to avoid band saturation. 
Data are expressed as mean ± S.E.M for four separate experiments (C-D).  
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3.3.2 Knockdown of TOP2 using siRNA.  
 
Conditions for TOP2 knockdown were characterised in K562, NB4 and HL60 cells 
using siRNA to individually target each isoform of TOP2. The targeting siRNA 
consisted of a pool of four individual siRNAs each targeted towards a different mRNA 
sequence for human TOP2A or TOP2B (Thermo Fisher Scientific, Leicestershire, 
UK) (siRNA target RNA sequences listed in Table 2.3). Each siRNA nucleotide 
sequence was analysed using Blast. Analysis of sequences using Blast confirmed 
the targeting sequence was specific to one isoform of TOP2. For each siRNA 
knockdown experiment, cells were electroporated separately with either TOP2A or 
TOP2B targeting siRNA and tested for the reduction in TOP2 protein levels 
compared to cells electroporated with a control siRNA (see section 2.6). The control 
siRNA consists of a four non-targeting siRNAs designed with patent modifications 
which are validated to have minimal targeting to human, mouse or rat genes (Thermo 
Fischer Scientific, Leicestershire, UK).   
K562  
In K562 cells, levels of both TOP2A and TOP2B were reduced more than two-fold 
compared to control siRNA cells up to 72hr post-electroporation (Figure.3.3.A-C). 
The greatest reduction in TOP2A was visualised at 72hr with 18.7% of TOP2A 
protein remaining compared to control cells (Figure. 3.3.A&C). TOP2B levels were 
the lowest at 72hr and 96hr time-points as less than 10% of TOP2B protein was 
detectable in comparison to control siRNA cells (Figure. 3.3.B-C). Electroporation 
with TOP2B siRNA gave a cell viability that was comparable to control siRNA cells 
(Figure.3.3.D). However, TOP2A siRNA electroporation initially reduced the cell 
viability at 24hr and 48hr time-points compared to control cells (Figure.3.3.D). But 
recovery in cell viability was detected at 72hr time-point with 100% viability at 96hr, 
this was accompanied by some recovery in TOP2A protein levels (Figure. 3.3.C-D). 
To check whether the reduction in protein levels of one TOP2 isoform would affect 
the other isoform. K562 cells electroporated with the TOP2A siRNA were probed for 
TOP2B by western blotting whilst cells electroporated TOP2B siRNA were probed for 
TOP2A (Figure. 3.4.A-B). Quantification of protein bands at the 72hr time-point 
revealed no detectable difference in protein band intensities between control and 
TOP2 siRNA targeted cells.  
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Figure 3.3. Down-regulation of TOP2A or TOP2B protein expression in K562 cells using siRNA. 
K562 cells were electroporated with 400nM (330mV and 10ms pulse) siRNA targeted against TOP2A 
or TOP2B. Representative blots for cells 72hr after electroporation are shown for TOP2A (A) and 
TOP2B (B), β-actin was used as a loading control. (C) The percentage reduction of TOP2 was 
quantified using densitometry for each loading at the specified time-point after electroporation and 
compared to cells electroporated with a control siRNA for the respective loading. Values are shown as 
an average of the percentage reduction for each loading quantified. (D) Cell viability of electroporated 
cells were assessed using trypan blue exclusion counts after electroporation. Data shown in this figure 
were obtained from a single experiment. 
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Figure 3.4. TOP2 siRNA specificity. K562 TOP2 siRNA extracts electroporated with siRNA targeted 
against one isoform of TOP2 were probed for the other isoform, to verify the isoform specificity of the 
siRNAs and to check whether the reduction in one isoform affects the protein levels of the other 
isoform. Blots 72hr after electroporation for one isoform of TOP2 were stripped using western stripping 
buffer and TOP2A siRNA extracts were probed using anti-TOP2B (4555 anti-sera) (A); TOP2B siRNA 
extracts were probed using anti-TOP2A (4566 anti-sera) (B).  
 
NB4 & HL60 
Electroporation of TOP2A or TOP2B targeted siRNA into NB4 cells resulted in 63% 
and 70% reduction in TOP2A and TOP2B protein levels 48hr post-electroporation 
(Figure. 3.5.A-C). NB4 cells before electroporation had cell viability of 70%, this is 
normal for NB4 cells growing in cell culture. Following electroporation with siRNA, the 
cell viability of cells targeted with TOP2B siRNA was similar to that of control siRNA 
cells (Figure.3.5.D). However, as observed in K562 cells, TOP2A siRNA 
electroporation reduced the cell viability at 24hr with recovery in cell viability 
observed at 48hr (Figure.3.5.D). 
TOP2 targeted knockdown in HL60 cells reduced the protein levels of both TOP2A 
and TOP2B by 55% and 63% respectively (Figure.3.6.A-C). The cell viability, as 
assessed using trypan blue (see section 2.2.4) post-electroporation, showed all 
siRNA-targeted cells had reduced viability, suggesting conditions used for 
electroporation require optimisation (Figure.3.6D). However at the 48hr time-point 
HL60 cells targeted using siRNA against either TOP2A or TOP2B had a recovery in 
cell viability but cells targeted with the control siRNA had a continual decline in cell 
viability up to 72hr post-electroporation (Figure.3.6D). 
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Figure 3.5. The siRNA targeted knockdown of TOP2A or TOP2B in NB4 cells. Cells were 
electroporated with 400nM siRNA targeted towards TOP2A (A) or TOP2B (B). Representative blots 
are shown for cells 48hr after electroporation. (C) The level of TOP2 knockdown was estimated using 
densitometry and the percentage reduction was calculated relative to cells electroporated with a 
control siRNA. (D) NB4 cells were assessed for cell viability using trypan blue for up to 72hr after 
electroporation. Data shown in this figure were obtained for a single experiment.  
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Figure 3.6. The knockdown of TOP2A or TOP2B in HL60 cells using siRNA.  Representative blots 
are shown for cells 48hr after electroporation with TOP2A siRNA (A) or TOP2B siRNA (B), β-actin was 
used as a loading control. (C) Quantification for the percentage reduction in TOP2 levels after 
electroporation were compared to cells electroporated with the control siRNA using densitometry. (D) 
Viability counts of cells were conducted using trypan blue for up to 72hr after electroporation. Data 
shown in this figure were obtained from a single experiment. 
 
3.3.3 MPO protein expression and activity in cell lines  
MPO protein expression 
The expression level of MPO protein expressed in normal cell culture conditions was 
examined in Kasumi-1, NB4, HL60, KG1 and K562 cells using western blotting with 
four separate commercial antibodies (Figure. 3.7.A-E) (see Table 2.2 for antibody 
details and section 2.3 to 2.5 for method). Band intensities were quantified to deduce 
the levels of precursor MPO and mature MPO (indicated by the level of heavy 
subunit) present in each cell line tested. Results were consistent with published data 
showing that Kasumi-1, NB4 and HL60 are positive for MPO protein expression, with 
Kasumi-1 having the highest level of MPO protein whilst K562 and KG1 cells are 
negative for MPO (Figure.3.7.B) (Hu et al., 1993; Kim et al., 2010).  
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Figure 3.7. Evaluation of the MPO protein expression levels in five myeloid cell lines and 
validation of anti-MPO antibodies. (A) Cell lines were tested for the presence of MPO protein using 
anti-MPO 132134. (B) Levels of precursor and heavy subunit of MPO were quantified using 
densitometry for whole cell extracts tested using anti-MPO 132134 (n=3). (C-E) Western blot data 
obtained for MPO protein expression were validated using an additional three different MPO targeting 
antibodies; names of antibodies are specified within each blot (n=2 for each antibody).  
 
MPO activity levels 
MPO activity levels were analysed in the above cell lines using a commercial 
colorimetric activity assay kit (see section 2.7). The principle of the assay is based on 
the unique ability of MPO to oxidise chloride (Cl-) to hypochlorous acid (HOCl) at 
physiological pH. In this reaction, the hypochlorous acid generated can be effectively 
trapped by taurine (TauNH2) generating taurine chloramine (TauNHCl), a stable 
oxidant (Figure. 3.8.A). The generated taurine chloramine can react with 5-thio-2-
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nitrobenzoic acid (TNB=412nm) producing disulphide,5,5’-dithiobis(2-nitrobenzoic 
acid) (DTNB), a colourless compound (Weiss et al., 1982). MPO activity is calculated 
by measuring the reduction in TNB absorbance. The activity assay data showed NB4 
cells have considerably higher MPO activity (203.02 nmol TNB consumed/min/mL) 
compared to HL60 (48.42 nmol TNB consumed/min/mL) and Kasumi-1 cells (53.03 
nmol TNB consumed/min/mL) (Figure.3.8.B). This suggests that a considerable 
proportion of MPO in HL60 and Kasumi-1 is in the inactive form. For further studies 
NB4 cells were employed as the main cell line used to study the effects of MPO on 
TOP2 poison activity.  
 
Figure 3.8. NB4 cells contain the highest level of MPO activity. (A) Principle of the MPO activity 
assay. (B) MPO activity levels were deduced by measuring the intensity of TNB probe at 415nm. Data 
are expressed as mean ± S.E.M from four separate experiments. The positive control supplied was 
used to ensure all assay components were working correctly (ab105135, Abcam UK).  
3.3.4 Modulation of MPO protein and activity levels 
Down regulation of MPO using siRNA 
Conditions for MPO knockdown in NB4, HL60 and Kasumi-1 were tested using two 
different commercially available siRNAs (Table 2.3 for siRNA information and target 
sequences). The first tested siRNA consisted of a single siRNA purchased from 
Qiagen, the second siRNA purchased from Thermo Scientific consisted of four 
different sequence specific siRNAs for MPO. All siRNA sequences were tested using 
Blast, analysis confirmed the targeting siRNA were specific to MPO RNA sequences. 
All cells were electroporated under the same conditions (330mV and 10ms pulse) 
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with different concentrations of siRNA. Published data were initially used to deduce a 
suitable siRNA concentration of 200nM (Qiagen) to use in NB4 cells (Kim et al., 
2010) however under these conditions there was no quantifiable difference in MPO 
band intensities between cells electroporated with MPO siRNA compared to control 
siRNA by western blotting (Table 3.1). Therefore, the concentration of siRNA used 
(Qiagen) was increased to 400nM, which resulted in a 32.9% decrease in MPO 
levels at 72hr (Table 3.1). A sequential electroporation of MPO siRNA was also 
tested, for this cells were electroporated with 400nM siRNA (Qiagen) followed by a 
second electroporation of 400nM siRNA 24hr after the initial electroporation. 
However this only resulted in a 37.5% decrease in MPO protein levels, a similar level 
of reduction compared to single electroporation with 400nM of siRNA (Table 3.1). 
siRNA supplier and 
catalogue number 
Cell line siRNA concentration 
used for electroporation 
(nM) 
% of total protein 
remaining  from 
control at 72hrs 
Qiagen SI00005425 NB4 200 100 
Qiagen SI00005425 Kasumi-1 200 100 
Qiagen 
SI00005425 
NB4 400 67.1 
Thermo Scientific 
L003228-00-0020 
NB4 400 97.1 
Thermo Scientific 
L003228-00-0020 
NB4 500 36.1 
Thermo Scientific 
L003228-00-0020 
NB4 400 (double 
electroporation) 
62.5 
Thermo Scientific 
L003228-00-0020 
NB4 1000 (1µM) 50.9 
Thermo Scientific 
L003228-00-0020 
HL60 400 100 
Thermo Scientific 
L003228-00-0020 
HL60 500 60.7 
Thermo Scientific 
L003228-00-0020 
HL60 1000 (1µM) 53.2 
 
 
Table 3.1. Testing the conditions required to knockdown MPO protein in three MPO positive 
cell lines using siRNA. Cells were electroporated (conditions 330mV and 10mS pulse) with the 
specified concentration of siRNA. The 400nM double electroporation was conducted by firstly 
electroporating NB4 cells with 400nM MPO siRNA followed by a second electroporation of 400nM 
siRNA 24hr after the initial electroporation. For each condition specified, extracts were prepared and 
tested using western blot analysis. Each siRNA condition listed was tested once for the level of MPO 
protein reduction.  
 
The siRNA purchased from Qiagen consisted of a single siRNA sequence. To 
increase the chances of protein knockdown a pool consisting of four-siRNAs targeted 
towards MPO were obtained (Thermo Scientific) and tested for MPO knockdown 
efficiency. The conditions that resulted in the greatest reduction in total MPO protein 
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were tested for MPO activity (Table 3.1 & Figure. 3.9.A-C). Electroporation of NB4 
cells with 500nM of the four MPO siRNAs (Thermo Scientific) resulted in an average 
reduction of 70.4% ± 3.6 in MPO activity and a 64% reduction in protein levels 
compared to cells electroporated with a control siRNA (Figure. 3.9.A and Table 3.1). 
Replicate conditions in HL60 cells resulted in a reduction of 64.8% ± 5.3 in MPO 
activity and a 39% reduction in MPO protein (Figure. 3.9.B and Table 1). However, 
doubling the siRNA concentration to 1µM in NB4 cells did not further reduce MPO 
activity (65% ± 20 reduction) or protein levels (51% reduction) (Figure. 3.9.C & Table 
3.1). As MPO is stored in granules once synthesised, the lack of reduction in MPO 
levels after increasing the siRNA concentration was perhaps not surprising. As the 
siRNA would target the destruction of MPO mRNA, reducing the level of newly 
synthesised MPO without affecting the protein already packaged into granules.  
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Figure 3.9. The siRNA targeted down regulation of MPO significantly reduces MPO activity. 
Both NB4 and HL60 cells were electroporated with siRNA targeted towards MPO or a control. 
Samples were probed for both MPO protein (anti-MPO ab132134) (left panel) and activity levels (right 
panel) 72hr post-electroporation. Activity assay data are expressed relative to the respective control 
siRNA and data are represented as mean ± S.E.M. (A) NB4 cells were electroporated with 500nM 
siRNA, (B) HL60 cells electroporated with 500nM siRNA and (C) NB4 cells electroporated with 1µM. 
The siRNA used in these experiments were purchased from Thermo Scientific (L003228-00-0020).  
Statistical analysis was conducted using the Students t-test, * P<0.05 and *** P<0.001 are considered 
statistically significant.  
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3.3.5 Inhibition of MPO activity using chemical inhibitors  
  
Two chemical inhibitors, SA and 4-ABAH were chosen to test their effect on MPO 
activity (Figure. 3.1). NB4 and HL60 cells were individually treated with either SA 
(200µM for 48hr) or 4-ABAH (100µM for 3hr) using previous published data and 
measured for MPO activity as previously described in section 3.3.3 and 2.7 (Kagan et 
al., 2001; Miyamoto et al., 2003; Knaapen et al., 2005; Vlasova et al., 2011). In both 
cell lines SA effectively abolished MPO activity to below the level of detection (assay 
sensitivity 0.05nmol TNB consumed/min/mL) (Figure. 3.10.A-B). Whereas the 
concentration selected for 4-ABAH reduced MPO activity in NB4 cells to 13.7% ± 4.2 
(Figure. 3.10.A) but substantial MPO activity remained in HL60 cells (83.3% ± 29.1 
activity remaining) under conditions tested (Figure. 3.10.B), suggesting a higher dose 
of 4-ABAH is required to inhibit MPO activity in HL60 cells.  
As SA reduces heam synthesis in cells, the lowering of MPO activity is likely due to 
reduction in mature protein synthesis. Western blotting analysis confirmed that SA 
treatment dramatically reduced the level of the heavy subunit of MPO, which 
indicates defective processing from the precursor MPO to the mature protein 
(Figure.3.11.A). Quantification data obtained from three separate experiments at 
48hr showed the heavy chain was reduced by 77.6% ± 6.1 compared to untreated 
NB4 cells (Figure. 3.11.B, right panel) (see section 2.3 to 2.5 for method). As 
indicated by quantification of the precursor MPO, this also reduced the overall pool of 
MPO protein in cells by 29.5% ± 4.6 (Figure. 3.11.B, left panel). Thus SA can 
effectively reduce both MPO activity and protein in cells and therefore, was employed 
as the main MPO inhibitor for further studies presented in this thesis.  
 
 
  
 
96 
 
Figure 3.10. Inhibition of MPO activity in NB4 and HL60 cells using 4-ABAH (a specific MPO 
inhibitor) or SA (a heam biosynthesis inhibitor). NB4 cells (A) and HL60 cells (B) were treated 
either with 150µM 4-ABAH for 3hr; or 200µM SA for 48hr and assayed for MPO activity. The 
percentage of activity remaining is shown compared to untreated cells. The untreated control level is 
set at 100% MPO activity. Data are expressed as mean ± S.E.M for three separate experiments.  
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Figure 3.11. Succinylacetone (SA) reduces the level of mature MPO protein in NB4 cells. 
Following SA pretreatment (200µM for 48hr or 72hr) NB4 cells were probed for the level of MPO 
protein (ab132134) by western blotting (A). (B) Band intensities were quantified to deduce the relative 
levels of precursor MPO (lower left panel) and heavy subunit (lower right panel) remaining compared 
to untreated NB4 cells. Data are expressed as mean ± S.E.M. relative to untreated NB4 cells, 
numbers of replicates are indicated within each figure.  
 
 
 
 
 
3.3.6 Testing the effect of SA on mitochondrial activity and TOP2 protein levels. 
 
SA inhibits total heam biosynthesis in cells, therefore it is feasible that under 
conditions used above, the cells energy sources may be comprised affecting 
mitochondrial function, an organelle where heam is synthesised and is a component 
of respiratory complex proteins (Kim et al., 2012). It is important to know this and 
whether SA alters cell viability or proliferation as this could affect the interpretation of 
the TARDIS and DNA damage assays performed later in this study. For this reason, 
the effect of SA on mitochondrial function, cell viability and growth of NB4 cells were 
assessed. Two assays were used to analyse the potential effect of SA on the 
mitochondrial activity of NB4 cells.  
The first assay (XTT Cell proliferation assay) involves measuring the reduction of a 
tetrazolium salt (XTT) to a water-soluble orange formazan salt, which is dependent 
on a functioning citric acid cycle and electron transport chain (Figure.3.12.A) (method 
described in 2.8). The XTT cell proliferation kit was used as a surrogate to measure 
mitochondrial function. The XTT salt is regularly used to assess cell growth and also 
to measure the activity of succinate dehydrogenase - a component of both the citric 
acid cycle and electron transport chain (Kregiel et al., 2008). NB4 cells were treated 
in the presence or absence of SA. At each 24hr timepoint, the XTT reagent 
supplemented with PMS (an electron carrier, helping to drive the reduction of the 
XTT salt) was added to the cells. Data generated showed that a 96hr incubation with 
SA does significantly increase the generation of the XTT formazan salt (P=0.0001) 
(Figure. 3.12B). SA pre-treatment did not affect cell growth (P=0.706) or cell viability 
compared to untreated NB4 cells, measured using trypan blue cell counts 
(Figure.3.13.A-B) (Pinnix et al., 1994).  
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Figure 3.12. SA increases formazan salt formation in NB4 cells. (A) Principle of the XTT assay. 
(B) NB4 cells were treated with 200µM of SA (red) and were measured for the level of salt cleavage 
using the XTT assay (Roche, Switzerland) compared to untreated NB4 cells (black) for up to 96hr of 
treatment. Data are expressed as mean ± S.E.M for four separate experiments each comprising of six 
technical replicates. Statistical analyses were performed using the two-way ANOVA P=0.0001. 
 
 
 
 
 
Figure 3.13. Treatment with SA does not affect cell growth (A) or viability (B) up to 72hr in NB4 
cells. Data are expressed as mean ± S.E.M for three separate experiments, statistical analysis was 
performed for (A) using the two-way ANOVA with Bonferroni’s multiple comparison test, P=0.706. 
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In addition to the XTT assay, the seahorse phenotype assay (section 2.9) was 
utilised to analyse the effects of SA on oxidative phosphorylation and glycolysis. In 
the Seahorse assay, to determine if certain parameters/conditions affect the cells 
energy phenotype it is important to ‘stress’ the mitochondria. In the assay two 
stressors were used; oligomycin, to inhibit ATP synthase and FCCP to uncouple the 
electron transport from oxidative phosphorylation. Once the mitochondria are 
stressed it is feasible to analyse if a condition affects the cells energy phenotype. 
NB4 cells were incubated with 200µM SA for 48hr, under these conditions SA did not 
affect the oxygen consumption level (OCR) or extracellular acidification rate (ECAR), 
either under baseline conditions or stressed conditions (Figure. 3.14.A-B). Taking the 
OCR and ECAR data together it can be concluded that SA does not impact the cells 
metabolic potential under baseline or stressed conditions (Figure. 3.14.C). In 
addition, the effect of SA on the rate of acidification of cell growth medium was 
evaluated and the results obtained show SA does not accelerate acidification of the 
cell culture media (P=0.317) (Figure. 3.15.).  
Additionally, whether SA affected TOP2 protein levels in NB4 cells was investigated. 
This was an important factor to examine, as this study has a central focus on TOP2-
DNA covalent complexes and if SA induced changes in overall TOP2 protein levels 
then this would need to be taken into account when conducting analyses. SA was 
added to NB4 cells and western blots were probed for TOP2A and TOP2B after 48hr 
and 72hr of treatment (Figure. 3.16.A). Quantification of replicate blots revealed SA 
did not affect TOP2A or TOP2B protein levels for up to 72hr of incubation (Figure. 
3.16.B). In addition 200µM SA treatment did not affect the in vitro activity TOP2 
(experiment conducted by C.A.Austin published in (Atwal et al., 2017)).  
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Figure 3.14. SA treatment does not alter the oxygen consumption rate (OCR) (A) or 
extracellular acidification rate (ECAR) (B) or the metabolic potential (C) of NB4 cells.  Seahorse 
Bioscience XF96 extracellular flux analyzer was used to assess the effect of SA (200µM for 48hr) on 
the cell energy phenotype. Measurements were performed at the baseline time point and under 
stressed conditions (2µM oligomycin and 1µM FCCP). (C) Metabolic potential rates were calculated 
from the difference between the stressed and baseline values obtained from A&B and are expressed 
as a percentage from the baseline. Data are expressed as mean ± S.E.M from three experiments; 
statistical analysis was performed using the Student’s t-test.  
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Figure 3.15. SA does not alter extracellular pH levels of NB4 cells. Cells were treated with 200µM 
SA for up to 96hr and pH measures were performed at the specified time-points. Data are represented 
as mean ± S.E.M for four separate experiments; statistical analysis were performed using the two-way 
ANOVA with Bonferroni’s multiple comparison test, P=0.317.  
 
 
Figure 3.16. SA treatment does not alter TOP2A or TOP2B protein levels in NB4 cells. (A) 
Representative blots of NB4 cell extracts probed with anti-TOP2A (4566) or anti-TOP2B (4555) anti-
sera after treatment with 200µM SA for 48hr or 72hr, blots were cut in half to probe for TOP2A and β-
actin (loading control), the TOP2A blot was stripped (Thermo Restore stripping buffer) and probed for 
TOP2B. (B) Protein bands were quantified from three separate experiments and compared to 
untreated NB4 cells for the relative levels of TOP2A (upper right panel) and TOP2B (lower right panel) 
protein. Data are expressed as mean ± S.E.M relative to untreated NB4 cells (black bars). 
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3.3.7 Chemical inhibition of MPO using recently developed small molecule 
inhibitors.  
 
Two recently developed MPO inhibitors; PF1355 and MPOi-II were also tested 
(Figure. 3.1). PF1355 has previously been tested in neutrophils (Zheng et al., 2015), 
but MPOi-II has not been previously tested in cell-based systems. Therefore, a series 
of doses of the two inhibitors were tested to establish suitable concentrations to 
reduce MPO activity in NB4 cells for use in further experiments. Figure 3.17A-B 
shows both PF1355 and MPOi-II are effective at reducing MPO activity as both 
inhibitors produced a dose dependent decrease in MPO activity. For PF1355 all 
doses tested were effective at reducing MPO activity to below 10%, resulting in 
undetectable levels of MPO activity at 10µM after a 4hr incubation (assay sensitivity 
0.05 nmol TNB consumed/min/mL) (Figure. 3.17.A). For later experiments a dose of 
10µM PF1355 for 4hr was used. At doses greater than 30µM, PF1355 becomes non-
specific and targets thyroid peroxidase (Zheng et al., 2015). For MPOi-II a dose of 
5µM for 4hr was selected, this dose reduced MPO activity by 92.8% ± 5.7 (Figure 
3.17.B).  
The effects of both PF1355 and MPOi-II on TOP2 protein levels were analysed at 
96hr using western blot analysis. Levels of TOP2A and TOP2B protein were 
analysed in NB4 cells treated with PF1355 (Figure.3.18.A-B). Quantification of 
protein bands showed PF1355 had minimal effect on the level of TOP2 protein 
(Figure. 3.18.C). Furthermore, PF1355 did not affect proliferation of NB4 cells under 
the concentrations tested (Figure. 3.18.D). A similar trend for TOP2 protein levels 
was seen for MPOi-II (Figure.3.19.A-C), however doses of 0.1µM to 5µM gave a 
growth advantage to cells (Figure. 3.19.D). The reason for this effect is unknown but 
this may have clinical implications.  
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Figure 3.17. PF1355 and MPOi-II inhibit MPO activity in NB4 cells. Two direct irreversible inhibitors 
of MPO; PF1355 (A) and MPOi-II (B) were used at the times and doses specified to test for the 
reduction in MPO activity using the MPO colorimetric activity assay (ab105136, Abcam UK). Data are 
expressed relative to the mean value obtained for DMSO treated (vehicle control) NB4 cells ± S.E.M 
for three separate experiments. (Experiment conducted partly by Emma L. Lishman) 
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Figure 3.18. Effect of PF1355 treatment on TOP2 levels. NB4 cells were treated with PF1355 (0-
30µM) for 96hr and probed for TOP2A (A) and TOP2B (B) protein levels. Protein band intensities were 
quantified electronically (C-digit) and compared relative to the vehicle control (DMSO) treated NB4 
cells (C) (n=1 for each inhibitor concentration). (D) PF1355 did not affect cell growth, using cell counts 
n=3, data are expressed as mean ± S.E.M. (Experiments conducted by Emma L. Lishman). 
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Figure 3.19. MPOi-II treatment and the effect on the TOP2 protein levels in NB4 cells.  MPOi-II 
(0-5µM) was added to NB4 cells and assayed for TOP2A (A) and TOP2B (B) protein levels after 96hr 
of inhibitor treatment, protein bands were quantified electronically (C-digit) (C) and compared relative 
to NB4 cells treated with DMSO (solvent control) n=1 for each concentration tested. (D) Cell counts 
were preformed up to 96hr of MPOi-II treatment with and data are expressed as mean ± S.E.M (n=3). 
(Experiments conducted by Emma L. Lishman). 
 
 
3.3.8 Transfection of an MPO expression construct into K562 cells 
 
In order to confirm conclusions drawn from studies using MPO inhibition in NB4 cells, 
K562 cells that do not express MPO, were transfected with a human MPO 
expression construct to generate MPO positive K562 clones. A plasmid construct 
consisting of the full-length human MPO gene with a C-terminal Myc-DDK tag 
expressed under the CMV promoter was transfected using a liposomal transfection 
method (Figure.3.20.A-B) (full details of the plasmid construct are given in section 
2.10 and appendix Figure. iv). To allow selection the vector encodes the gene which 
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gives rise to resistance to geneticin (G148). To determine the dose of G418 required 
for selection a series of G418 doses (0- 1mg/mL) were tested in K562 cells. A dose 
of 750µg/mL was selected for initial selection of clones, after which clones were 
cultured in medium containing 500µg/mL of G418, this was the lowest dose which 
inhibited cell proliferation of K562 cells (Figure.3.21).  
 
 
Figure 3.20. (A) MPO expression construct, taken from Orgiene. (B) Diagrammatic 
representation of the transfection procedure. (A) K562 cells were transfected with the expression 
construct RC216029 that encodes the human full-length MPO gene and G418 resistance gene. (B) 
K562 cells were transfected with the expression construct using a liposomal transfection method, in 
this method the expression construct and Dharmafect Duo are mixed prior to transfection allowing a 
DNA-liposome complex to form. Cells are transfected with the expression construct-Dharmafect duo 
mixture and incubated overnight at 37oC. The following day 750µg/mL of G418 is added to allow 
selection, when cells become sufficiently dense they are tested for MPO expression by 
immunofluorescence. 
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Figure 3.21. Testing G418 doses, a selection antibiotic, in K562 cells. K562 cells were treated 
with G418 (0-1mg/mL) for up to 6 days and assessed for cell growth at each 24hr timepoint.   
 
The transfection efficiency of K562 cells was 18%, determined from the number of 
cells remaining after addition of G418, which is in line with published data 
(Schakowski et al., 2004). Due to the low transfection efficiency, the K562 expressing 
MPO cells were isolated using a serial dilution method (method described in section. 
2.10.1). In this method K562 cells were seeded in one well of a 96-well plate and 
were serially diluted 1:2 across the entire plate. The aim is to dilute cells down to a 
single cell which after cycles of cell doubling will form discrete colonies containing a 
monoclonal cell population. Five clones were selected that were positive for both 
MPO activity and positive for MPO protein expression across the whole cell 
population (Figure. 3.22.) (see section 2.10.1 and 2.11). None of the five K562MPO cell 
clones had MPO activity above 40% of that in NB4 cells, however the activity of 
K562MPO cell lines 4 and 5 were comparable to HL60 and Kasumi-1 cells (Figure. 
3.8.B). Additionaly, K562 cells were transfected with a empty vector and clones were 
selected as a non-MPO expressing control. The selected K562 MPO expressing 
clones were probed using quantitative immunofluorescence for the level of TOP2 
protein (method described in section 2.11). This was important to investigate as if 
introduction of an MPO expression construct into K562 cells causes changes in 
overall TOP2 levels then this would effect data interpretation in latter experiments. 
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Results indicated the level of TOP2A or TOP2B did not differ between K562 and 
K562-derived MPO cell lines (Figure. 3.23).  
A limitation of the transfection of an MPO cDNA into K562 cells was the gradual 
silencing of the expression construct. MPO positive K562 cells that had been cultured 
for three weeks were probed for MPO expression. The tested cell lines had reduced 
MPO positive immunofluorescence compared to cells tested immediately after initial 
selection (Figure. 3.24). This limited the time available to conduct experiments on the 
K562-dervived MPO lines. 
3.3.9 Use of buthionine sulphoximine (BSO) to reduce glutathione levels.  
 
The metabolites of TOP2 poisons generated by MPO-mediated oxidation can be 
reduced by glutathione, limiting the level of DNA damage (Kagan et al., 1999; Kagan 
et al., 2001; Vlasova et al., 2011). Patients undergoing chemotherapy regimens 
generally have reduced levels of glutathione (Mukundan et al., 1999; Charushila and 
Subodhini, 2013; Kadam and Abhang, 2015). Therefore, glutathione levels were 
reduced using BSO, to investigate the effects of glutathione on TOP2 poison 
mediated DNA damage in Chapter 5. BSO is an irreversible inhibitor of glutamate 
cysteine ligase (γ-glutamylcysteine synthetase), inhibiting glutathione synthesis 
(Drew and Miners, 1984). The level of total and reduced glutathione remaining was 
analysed spectrophotometrically after the addition of BSO to NB4 cells (method 
described in 2.12). This assay relies on the glutathione recycling system in which 
glutathione reacts with exogenously added DTNB to produce TNB (=412nm), a 
substrate yellow in colour, allowing the determination of total and reduced glutathione 
(by omitting glutathione reductase) (Figure. 3.25.A). The addition of BSO in NB4 cells 
leads to a dose dependent decrease in both total and reduced levels of glutathione. 
A dose of 150µM gave the highest reduction in total glutathione (74.3% ± 8.4) and 
reduced glutathione (79.3% ± 8.57) (Figure. 3.25.B) and did not affect the in vitro 
TOP2 activity (experiment conducted by C.A. Austin published in Atwal et al., 2017).  
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Figure 3.22. Determination of MPO activity in five K562-dervived MPO expressing cells lines. 
(A) K562 derived MPO expressing cell lines were tested for the level of MPO activity colourimetrically 
and compared to NB4 cells (ab105135, Abcam UK). (B) K562 derived MPO expressing cell lines were 
tested for protein expression using immunofluorescence. All cells in the K562 MPO cell population 
were 100% positive for MPO expression. DAPI stains for DNA and MPO was probed using anti-MPO 
ab9535 (Abcam, UK).  
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Figure 3.23. Relative levels of TOP2A and TOP2B protein in K562 MPO expressing cell lines. 
TOP2 levels were quantified by immunofluorescence using antibodies specific to TOP2A (4566) or 
TOP2B (4555). Integrated fluorescence (IF) values were obtained per nucleus, data were combined 
from three separate experiments and expressed as a percentage relative to the mean of TOP2 IF 
levels in K562 cells ± S.E.M.  
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Figure 3.24. Silencing of MPO expression in K562-derived MPO cell lines. Cell lines were tested 
for MPO expression by immunofluorescence. DAPI stains for DNA and MPO was probed using anti-
MPO ab9535 (Abcam, UK).   
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Figure 3.25. Reduction of glutathione levels in NB4 cells upon BSO treatment. (A) Principle of 
colorimetric glutathione assay (KA0797, Abnova, Taiwan). (B) NB4 cells were treated with BSO (0-
200µM for 4.5hr) and assayed for the level of total (black) and reduced (grey) glutathione remaining 
following treatment. Data are expressed as mean ± S.E.M, n=3 except 0µM and 150µM 
measurements were conducted to n=6.  
 
3.4 Discussion  
 
This chapter describes how the various ‘tools’ required to address the question 
posed in this thesis were generated. The aim was to have a robust system in which 
MPO activity could be modulated. The siRNA knockdown approach specifically 
reduced the level of MPO protein and activity, but 25% or more activity remained 
after knockdown (Figure. 3.9 and Table 3.1). It was judged that this degree of 
residual MPO activity would make it difficult to determine any effect of MPO on TOP2 
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poison-mediated DNA damage. Therefore, a chemical inhibition strategy was 
pursued initially focussing on SA. Despite SA being a heam biosynthesis inhibitor 
rather than a direct inhibitor of MPO, SA has been extensively used as the main-line 
inhibitor for MPO inhibition in cellulo studies (Kagan et al., 1999; Kagan et al., 2001; 
Fan et al., 2006; Nakazato et al., 2007; Vlasova et al., 2011). SA behaves as a dual 
inhibitor of MPO as it reduces both protein and activity levels (Figure. 3.10-3.11). 
Previous studies have shown that the addition of SA does not disrupt cellular 
morphology (Pinnix et al., 1994). However, to our knowledge published studies 
lacked appropriate controls to analyse whether SA, under the conditions used in this 
work (200µM, 48hr) would affect the cell growth, viability or cellular respiration. On 
the basis of the control experiments conducted in this work, SA treated cells behave 
similarly to untreated NB4 cells in terms of cell respiration and proliferation (Figures. 
3.13-3.15). Treatment with SA for up to 96hr did induce an increase in the reduction 
of the XTT tetrazolium salt (Figure 3.12B). But experiments conducted using the 
Seahorse assay confirm that mitochondrial respiration and glycolytic activity remain 
unaffected with a 48hr pre-incubation of SA, which is the incubation time used to 
conduct further experiments (Figure.3.14). 
In addition, direct inhibitors of MPO became available during this work and two of 
these inhibitors; PF1355 and MPOi-II were also used to confirm the effects seen with 
SA. PF1355 and MPOi-II are chemically different in structure to each other 
(Figure.3.1). To allow confirmation of the data generated using inhibitors in NB4 cells, 
MPO expressing K562-dervived cell lines were established in which five cells lines 
were shown to be positive for MPO activity at a level comparable to HL60 and 
Kasumi-1 cells (Figure.3.22).  
With the conditions to modulate MPO expression and to reduce glutathione levels, 
the effect of TOP2 poison activity in relation to MPO and glutathione were 
investigated.  
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Chapter 4. Effect of MPO expression on TOP2 poison mediated DNA 
damage. 
4.1 Introduction  
 
Myeloperoxidase (MPO) expression is restricted to developing myeloid progenitor 
cells and neutrophils (Klebanoff, 2005; Malle et al., 2007). In neutrophils, MPO aids 
in the killing of pathogenic microorganisms by generating hypochlorous acid and is 
involved in the formation of neutrophil extracellular traps (NETs) (Harrison and 
Schultz, 1976; Metzler et al., 2011). MPO is also capable of the biotransformation of 
both etoposide and mitoxantrone resulting in metabolites that have altered DNA 
damaging properties (Haim et al., 1986; Haim et al., 1987b; Kagan et al., 1994; 
Panousis et al., 1994; Panousis et al., 1997; Kagan et al., 1999; Kagan et al., 2001; 
Vlasova et al., 2011; Gibson et al., 2016) (Details in section 1.2 and 1.3). 
The mechanism of MPO-mediated oxidation of etoposide has been well documented. 
However, less is known about the mechanisms of mitoxantrone oxidation. MPO can 
catalyse the sequential one-electron oxidation of etoposide generating etoposide 
quinone via a phenoxyl radical intermediate (Fan et al., 2006) (Figure. 4.1). 
Additionally MPO can oxidise etoposide catechol to etoposide quinone. Etoposide 
catechol is a metabolite generated from the action of CYP3A4 and/or CYP3A5, and 
can poison TOP2 with a two-fold greater potency compared to etoposide in vitro 
(Figure. 4.1) (Zhuo et al., 2004; Jacob et al., 2013; Zheng et al., 2015). However, 
etoposide quinone is reported to be several fold more potent at poisoning TOP2 in 
vitro and can also covalently interact with the N-terminal clamp of TOP2 acting as a 
covalent TOP2 poison (Vlasova et al., 2011; Jacob et al., 2013; Gibson et al., 2016) 
(described in section 1.3.1).   
 
Figure. 4.1. Chemical structure of etoposide metabolites. 
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Mitoxantrone undergoes biotransformation at its phenylenediamine substructure 
resulting in the formation of a reactive quinone-diimine intermediate, which further 
undergoes intramolecular cyclisation to a naphthoquinoxaline metabolite (Figure. 4.2) 
(Blanz et al., 1991). Naphthoquinoxaline is the intermediate product of the MPO 
catalysed reaction and is further oxidised to an additional two metabolites of 
unknown identity (Panousis et al., 1994).  
 
Figure 4.2. Chemical structures of mitoxantrone and naphthoquinoxaline metabolite. 
 
The presence of active MPO expression has been shown to increase the level of 
etoposide mediated DNA damage in CD34+ cells (multipotent hematopoietic stem 
cells) and may also increase the level of drug stabilised TOP2-DNA complexes in the 
absence of glutathione in myeloid cell lines (Kagan et al., 2001; Vlasova et al., 2011). 
However, the studies reported used the SDS-KCl precipitation assay which allows 
the detection of all covalent proteins bound to DNA, but is not specific for TOP2 and 
neither does it identify which isoform of TOP2 is bound to DNA (Zhitkovich and 
Costa, 1992). The identity the TOP2 isoform is of interest, as TOP2B appears to be 
required for etoposide mediated carcinogenesis in mice and for etoposide-mediated 
chromosomal breaks at MLL and RUNX1 loci (Azarova et al., 2007; Cowell et al., 
2012; Smith et al., 2014a). Therefore it is of interest to investigate whether the 
inhibition of MPO affects the level of TOP2 poison stabilised TOP2-DNA complexes 
differentially between the two TOP2 isoforms. 
4.2 Aims 
  
The aims of this chapter are to investigate the effects of MPO expression on the level 
of etoposide- and mitoxantrone-induced TOP2-mediated DNA damage. To address 
this, two separate cell based systems were employed to deduce the effects of MPO. 
Firstly, MPO activity was inhibited in the MPO expressing cell line, NB4 and secondly 
MPO was exogenously expressed in the MPO non-expressing cell line, K562. MPO 
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inhibition was achieved using succinylacetone (SA) and when they became available, 
new direct MPO inhibitors, PF1355 and MPOi-II. Using these systems, the effects of 
MPO activity on the accumulation of TOP2 poison induced TOP2-DNA complexes 
and DNA DSB, as measured by γH2Ax phosphorylation at Ser139 was investigated.   
4.3 Results 
4.3.1 Stabilisation of TOP2-DNA covalent complexes by etoposide and 
mitoxantrone  
 
To quantify the level of TOP2 poison-stabilised TOP2-DNA covalent complexes the 
TARDIS assay was employed (Willmore et al., 1998; Cowell et al., 2011). Previous 
work from the Austin lab has determined the range of etoposide and mitoxantrone 
concentrations for which the TARDIS assay can reliably quantify TOP2-DNA 
complexes. For etoposide, the dose range was determined to be 1µM to 100µM for 
detecting stabilised TOP2A-DNA complexes and 10µM to 100µM etoposide for 
TOP2B-DNA complexes (Willmore et al., 1998; Errington et al., 1999). For 
mitoxantrone, 0.5µM and 1µM were the optimal doses to detect both stabilised 
TOP2A and TOP2B complexes. However, these concentrations were determined in 
human lymphoblast cell lines, K562 cells and in mouse embryonic fibroblasts 
(MEFs). To ascertain whether these doses are also suitable in NB4 cells, NB4 cells 
were exposed to a range of concentrations of either etoposide (1µM to 100µM) or 
mitoxantrone (0.1µM to 20µM) for 1 hour.  Following this the drug was removed from 
the cell medium and cells were embedded in agarose on slides, lysed, and probed 
using quantitative immunofluorescence to detect TOP2 protein covalently bound to 
DNA, using the TARDIS assay. This assay allows the quantification of TOP2 protein 
bound to DNA after removal of cellular constituents and non-covalently bound 
proteins from nuclear DNA by SDS-salt extraction (see section 2.13). 
Consistent with previous data, etoposide produced a dose-dependent increase in 
TOP2A- and TOP2B-DNA covalent complex stabilisation (Figure. 4.3.A-D). (Willmore 
et al., 1998). In Figures 4.3.A and B data are represented as scatter-grams where 
each data-point represents the integrated fluorescence signal obtained from a single 
nucleus, a minimum of 300 nuclei were analysed per treatment. The intensity of 
integrated fluorescence is distributed heterogeneously in the cell population, which 
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may be due to the differences in cell-cycle phases of each individual cell (Figure. 
4.3A-B). For this reason when conducting analysis of replicate experiments, the 
median value, indicated by the red line (Figure. 4.3A-B), is selected to combine data 
from biological replicates (normalisation details described in section. 2.14). Figure. 
4.3.A and B represent data obtained from a single biological replicate, data from four 
additional experiments were combined using the median values, to produce the data 
shown in Figure. 4.3.C and D. The intensity of the integrated fluorescence was lower 
for TOP2B than TOP2A, an observation that is consistent with previous data and is 
seen with different anti-TOP2 antibodies (Willmore et al., 1998). As a result 1µM 
etoposide gave a fluorescence signal reproducibly above background for TOP2A 
(P=0.016), however for TOP2B 10µM etoposide was required to obtain a signal that 
was significantly above background (P=0.045). Therefore, for subsequent TARDIS 
experiments, a higher dose of 100µM and a lower dose of 10µM of etoposide were 
chosen. The chosen etoposide dose range can robustly allow the quantification of 
TOP2-DNA complexes by the TARDIS assay in NB4 cells. These doses are 
comparable with previous observations reported data in CCRF-CEM (human 
lymphoblast cell line) and MEFs (Willmore et al., 1998; Errington et al., 1999). 
Similar dose range experiments were performed for mitoxantrone using doses 
ranging from 0.1µM to 20µM. In contrast to the results obtained for etoposide, 
mitoxantrone reached a peak in fluorescence intensity at 1µM and higher doses of 
10µM and 20µM resulted in a lower signal (Figure. 4.4.A-D). Notably this 
phenomenon was observed previously in MEFs cells (Errington et al., 1999). The 
reason for the decline could be that in addition to poisoning TOP2, mitoxantrone can 
behave as a catalytic inhibitor of TOP2 (see chapter 6 section 6.3.5). The mechanism 
of catalytic inhibition is likely to be indirect, through either mitoxantrone oxidation 
leading to mitoxantrone-DNA adducts or through chromatin compaction, hence 
preventing TOP2 from binding to DNA (Parker et al., 1999; Parker et al., 2000; 
Hajihassan and Rabbani-Chadegani, 2009). In addition, the relative intensity of 
integrated fluorescence for mitoxantrone was lower than that obtained with etoposide 
suggesting mitoxantrone is a less potent TOP2 poison compared to etoposide 
(Figure. 4.3A-B & 4.4A-B). For subsequent experiments, a dose of 1µM of 
mitoxantrone was selected as the higher dose and a lower dose of 0.5µM was also 
chosen. The effect of mitoxantrone at 20µM is presented in chapter 6 section 6.3.5. 
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Figure 4.3. Dose response for etoposide mediated TOP2A and TOP2B-DNA covalent complex 
stabilisation. NB4 cells were treated with the specified doses of etoposide or a vehicle control 
(DMSO 0.02%(v/v)), for 1hr. TOP2-DNA covalent complexes were quantified by TARDIS analysis 
using antibodies specific to TOP2A (A) or TOP2B (B) n=1. Integrated fluorescence values were 
determined per nucleus (at least 300 nuclei per treatment), data are depicted as scatterplots, and 
each point corresponds to the integrated fluorescence value obtained for a single nucleus. From these 
experiments the median values (red line) were obtained and the mean of medians were calculated for 
replicate experiments (n=5). Data are expressed relative to 100µM etoposide (n=5) for stabilised 
TOP2A (C) and TOP2B (D) DNA complexes ± S.E.M.  
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Figure 4.4. Mitoxantrone stabilises TOP2A and TOP2B-DNA covalent complexes. NB4 cells were 
treated with the specified doses of mitoxantrone for 1 hr. Mitoxantrone stabilised TOP2-DNA covalent 
complexes were quantified using the TARDIS assay for either TOP2A (A) or TOP2B (B) (n=1). Data in 
(A) and (B) are depicted as scatterplots, each point represents the integrated fluorescence value 
obtained for a single nucleus, the red line indicates the median value. The means of medians were 
calculated from replicate experiments (n=5). Data are expressed as a percentage from the mean value 
obtained with 1µM mitoxantrone for TOP2A (C) and TOP2B (D) stabilised DNA complexes ± S.E.M. 
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4.3.2 Active MPO expression enhances etoposide-mediated TOP2-DNA 
covalent complex stabilisation.  
 
MPO activity can be effectively reduced in the MPO-expressing cell line NB4 using 
the heam biosynthesis inhibitor, SA. A 48hr pre-incubation of NB4 cells with 200µM 
SA resulted in complete loss of detectable MPO activity accompanied by the 
reduction in mature MPO protein with no effect on TOP2 protein levels or activity 
(see sections 3.3.4, 3.3.6 and (Atwal et al., 2017). This system was employed to 
determine the affect of MPO activity on the accumulation of TOP2A and TOP2B 
enzyme-DNA complexes measured by the TARDIS assay. Inhibition of MPO using 
SA pre-treatment in NB4 cells reduced the level of etoposide stabilised TOP2A- and 
TOP2B-DNA complexes at both 10µM and 100µM etoposide for all cells within the 
population (Figure.4.5A-B). Notably the magnitude of complex reduction after 
etoposide treatment was greater for TOP2B than TOP2A (Figure.4.5.C-D). At 10µM 
etoposide, there was a 55% (P=0.013) reduction in the level of TOP2B-DNA 
complexes whereas for TOP2A, levels reduced by 18% (P=0.033) (Figure 4.5.E). A 
similar trend was observed at 100µM etoposide treatment, the level of complex 
reduction for SA pre-treated cells was 38% for TOP2B (P=0.019) and 12% for 
TOP2A (P=0.025) (Figure.4.5.C-E). To confirm the reduced TARDIS signal in SA-
pretreated cells was due to suppression of MPO activity, similar experiments were 
performed in K562 cells, a cell line that does not express MPO (Ch3.3.3). As 
expected, SA pretreatment did not affect the level of etoposide stabilised TOP2 
complexes in K562 cells (Figure.4.6.A-C).  
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E Cell 
line 
TARDIS 
Assay 
Pre-
treatment 
Etoposide/
µM 
%+ve 
control  SEM  
Sig (P-
value) 
% 
reduction 
by SA 
 NB4 TOP2A None  10 39.4 2.3 
 
  
 NB4 TOP2A SA 10 32.3 3.9 0.033 18.1 
 NB4 TOP2A None  100 100 1.4 
 
  
 NB4 TOP2A SA 100 87.7 0.2 0.025 12.4 
 NB4 TOP2B None  10 50.5 4.9     
 NB4 TOP2B SA 10 22.6 6.7 0.013 55.3 
 NB4 TOP2B None  100 100 11.1 
 
  
 
NB4 TOP2B  SA 100 59.6 7.9 0.019 38.3 
 
Figure 4.5. Inhibition of MPO reduces etoposide stabilised TOP2-DNA covalent complexes. NB4 
cells were pre-incubated with 200µM SA for 48hr followed by 1hr incubation with etoposide (10µM or 
100µM), or a vehicle control. Cells were processed and analysed for the level of etoposide stabilised 
TOP2-DNA covalent complexes for TOP2A (A) or TOP2B (B). Data in A-B are represented as the 
integrated fluorescence obtained per nucleus for a single biological replicate (a minimum of 600 nuclei 
were analysed per treatment). Data obtained from an additional two experiments were combined and 
expressed as histograms shown in C and D for TOP2A and TOP2B respectively and are expressed 
relative to the mean value obtained with 100µM etoposide in the absence of SA. (E) Percentage 
values are expressed relative to the mean value obtained with 100µM etoposide in the absence of SA 
and significance (Sig) values are shown for the difference between control and SA pretreatment. 
Statistical analysis was performed by the one-way ANOVA with post hoc Tukey’s multiple comparison 
test.   * P <0.05. 
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    C 
Cell line 
TARDIS 
Assay 
Pre-
treatment 
Etoposide/
µM 
%+ve 
control SEM 
Sig       
(P-value) 
 K562 TOP2A None  10 31.2 2.8   
 K562 TOP2A SA 10 32.7 0.3 0.979 
 K562 TOP2A None  100 100 4.6   
 K562 TOP2A SA 100 107.6 1.9 0.271 
 K562 TOP2B None  10 17.1 3.3   
 K562 TOP2B SA 10 20.2 1.2 0.993 
 K562 TOP2B None  100 100 10.6   
 
K562 
TOP2B-
TOP2B SA 100 98.8 12.3 >0.999 
 
Figure 4.6. SA does not affect etoposide TOP2 poisoning ability in cells that do not express 
MPO. K562 cells were incubated with 200µM of SA for 48hr followed by the treatment with etoposide 
or a vehicle control and evaluated for the level of stabilised TOP2A (A) and TOP2B (B) DNA 
complexes. Data are expressed relative to 100µM etoposide in the absence of SA ±S.E.M. (C) 
Percentage values are expressed relative to the mean value obtained with 100µM etoposide in the 
absence of SA and significance (Sig) values are shown for the difference between control and SA 
pretreatment for each drug dose tested. Statistical analysis was performed by the one-way ANOVA 
with post hoc Tukey’s multiple comparison test.    
 
To further verify the role of MPO in elevating the level of TOP2-DNA complexes 
induced by etoposide, MPO expressing K562 clones were produced by the stable 
transfection of a human full-length MPO expression construct using a liposomal 
transfection method (see section 3.3.8). Using this method, five K562-dervived MPO 
expressing cell lines were obtained, all cells were positive for MPO expression by 
immunofluorescence. Results from the MPO colorimetric activity assay showed the 
K562MPO cells have MPO activity ranging from 15% to 40% of that compared to NB4 
cells, with lines 4 and 5 having more MPO activity compared to HL60 and Kasumi-1 
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cells (Table 4.1). Additionally, the K562MPO cell lines were tested for TOP2A and 
TOP2B expression levels using quantitative immunofluorescence. This was important 
to examine, as variations in TOP2 protein levels between the K562MPO cell lines and 
parental K562 cells would affect the data obtained from the TARDIS and γH2Ax 
assays.  Data obtained for TOP2 protein expression showed both the K562MPO cell 
lines and parental K562 cells express TOP2A and TOP2B at similar levels (Table 
4.2).   
Cell line  
Average MPO 
activity (nmol TNB 
consumed/min/mL) 
% MPO activity 
compared to NB4 
cells  
NB4 203.02 100.0±8.8 
HL60 48.42 23.8±5.9 
Kasumi-1 53.03 26.1±10.2 
K562MPO Line 1 39.11 19.3±3.3 
K562MPO Line 2 37.32 18.4±1.6 
K562MPO Line 4 60.25 29.7±3.5 
K562MPO Line 5 77.06 38.0±2.5 
K562MPO Line 6 30.13 14.8±1.9 
 
Table 4.1 MPO activity in cells lines, assayed using the MPO colorimetric activity assay (ab105136, 
Abcam) (for further details see 3.3.3 and 3.3.8).  
 
Cell line  
Relative levels of 
TOP2A 
Relative levels of 
TOP2B 
K562 100 100 
K562MPO Line 1 121.7±27.8 106.3±31.5 
K562MPO Line 2 131.3±9.42 99.7±21.3 
K562MPO Line 4 111±13.4 96.7±2.0 
K562MPO Line 5 95.1±7.1 95.2±4.2 
K562MPO Line 6 132.2±20.3 85.4±9.6 
 
Table 4.2 Protein expression levels of TOP2A and TOP2B determined by quantitative 
immunofluorescence (for further details see 3.3.8) 
 
The K562MPO cell lines were treated with either 10µM or 100µM etoposide and 
assayed for the level of drug-stabilised complexes by the TARDIS assay. The 
K562MPO cell lines displayed greater levels of etoposide-stabilised complexes for both 
TOP2A and TOP2B compared to parental K562 cells, the level of increase in 
complex stabilisation correlated with MPO activity (Figure.4.7.A-C). K562MPO line 5 
expresses 77.06 nmol TNB consumed/min/mL MPO activity which is 38% of that 
observed in NB4 cells (Table 4.1). Etoposide (10µM) treatment in line 5 induced 58% 
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(P<0.001) and 46% (P=0.042) more stabilised TOP2A and TOP2B complexes 
compared to parental K562 cells (Figure. 4.7B-D). For 100µM etoposide, the figures 
were 39% (P<0.001) and 48% (P=0.002) for TOP2A and TOP2B respectively 
(Figure. 4.7B-C). Whereas, K562MPO line 1, which has 39 nmol TNB 
consumed/min/mL MPO activity (Figure. 4.7A) displayed an increase in TOP2A 
stabilised complexes with 10µM and 100µM etoposide, but no difference in TOP2B 
stabilised complexes were observed compared to parental K562 cells (Figure. 4.7B-
C). The results generated in the K562MPO cell lines show greater level of etoposide-
stabilised complexes compared to parental K562 cells that do not contain MPO 
expression. The level of increase in etoposide-stabilised complexes is dependent on 
the level of MPO activity present within a cell. 
K562 cells were transfected with an empty plasmid vector using the equivalent 
transfection conditions used to produce the K562MPO cell lines. K562 cells transfected 
with the empty plasmid vector were tested for the level of etoposide stabilised TOP2-
DNA complexes. The empty vector did not affect the level of etoposide-stabilised 
complexes for either TOP2A or TOP2B compared to non-transfected K562 cells, 
further confirming the effect observed in the K562MPO cells was due to the expression 
of active MPO (Figure. 4.8A-B).  
If the elevated level of etoposide-induced TOP2A and TOP2B TARDIS signal is due 
to the exogenous expression of MPO in K562 cells, then it should be abolished by 
the inhibition of MPO. The effect of SA pretreatment in K562MPO cell line 2 was 
analysed for the level of TOP2 covalent complex stabilisation at 100µM etoposide. As 
shown in Figure 4.9, pretreatment with SA reduced the level of etoposide stabilised 
TOP2 complexes in comparison to non-SA pretreated K562MPO cell line 2. For 
TOP2A, SA pretreatment resulted in a 52% (P<0.001) reduction in TOP2A 
complexes and for TOP2B the reduction was 46% (P<0.001) (Figure 4.9.A-C). 
Notably, SA reduced the level of etoposide-stabilised complexes in the K562MPO cell 
line 2 to a level that was no longer significantly different to parental K562 cells 
(P>0.999 for TOP2A and P= 0.830 for TOP2B) (Figure.4.9 A-B). The effect of SA 
pre-treatment could not be tested in the remaining K562MPO cells lines due to 
silencing of the MPO expression construct, which limited the time available to 
conduct experiments.  
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     D 
Cell line 
TARDIS 
Assay 
Etoposide
/µM 
%+ve 
control SEM Sig (P-value) 
% increase 
compared to 
K562 
 K562  TOP2A 10 31.2 3.2 
!
  
 K562-line 1 TOP2A 10 59.1 6 0.003 47.2 
 K562-line 2 TOP2A 10 35.6 6.4 0.988 - 
 K562-line 4 TOP2A 10 59.8 2.4 <0.001 47.7 
 K562-line 5 TOP2A 10 75.2 0.5 <0.001 58.4 
 K562-line 6 TOP2A 10 47.1 2.1 0.160 - 
 K562  TOP2A 100 100 2.7 
 
  
 K562-line 1 TOP2A 100 168.4 10.1 <0.001 40.1 
 K562-line 2 TOP2A 100 169.6 15.8 <0.001 41 
 K562-line 4 TOP2A 100 134.5 7.2 0.027 25.6 
 K562-line 5 TOP2A 100 163.9 8.5 <0.001 39.0 
 K562-line 6 TOP2A 100 201.9 19.2 <0.001 50.4 
 K562  TOP2B 10 22.6 2.6     
 K562-line 1 TOP2B 10 23 2.7 >0.99  - 
 K562-line 2 TOP2B 10 26.3 3.7 >0.99 12.7 
 K562-line 4 TOP2B 10 32.9 5.5 0.030 30.1 
 K562-line 5 TOP2B 10 42.6 6.7 0.042 45.6 
 K562-line 6 TOP2B 10 41.4 4 0.026 43.8 
 K562  TOP2B 100 100 5.4 
 
  
 K562-line 1 TOP2B 100 104.2 14.8 >0.99 - 
 K562-line 2 TOP2B 100 161.4 23.9 <0.001 37.9 
 K562-line 4 TOP2B 100 135.4 6.7 0.046 26 
 K562-line 5 TOP2B 100 191.8 8 0.002 48 
 K562-line 6 TOP2B 100 161.8 13.7 <0.001 37.9 
 
Figure 4.7. Expression of active MPO potentiates the level of etoposide-stabilised TOP2-DNA 
covalent complexes. (A) MPO activity of K562MPO cell lines.  Parental K562 and five MPO expressing 
K562-derived cell lines were treated with etoposide (10µM or 100µM), or a vehicle control for 1hr. 
TOP2-DNA complexes were quantified using the TARDIS assay for TOP2A (B) or TOP2B (C). (D) 
Supporting percentage values expressed relative 100µM etoposide and p values obtained for the 
significance between parental K562 cells and K562MPO cell lines following each treatment.  Data are 
expressed relative to the mean value obtained for parental K562 cells treated with 100µM etoposide 
±S.E.M. Statistical analysis was performed by the one-way ANOVA with post hoc Tukey’s multiple 
comparison test.    *P<0.05; **P<0.01; and ***P<0.001. 
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C 
Cell line 
TARDIS 
Assay 
Etoposide
/µM 
%+ve 
control SEM 
Sig (P-
value) 
 K562 TOP2A 10 31.9 2.3   
 
Empty vector  
TOP2A 
10 27.0 2.9 0.960 
 K562 TOP2A 100 100.0 15.5   
 
Empty vector  
TOP2A 
100 88.2 6.3 0.670 
 K562 TOP2B 10 28.5 4.0   
 Empty vector  TOP2B 10 21.5 5.2 0.890 
 K562 TOP2B 100 100.0 5.5   
 Empty vector  TOP2B 100 87.2 11.1 0.600 
 
Figure 4.8. K562 cells transfected with an empty plasmid vector does not alter etoposide-
stabilised TOP2-DNA complexes. K562 cells were transfected with a p-CMV-6 empty plasmid 
vector. Parental K562 cells and K562 transfected cells were treated with etoposide (10µM or 100µM), 
or a vehicle control for 1hr. TOP2-DNA covalent complexes were quantified using antibodies specific 
to TOP2A (A) or TOP2B (B). (C) Supporting table to show the percentage values relative to the mean 
value obtained with 100µM etoposide and significance values obtained for the difference between the 
control and empty vector drug treatments. Data are expressed relative to the mean value obtained for 
parental K562 cells treated with 100µM etoposide ±S.E.M. Statistical analysis was performed by the 
one-way ANOVA with post hoc Tukey’s multiple comparison test.    
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C 
Cell line 
Pre-
treatment 
TARDIS 
Assay 
Etoposide
/µM 
%+ve 
control SEM 
Sig   (P-
value) 
% 
reduction 
by SA 
 K562 None TOP2A 100 100 3.2 
 
  
 K562-line 2 None TOP2A 100 191.8 16.0 <0.001 51.6 
 K562-line 2 SA TOP2A 100 93.3 2.6 <0.001   
 K562 None TOP2B 100 100 46.8     
 K562-line 2 None TOP2B 100 255.5 10.9 <0.001 46.4 
 K562-line 2 SA TOP2B 100 136.9 22.8 <0.001   
 
Figure 4.9. SA reduces the level of etoposide stabilised TOP2-DNA covalent complexes in 
K562MPO cell line 2. K562 MPO cell line 2 was pre-incubated in the presence or absence of SA (200µM 
48hr) followed by the treatment with 100µM etoposide, or a vehicle control for 1hr. TOP2-DNA 
complex levels were analysed using the TARDIS assay for (A) TOP2A or (B) TOP2B. (C) Percentage 
values relative to the mean value obtained for 100µM etoposide in the absence of SA and significance 
of the difference between the control (non SA treated K562 MPO cell line 2) and SA treated K562 MPO 
cell line 2. Data are expressed relative to the mean of parental K562 treated with 100µM etoposide 
±S.E.M. Statistical analysis was performed by the one-way ANOVA with post hoc Tukey’s multiple 
comparison test.   *P<0.05; ***P<0.001.  
 
A limitation in the stable transfection of MPO expression into K562 cells was the 
silencing of the expression construct. Figure. 4.10.A-B shows cells three weeks after 
the selection of K562MPO cell line 6, this clone displayed a reduction in MPO 
expression and activity (P=0.023) compared to immediately after selection. The MPO 
silenced Line 6 was tested in the TARDIS assay and the silenced Line 6 did not differ 
in the level of etoposide stabilised complexes compared to parental K562 cells for 
either TOP2A or TOP2B (Figure. 4.10.C-E). Taken together, the data generated in 
the K562 derived MPO expressing cell lines and NB4 cells supports the hypothesis 
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that active MPO protein has a role in enhancing etoposide stabilised TOP2-DNA 
complexes.   
 
     E 
Cell line 
TARDIS 
Assay 
Etoposide/
µM 
%+ve 
control SEM Sig (P-value) 
 K562 TOP2A 10 24.9 1   
 K562-line 6 TOP2A 10 26.2 3.3 0.999 
 K562 TOP2A 100 100 10   
 K562-line 6 TOP2A 100 113 13 0.747 
 K562 TOP2B 10 6.7 0.9   
 K562-line 6 TOP2B 10 11 3.6 0.982 
 K562 TOP2B 100 100 14   
 K562-line 6 TOP2B 100 91 8.1 0.865 
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Figure 4.10. Silencing of the MPO expression construct in K562 cells results in a comparable 
level of etoposide stabilised TOP2-DNA complexes to parental K562 cells. Comparison of (A) 
MPO immunofluorescence and (B) MPO activity in NB4, K562 MPO cell line 6 and K562 cell line 6 three 
weeks after selection. (C-D) K562 and K562MPO cell line 6 (three week after selection) were treated 
with etoposide or vehicle control for 1hr and processed for the level of TOP2A (C) and TOP2B (D) 
complexes. (E) Supporting table to show mean percentage values of integrated fluorescence obtained 
relative to the mean value of 100µM etoposide in K562 cells and the significance values between 
parental K562 and K562 cell line 6 three weeks after selection. Data are expressed relative to the 
mean value obtained for parental K562 cells treated with 100µM etoposide ±S.E.M. Statistical analysis 
was performed by the one-way ANOVA with post hoc Tukey’s multiple comparison test.    
 
4.3.3 MPO expression enhances mitoxantrone stabilised TOP2 covalent 
complexes 
 
The previous section demonstrated MPO-dependent stimulation of etoposide 
induced TOP2-DNA covalent complex accumulation. Next, the effect of MPO on 
TOP2 DNA complex formation by the anthracenedione, mitoxantrone was studied 
using the TARDIS assay.  NB4 cells were pre-treated with 200µM SA for 48hr to 
inhibit MPO activity. SA pre-treatment in NB4 cells substantially reduced the level of 
mitoxantrone-stabilised complexes compared to control cells (Figure.4.11.A-D), 
reducing the level of complexes across the cell population (Figure.4.11A-B). At 
0.5µM mitoxantrone, SA pre-treatment reduced TOP2A complexes by 49% 
(P<0.001) and by 50% (P=0.020) for TOP2B, for 1µM the figures were 31% 
(P<0.001) and 46% (P<0.001) respectively (Figure.4.11.E) This supports the 
hypothesis that active MPO protein enhances mitoxantrone stabilisation of TOP2-
DNA complexes. 
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  E 
Cell 
line 
TARDIS 
Assay 
Pre-
treatment 
Mitoxantrone
/µM 
%+ve 
control SEM 
Sig (P-
value) 
% 
reduction 
by SA 
 NB4 TOP2A None  0.5 59.43 3.7 
 
  
 NB4 TOP2A SA 0.5 30.21 2.6 <0.001 49.2 
 NB4 TOP2A None  1 100 4.8 
 
  
 NB4 TOP2A SA 1 69.1 2.9 <0.001 31 
 NB4 TOP2B None  0.5 65.6 9.8     
 NB4 TOP2B SA 0.5 32.8 3.1 0.020 50 
 NB4 TOP2B None  1 100 10.5 
 
  
 NB4 TOP2B SA 1 54.3 5.7 <0.001 45.7 
 
Figure 4.11. MPO inhibition reduces the level of mitoxantrone stabilised TOP2A and TOP2B-
DNA complexes. NB4 cells were pre-incubated in presence or absence of 200µM SA for 48hrs 
followed by a 1hr treatment with mitoxantrone (0.5 or 1µM). TOP2-DNA covalent complexes were 
quantified for (A&C) TOP2A or (B&D) TOP2B. A-B represents data obtained from a single experiment 
with at least 600 nuclei analysed per treatment. Data from additional experiments were combined 
using median values (red line) and represented in figures C-D for TOP2A or TOP2B respectively and 
expressed relative to the mean value obtained with 1µM mitoxantrone in the absence of SA ± S.E.M.. 
(E) Percentage values are expressed relative to the mean value obtained with 1µM mitoxantrone in 
the absence of SA and significance (Sig) values are shown for the difference between control and SA 
pretreatment. Statistical analysis was performed by the one-way ANOVA with post hoc Tukey’s 
multiple comparison test.  *P<0.05 and ***P<0.001.  
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TOP2B gives a noticeable TARDIS signal in non-drug treated cells. Therefore, the 
non-drug treated levels were subtracted from the mitoxantrone treated values for 
both TOP2A and TOP2B. The data processed in this way is shown in Figure 4.12. 
After subtraction of the signal obtained in untreated cells, TOP2A and TOP2B 
complexes reduced by 59% (P<0.001) and 67% (P=0.043) with 0.5µM mitoxantrone 
in SA treated cells, and with 1µM mitoxantrone complexes reduce by 37% (P<0.001) 
and 64% (P=0.003) (Figure.4.12 A-C). Additionally, the level of stabilised complexes 
with 1µM mitoxantrone in SA pre-treated cells were comparable to the level of 
complexes stabilised at 0.5µM mitoxantrone in non-SA treated cells for both TOP2A 
(P=0.253) and TOP2B (P=0.695).  
As expected, SA pre-treatment in K562 cells did not alter the level of mitoxantrone-
stabilised complexes (Figure.4.13.A-B). The effect of mitoxantrone-stabilised 
complexes in the K562MPO cell line 2 was tested. Line 2 exhibits MPO activity of 37.3 
nmol TNB/consumed/min/mL which is 18% compared to NB4 cells (Table.4.1) 
Treatment with 1µM mitoxantrone induced a 54% (P<0.001) and 60% (P=0.021) 
increase in TOP2A and TOP2B complexes in K562MPO cell line 2 compared to 
parental K562 cells (Figure. 4.14.A-C). This further supports the idea that MPO 
increases mitoxantrone stabilised TOP2-DNA complexes.  
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  C Cell 
line 
TARDIS 
Assay 
Pre-
treatment 
Mitoxantrone
/µM 
%+ve 
control SEM 
Sig (P-
value) 
% reduction 
by SA 
 NB4 TOP2A None  0.5 57.44 4.3 !    NB4 TOP2A SA 0.5 24.41 2.3 <0.001 57.5 
 NB4 TOP2A None  1 100 4.9 !    NB4 TOP2A SA 1 62.89 3.3 <0.001 37.1 
 NB4 TOP2B None  0.5 43.63 9.8     
 NB4 TOP2B SA 0.5 14.84 3.1 0.043 67 
 NB4 TOP2B None  1 100 10.5 !    NB4 TOP2B SA 1 36.08 5.7 0.003 64 
 
Figure 4.12. Subtraction of non-drug treated levels: MPO inhibition reduces the level of 
mitoxantrone stabilised TOP2A and TOP2B-DNA complexes. NB4 cells were pre-incubated in 
presence or absence of 200µM SA for 48hr followed by a 1hr treatment with mitoxantrone (0.5 or 
1µM) and analysed for the level of drug-stabilised TOP2A- (A) or TOP2B- (B) DNA complexes. (C) 
Supporting table to show percentage values expressed relative to the mean value obtained with 1µM 
mitoxantrone in the absence of SA and significance (Sig) values are shown for the difference between 
control and SA pretreatment. Data are expressed relative to the mean value obtained with 1µM 
mitoxantrone after subtraction of non-drug treated integrated fluorescence values, in the absence of 
SA ± S.E.M. Statistical analysis was performed by the one-way ANOVA with post hoc Tukey’s multiple 
comparison test.  *P<0.05; **P<0.01; and ***P<0.001.  
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    C Cell 
line 
TARDIS 
Assay 
Pre-
treatment 
Mitoxantrone
/µM 
%+ve 
control SEM 
Sig (P-
value) 
 K562 TOP2A None  0.5$ 41.8$ 7.6$ $$
 K562 TOP2A SA 0.5$ 51.3$ 2.3$ 0.888$
 K562 TOP2A None  1$ 100.0$ 12.6$ $$
 K562 TOP2A SA 1$ 93.5$ 7$ 0.967$
 K562 TOP2B None  0.5$ 39.1$ 3.9$ $$
 K562 TOP2B SA 0.5$ 43.6$ 8.6$ 0.998$
 K562 TOP2B None  1$ 100.0$ 19.1$ $$
 K562 TOP2B SA 1$ 104.0$ 9.2$ 0.999$
 
Figure 4.13. SA does not alter the level of mitoxantrone stabilised TOP2-DNA complexes in 
K562 cells (a non-MPO expressing cell line). Cells were pre-incubated with 200µM SA for 48hr 
followed by 1hr incubation with mitoxantrone (0.5µM or 1.0µM), or a vehicle control. TOP2A (A) or 
TOP2B (B)-DNA covalent complexes were quantified as specified using the TARDIS assay. (C) 
Supporting table to show percentage values are expressed relative to the mean value obtained with 
1µM mitoxantrone in the absence of SA and significance (Sig) values are shown for the difference 
between control and SA pretreatment. Data are expressed relative to the mean value obtained with 
1µM mitoxantrone in the absence of SA ± S.E.M. Statistical analysis was performed by the one-way 
ANOVA with post hoc Tukey’s multiple comparison test.    
 
 136  
 
     C 
Cell line 
TARDIS 
Assay 
Mitoxantrone
/µM 
%+ve 
control SEM 
Sig (P-
value) 
% increase 
compared 
to K562 
 K562 TOP2A 1" 100" 9.8"
"
""
 K562-line 2 TOP2A 1" 214.9" 4.3" <0.001" 53.5"
 K562 TOP2B 1" 100" 37.8" "" ""
 K562-line 2 TOP2B 1" 247.6" 13.8" 0.021" 60"
 
Figure 4.14. Active MPO expression in K562 cells enhances mitoxantrone stabilised TOP2-DNA 
covalent complexes. Parental K562 cells and K562MPO line 2 were treated with 1µM mitoxantrone or 
a vehicle control for 1hr. TOP2A (A) and TOP2B (B) DNA covalent complexes were quantified using 
the TARDIS assay. (C) Percentage values relative to the mean value obtained for parental K562 cells 
treated with 1µM mitoxantrone and significance values show the difference between K562 and 
K562MPO line. Data are expressed relative to the mean value obtained for 1µM mitoxantrone in 
parental K562 cells ±S.E.M. Statistical analysis was performed by the Students t-test.**P<0.01; 
***P<0.001 
4.3.4 MPO increases the level of etoposide induced DNA double strand breaks.  
 
Etoposide elicits the induction of γH2Ax formation in cells, which indicates the 
processing of stabilised TOP2-DNA complexes to DNA double strand breaks (DSB) 
(Soubeyrand et al., 2010; Sunter et al., 2010; Cowell et al., 2011; Cowell et al., 2012; 
Álvarez-Quilón et al., 2014). The γH2Ax assay is commonly used as a surrogate for 
DNA DSB formation and was employed here to quantify DSB formation following 
TOP2 poison addition (method described in section 2.11).   
For each experiment, the γH2Ax integrated fluorescence values were determined per 
nucleus. Data were then calculated for the mean of the median values (red line) 
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obtained from at least three biological replicates using this assay (Figure.4.15.A). 
Etoposide exposure induces a dose-dependent increase in γH2Ax (Figure.4.15.A-B). 
Pre-treatment of NB4 cells with SA reduced the level of etoposide induced γH2Ax 
formation by 51% at 100µM etoposide (P<0.001), but had no significant effect at 
lower etoposide doses (Figure.4.15.B-C). The γH2Ax signal after SA pre-treatment at 
100µM etoposide was equivalent to the γH2Ax signal obtained at 10µM etoposide in 
the absence of SA (P>0.999). SA treatment alone did not alter the level of basal 
γH2Ax signal obtained in cells (Figure.4.15.B). The basal level of γH2Ax signal is 
thought to be due to DSBs caused during normal cell cellular progresses (McManus 
and Hendzel, 2005; An et al., 2010). The addition of SA to K562 cells did not affect 
the level of etoposide-induced γH2Ax at either 10µM (P>0.999) or 100µM (P=0.992) 
etoposide treatment, suggesting the effect seen with SA pre-treatment is due to the 
inhibition of MPO activity (Figure. 4.16. A-B).  
To further support the finding obtained in NB4 cells, the K562MPO cell lines 4, 5 and 6 
were treated with 10µM or 100µM etoposide and processed for the detection of 
γH2Ax formation (Figure. 4.17). At 10µM etoposide, all three K562MPO cell lines had 
significantly higher levels of γH2Ax signal compared to parental K562 cells with 
K562MPO cell lines 5 and 6 producing more than 50% higher γH2Ax signal than 
parental cells (P<0.001 and P=0.005 respectively). At 100µM etoposide, only line 5 
produced a significant increase of 19% in γH2Ax signal intensity (P=0.020) (Figure. 
4.17A-B). However, it was observed the level γH2Ax signal reaches saturation by 
100µM etoposide treatment in K562 cells (Figure.4.18). Therefore, it was not 
surprising that lines 4 and 6 did not show an elevated signal with 100µM etoposide 
as the γH2Ax signal had reached saturation.  
The empty vector K562 control line was also tested for γH2Ax formation after 
treatment with 10µM or 100µM etoposide. This cell line had a level of γH2Ax 
fluorescence comparable to non-transfected K562 cells at both 10µM (P>0.999) and 
100µM etoposide (P=0.930) (Figure.4.19.A-B). The data generated supports the idea 
that active MPO expression increases the DNA damage caused by etoposide in 
cells.  
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Figure 4.15. Inhibition of MPO reduces the level of etoposide induced global H2Ax 
phosphorylation at 100µM etoposide. NB4 cells were pre-treated with SA (200 µM for 48hrs) 
followed by the treatment with etoposide (0-100µM) or a vehicle control and processed by 
immunofluorescence to quantify the level of H2Ax phosphorylation. (A) A single biological replicate 
experiment is shown for the γH2Ax phosphorylation obtained per nucleus (a minimum of 2000 cells 
were analysed per treatment), data from additional biological experiments were combined using 
median values (red line) obtained (see section 2.14). (B) Data are expressed relative to the mean 
value of NB4 cells treated with 100µM etoposide ±S.E.M in the absence of SA. (C) Supporting table to 
show percentage values expressed relative to the mean value obtained with 100µM etoposide in the 
absence of SA and significance (Sig) values are shown for the difference between control and SA 
pretreatment. Statistical analysis was performed by the one-way ANOVA with post hoc Tukey’s 
multiple comparison test.  ***P<0.001.   
 
    C Cell 
line Assay 
Pre-
treatment 
Etoposide
/µM 
%+ve 
control SEM 
Sig (P-
value) 
% reduction 
by SA 
 NB4 γH2Ax None  5 31.7 4.1 
 
  
 NB4 γH2Ax SA 5 31 6.9 >0.999 2.2 
 NB4 γH2Ax None  10 45.6 3 
 
  
 NB4 γH2Ax SA 10 35.1 1.5 0.880 23 
 NB4 γH2Ax None  20 69.4 5 
 
  
 NB4 γH2Ax SA 20 49.7 15 0.453 28.3 
 NB4 γH2Ax None  100 100 7.5 
 
  
 NB4 γH2Ax SA 100 48.2 4.7 <0.001 51.2 
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B 
Cell 
line Assay 
Pre-
treatment 
Etoposide/
µM 
%+ve 
control SEM 
Sig (P-
value) 
 K562  γH2Ax None  10 43.6 4.4   
 K562  γH2Ax SA 10 43.9 7.0 >0.999 
 K562  γH2Ax None  100 100.0 9.0   
 K562  γH2Ax SA 100 94.5 7.0 0.992 
 
Figure 4.16. SA does not alter the level of etoposide induced H2Ax phosphorylation in non-
MPO expressing cells. K562 cells were incubated with 200µM of SA for 48hr followed by the 
treatment with etoposide or a solvent control (DMSO 0.02%(v/v)). Cells were processed as previously 
described to detect the level H2Ax phosphorylation.(B) Supporting table to show percentage values 
expressed relative to the mean value obtained with 100µM etoposide in the absence of SA and 
significance (Sig) values are shown for the difference between control and SA pretreatment. Data are 
expressed relative to the mean value obtained with 100µM etoposide in non-SA treated K562 cells 
±S.E.M. Statistical analysis was performed by the one-way ANOVA with post hoc Tukey’s multiple 
comparison test.    
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B 
Cell line Assay 
Etoposide
/µM 
%+ve 
control SEM 
Sig (P-
value) 
%increase 
compared 
to K562  
 K562 γH2Ax 10 33.2 0.9 
 
  
 K562-line 4 γH2Ax 10 48.8 2.1 0.035 31.9 
 K562-line 5 γH2Ax 10 71.0 20.0 <0.001 53.2 
 K562-line 6 γH2Ax 10 76.4 7.3 0.005 56.6 
 K562 γH2Ax 100 100.0 3.4 
 
  
 K562-line 4 γH2Ax 100 113.4 2.7 0.970 11.8 
 K562-line 5 γH2Ax 100 122.8 6.3 0.020 18.6 
 K562-line 6 γH2Ax 100 118.6 9.0 0.650 15.7 
 
Figure 4.17. Active MPO Expression increases etoposide-induced global H2Ax 
phosphorylation. K562 and K562MPO cell lines 4,5 and 6 were treated with etoposide (10µM or 
100µM), or a vehicle control for 1hr.  Etoposide-induced H2Ax phosphorylation was quantified by 
immunofluorescence. (B) Table shows the percentage values relative to 100µM etoposide obtained for 
parental K562 cells and significance values compare between parental K562 cells to K562MPO cell 
lines. Data are expressed relative to the mean value obtained with 100µM etoposide for parental K562 
cells ±S.E.M. Statistical analysis was performed by the one-way ANOVA with post hoc Tukey’s 
multiple comparison test.   *P<0.05; **P<0.01; and ***P<0.001.  
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Figure 4.18. Etoposide-induced H2Ax phosphorylation plateaus at 50µM. K562 cells were treated 
with etoposide (0,10,20,50,100 and 200µM) or a vehicle control for 1hr. Cells were quantified for the 
level of H2Ax fluorescence. Data are expressed as mean value obtained for 100µM etoposide ±S.E.M. 
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       B Cell 
line Assay 
Etoposide
/µM 
%+ve 
control SEM 
Sig (P-
value) 
 K562 γH2Ax 10 34.9 1.1   
 Empty 
vector γH2Ax 10 36.0 3.1 >0.999 
 K562 γH2Ax 100 100.0 4.7   
 Empty 
vector γH2Ax 100 92.3 17.3 0.930 
 
Figure 4.19. K562 cells transfected with an empty vector have comparable level of H2Ax 
phosphorylation to parental cells. K562 and K562 cells transfected with an empty plasmid vector 
(K562+empty vector) were treated with etoposide (10µM or 100µM), or a vehicle control for 1hr. 
Etoposide-induced γH2Ax phosphorylation was quantified. (B) Supporting table shows the percentage 
values relative to 100µM etoposide obtained for parental K562 cells, significance values are shown for 
the difference between K562 cells and K562+empty vector. Data are expressed relative to the mean 
value obtained with 100µM etoposide for parental K562 cells ±S.E.M. Statistical analysis was 
performed by the one-way ANOVA with post hoc Tukey’s multiple comparison test.    
 
4.3.5 MPO increases mitoxantrone induced γH2Ax formation.  
 
Mitoxantrone mediated DNA damage initiates γH2Ax formation (Huang et al., 2003). 
Analogous experiments to those performed etoposide were carried out for 
mitoxantrone to detect γH2Ax phosphorylation in NB4 cells. Mitoxantrone produced a 
dose dependent increase in γH2Ax formation up to 1µM mitoxantrone (Figure 4.20), 
with a decrease in signal intensity observed from 10µM, mirroring the trend observed 
for TOP2-DNA complex stabilisation (Figure. 4.4.A-D). 
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H2Ax phosphorylation was quantified in cells exposed to 0.5µM or 1µM mitoxantrone 
in the presence or absence of SA (to inhibit MPO). Pretreatment with SA in NB4 cells 
reduced the mitoxantrone induced γH2Ax formation by 40% at 1µM (P<0.001), 
resulting in a γH2Ax signal which is comparable to 0.5µM mitoxantrone treatment in 
non-pretreated NB4 cells (P=0.673) (Figure.4.21.A-B). In addition, SA pre-treatment 
did not alter the mitoxantrone induced γH2Ax formation in K562 cells (Figure.4.22). 
This data supports the idea that MPO has a role in mitoxantrone mediated DNA 
damage.  
 
Figure 4.20. Mitoxantrone induces H2Ax phosphorylation in NB4 cells.  Cells were treated with 
mitoxantrone (dose specified) or a vehicle control for 1hr. Cells were then analysed for the level of 
H2Ax phosphorylation by quantitative immunofluorescence (a surrogate measure for DNA double 
strand breaks). Data are expressed relative to 1µM mitoxantrone ±S.E.M. 
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    B 
Cell line Assay 
Pre-
treatment 
Mitoxantrone
/µM 
%+ve 
control SEM 
Sig (P-
value) 
% reduction 
by SA 
 
NB4 γH2Ax None  0.5 49.3 1.5 
 
  
 NB4 γH2Ax SA 0.5 36.4 2.2 0.692 26.2 
 NB4 γH2Ax None  1 100.0 7.5 
 
  
 NB4 γH2Ax SA 1 59.9 3.9 <0.001 40.1 
 
Figure 4.21. Inhibition of MPO reduces H2Ax phosphorylation at a higher dose of mitoxantrone. 
NB4 cells were pre-incubated with 200µM SA for 48hr followed by the treatment with mitoxantrone 
(0.5µM or 1.0µM) or a vehicle control for 1hr. Mitoxantrone induced H2Ax phosphorylation was 
quantified by immunofluorescence. (B) Percentage values are expressed relative to the mean value 
obtained with 1µM mitoxantrone in the absence of SA and significance (Sig) values are shown for the 
difference between control and SA pretreatment. Data are expressed relative to 1µM mitoxantrone in 
the absence of SA ±S.E.M. Statistical analysis was performed by the one-way ANOVA with post hoc 
Tukey’s multiple comparison test.  ***P<0.001. 
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     B 
Cell line Assay 
Pre-
treatment 
Mitoxantrone/ 
µM 
%+ve 
control SEM 
Sig (P-
value) 
 K562 γH2Ax None  0.5 69.6 1.3   
 K562 γH2Ax SA 0.5 76.4 5.9 0.780 
 K562 γH2Ax None  1 100.0 8.2   
 K562 γH2Ax SA 1 97.3 1.5 0.980 
 
Figure 4.22. SA does not alter mitoxantrone induced H2Ax phosphorylation in non-MPO 
expressing cells. K562 cells were pre-incubated with 200µM of SA for 48hr followed by the treatment 
with mitoxantrone (0.5µM or 1µM), or vehicle controls for 1hr. γH2Ax signals were quantified by 
immunofluorescence. (B) Percentage values are expressed relative to the mean value obtained with 
100µM etoposide in the absence of SA and significance (Sig) values are shown for the difference 
between control and SA pretreatment. Data are expressed relative to the mean obtained with 1µM 
mitoxantrone in the absence of SA ±S.E.M. Statistical analysis was performed by the one-way ANOVA 
with post hoc Tukey’s multiple comparison test.     
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4.3.6 Direct inhibition of MPO significantly reduces mitoxantrone and etoposide 
mediated TOP2 DNA damage.  
 
The data presented above in this chapter has shown the impact of active MPO 
expression on TOP2 poison induced TOP2-DNA complex and γH2Ax formation. 
However, the work conducted in NB4 cells employed the heam biosynthesis inhibitor 
SA to modulate MPO activity. Recently two specific MPO inhibitors; PF1355 and 
MPOi-II have become commercially available. PF1355 and MPOi-II were used in 
NB4 cells to test whether direct inhibition of MPO could reduce TOP2-DNA complex 
stabilisation and γH2Ax formation following exposure with etoposide or mitoxantrone. 
Optimal concentrations of PF1355 and MPOi-II to inhibit MPO in NB4 cells were 
determined as shown in section 3.3.7. To inhibit MPO either 10µM PF1355 or 5µM 
MPOi-II were added to NB4 cells for 4 hours prior to TOP2 poison addition. These 
doses of inhibitors were shown to significantly reduce MPO enzymatic activity whilst 
having minimal effect on cell growth or TOP2 levels (see section 3.3.7). Following 
drug removal, analysis of stabilised TOP2-DNA complexes using the TARDIS assay 
or DSB formation using γH2Ax detection by quantitative immunofluorescence were 
conducted.  
The addition of MPO inhibitors suppresses etoposide induced TOP2A- and TOP2B- 
DNA complex formation, the magnitude of reduction being more prominent for 
TOP2B (Figure.4.23.A-B), following a similar trend to that observed with SA 
(Figure.4.5.A-D). At 100µM etoposide treatment, TOP2B-DNA complexes reduced by 
47% in PF1355 treated cells (P<0.001) and by 58% with MPOi-II (P<0.001) 
(Figure.4.23.E). Notably the level of stabilised TOP2B complexes at 100µM 
etoposide in the presence of MPO inhibitors were comparable to the TARDIS signal 
obtained with 10µM etoposide in the absence of inhibitors (P=0.144 and P=0.797 for 
PF1355 and MPOi-II respectively). For TOP2A the reduction in stabilised complexes 
was 21% with PF1355 (P<0.001) and 18% with MPOi-II (P<0.001) in the presence of 
100µM etoposide. Prior treatment with PF1355 or MPOi-II reduced the level of 
mitoxantrone stabilised TOP2-DNA complexes (Figure.4.23.C-D). With 1µM 
mitoxantrone, the addition of PF1355 reduced the level of TOP2A-DNA complexes 
by 46% (P=0.005), for MPOi-II the reduction was 52% (P<0.001) (Figure.4.23.C-D). 
For TOP2B the addition of PF1355 or MPOi-II reduced the level of complexes by 
50% (P<0.001) and 53% (P<0.001) respectively with 1µM mitoxantrone treatment. 
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With 0.5µM mitoxantrone the level of TOP2B complexes reduced by 39% for both 
PF1355 and MPOi-II (Figure.4.23C-F). 
 
Figure 4.23. Direct MPO inhibition reduces etoposide or mitoxantrone (C-D) stabilised TOP2-
DNA complexes. NB4 cells were pre-treated with MPO inhibitors PF1355 (10µM 4hr) or MPOi-II (5µM 
4hr) or neither before adding etoposide (10µM or 100µM) (A,B) or mitoxantrone (0.5µM or 1µM) for 
1hr or a vehicle control. TOP2 poison stabilised TOP2-DNA complexes were quantified by TARDIS for 
TOP2A (A&C) or TOP2B (B&D). Data are expressed relative to the mean of 100µM etoposide 
obtained from untreated NB4 cells (black bars) ±S.E.M. Statistical analysis was performed by the one-
way ANOVA with post hoc Tukey’s multiple comparison test. *P<0.05; **P<0.01; ***P<0.001. (E-F) 
Supporting tables on next page to show the percentage values expressed relative the mean value 
obtained for 100µM etoposide (E) or 1µM mitoxantrone (F) in non-pretreated NB4 cells and 
significance values compare non-pretreated NB4 cells to inhibitor treated cells for each specified drug 
dose. 
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E Cell 
line 
TARDIS 
Assay 
Pre-
treatment 
Etoposide
/µM 
%+ve 
control SEM 
Sig (P-
value) 
% decrease with 
MPO inhibitors 
 NB4 TOP2A None  10 46.5 1.2 
 
  
 NB4 TOP2A PF1355 10 28.9 0.8 <0.001 37.8 
 NB4 TOP2A MPOi-II 10 28.8 1.0 <0.001 38.1 
 NB4 TOP2A None  100 100.0 1.9 
 
  
 NB4 TOP2A PF1355 100 79.1 3.0 <0.001 20.9 
 NB4 TOP2A MPOi-II 100 81.7 2.1 <0.001 18.3 
 NB4 TOP2B None  10 37.0 3.9     
 NB4 TOP2B PF1355 10 20.5 1.6 <0.01 44.6 
 NB4 TOP2B MPOi-II 10 15.9 2.0 <0.001 57 
 NB4 TOP2B None  100 100.0 4.5 
 
  
 NB4 TOP2B PF1355 100 52.3 3.8 <0.001 46.8 
 NB4 TOP2B MPOi-II 100 42.2 8.8 <0.001 57.8 
 
 
F Cell 
line 
TARDIS 
Assay 
Pre-
treatment 
Mitoxantrone
/µM 
%+ve 
control SEM 
Sig (P-
value) 
% decrease 
with MPO 
inhibitors 
 NB4 TOP2A None  0.5 66.1 3.9 
 
  
 NB4 TOP2A PF1355 0.5 37.6 3.9 <0.001 43.1 
 NB4 TOP2A MPOi-II 0.5 31.8 3.3 <0.001 51.9 
 NB4 TOP2A None  1 100.0 8.2 
 
  
 NB4 TOP2A PF1355 1 53.7 6.6 0.005 46.3 
 NB4 TOP2A MPOi-II 1 47.2 1.8 <0.001 52.8 
 NB4 TOP2B None  0.5 60.1 5.4     
 NB4 TOP2B PF1355 0.5 36.5 3.3 0.005 39.3 
 NB4 TOP2B MPOi-II 0.5 36.7 4.7 0.042 38.9 
 NB4 TOP2B None  1 100.0 3.7 
 
  
 NB4 TOP2B PF1355 1 50.4 5.3 <0.001 50 
 NB4 TOP2B MPOi-II 1 47.3 6.4 <0.001 52.7 
 
 
 
As previously mentioned, TOP2B gives a noticeable TARDIS signal in non-drug 
treated cells therefore the non-drug treated levels were subtracted for TOP2B and 
TOP2A. After subtraction of the signal detected in non-drug treated cells, PF1355 
treatment reduced TOP2A and TOP2B complexes by 45% (P=0.005) and 64% 
(P=0.037) at 0.5µM mitoxantrone and by 49% (P<0.001) and 76% (P<0.001) at 1µM 
mitoxantrone (Figure.4.24A-B). Similarly, in MPOi-II treated cells the figures were 
54% (P<0.001) and 70% (P=0.019) at 0.5µM mitoxantrone for TOP2A and for 
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TOP2B and a reduction of 78% (P<0.001) and 77% (P<0.001) was observed for 1µM 
mitoxantrone (Figure.4.24A-C).  
As seen with SA (Figure.4.15), the level of etoposide induced γH2Ax formation at 
100µM was reduced by 45% (P<0.001) in PF1355 and 51% (P<0.001) in MPOi-II 
treated cells yet no significant difference was observed at 10µM etoposide (Figure 
4.25.A and C). In contrast, MPO inhibition by PF1355 or MPOi-II reduced the levels 
of γH2Ax formation at 0.5µM and 1µM mitoxantrone (Figure.4.25B and D), whilst SA 
treatment only showed a significant reduction at 1µM mitoxantrone (Figure 4.21). 
PF1355 and MPOi-II had no effect on either etoposide or mitoxantrone induced 
TOP2 complex stabilisation or γH2Ax formation in the MPO non-expressing K562 
cells (Figures. 4.26-27). Taken together the results generated using the MPO 
inhibitors, PF1355 and MPOi-II support the conclusions obtained using SA and 
K562MPO cell lines, that MPO enhances etoposide and mitoxantrone mediated 
damage.  
 
 
 
 
 
 
  
 
150 
 
 
   
C Cell line 
TARDIS 
Assay 
Pre-
treatment 
Mitoxantrone
/µM 
%+ve 
control SEM 
Sig (P-
value) 
% decrease 
with MPO 
inhibitors 
 NB4 TOP2A None  0.5 63.44 3.9 !    NB4 TOP2A PF1355 0.5 34.88 3.9 0.005 45 
 NB4 TOP2A MPOi-II 0.5 29.12 3.3 <0.001 54.1 
 NB4 TOP2A None  1 100 8.2 !    NB4 TOP2A PF1355 1 51 6.6 <0.001 49 
 NB4 TOP2A MPOi-II 1 22.51 1.8 <0.001 77.5 
 NB4 TOP2B None  0.5 40.09 5.4     
 NB4 TOP2B PF1355 0.5 14.59 4.9 0.037 63.6 
 NB4 TOP2B MPOi-II 0.5 12.05 4.7 0.019 70 
 NB4 TOP2B None  1 95.39 4.7 !    NB4 TOP2B PF1355 1 23.22 4.1 <0.001 75.7 
 NB4 TOP2B MPOi-II 1 22 7.4 <0.001 77 
 
Figure 4.24. Non-drug treated levels subtracted: Direct inhibition of MPO reduces the level of 
mitoxantrone stabilised TOP2A and TOP2B-DNA complexes. NB4 cells were pre-treated with 
MPO inhibitors PF1355 (10µM 4hr) or MPOi-II (5µM 4hr) or neither before the adding mitoxantrone 
(0.5µM or 1µM) for 1 hr. TOP2 poison stabilised TOP2-DNA complexes were quantified by TARDIS for 
TOP2A (A) and TOP2B (B). (C) Supporting tables to show the percentage values expressed relative 
the mean value obtained for 1µM mitoxantrone non-pretreated NB4 cells and significance values 
compare non-pretreated NB4 cells to inhibitor treated cells for each specified drug dose. Data are 
expressed relative to the mean of 1µM mitoxantrone after non-drug treated levels were subtracted 
±S.E.M. Statistical analysis was performed by the one-way ANOVA with post hoc Tukey’s multiple 
comparison test. *P<0.05; **P<0.01; ***P<0.001. 
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C 
Cell 
line Assay 
Pre-
treatment 
Etoposide
/µM %+ve control SEM 
Sig (P-
value) 
% decrease 
with MPO 
inhibitors 
 NB4 γH2Ax None  10 48.1 2 
 
  
 NB4 γH2Ax PF1355 10 43.2 3.7 >0.999 10.2 
 NB4 γH2Ax MPOi-II 10 41.1 3.3 >0.999 14.6 
 NB4 γH2Ax None  100 100 4.5 
 
  
 NB4 γH2Ax PF1355 100 54.7 5.6 <0.001 45.3 
 NB4 γH2Ax MPOi-II 100 49.5 3.9 <0.001 50.5 
 
D 
Cell line Assay 
Pre-
treatment 
Mitoxantrone
/µM %+ve control SEM 
Sig (P-
value) 
% decrease 
with MPO 
inhibitors 
 NB4 γH2Ax None  0.5 71.3 4.7 
 
  
 NB4 γH2Ax PF1355 0.5 50.3 3.4 0.010 29.5 
 NB4 γH2Ax MPOi-II 0.5 55.4 1.2 0.009 15.9 
 NB4 γH2Ax None  1 100 1.7 
 
  
 NB4 γH2Ax PF1355 1 65.8 3.2 <0.001 34.2 
 NB4 γH2Ax MPOi-II 1 68.7 3.8 <0.001 31.3 
 
Figure 4.25. PF1355 and MPOi-II protect against etoposide and mitoxantrone induced H2Ax 
phosphorylation. Cells were pre-treated with either PF1355 (10µM 4hr) or MPOi-II (5µM 4hr) 
followed by the treatment with etoposide (10µM or 100µM) (A) or mitoxantrone (0.5µM or 1µM) (B) for 
1hr or a vehicle control and processed for detection of H2Ax phosphorylation. Data are expressed 
relative to the mean of 100µM etoposide (black bars) (A) or 1µM mitoxantrone (B) ±S.E.M. Statistical 
analysis was performed by the one-way ANOVA with post hoc Tukey’s multiple comparison test.   
**P<0.01, ***P<0.001. (C-D) Supporting tables to show the percentage values expressed relative the 
mean value obtained for 100µM etoposide (C) or 1µM mitoxantrone (D) in non-pretreated NB4 cells 
and significance values compare non-pretreated NB4 cells to inhibitor treated cells for each specified 
drug dose. 
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E Cell 
line 
TARDIS 
Assay 
Pre-
treatment 
Etoposide
/µM 
%+ve 
control SEM Sig (P-value) 
 K562 TOP2A None  10 50 4.5   
 K562 TOP2A PF1355 10 44.4 6.3 >0.999 
 K562 TOP2A MPOi-II 10 52.2 3.7 >0.999 
 K562 TOP2A None  100 100 8.8   
 K562 TOP2A PF1355 100 91 4.7 >0.999 
 K562 TOP2A MPOi-II 100 90.7 19.1 >0.999 
 K562 TOP2B None  10 14.7 1.3   
 K562 TOP2B PF1355 10 14.8 2.6 >0.999 
 K562 TOP2B MPOi-II 10 15.8 0.9 >0.999 
 K562 TOP2B None  100 100 25.6   
 K562 TOP2B PF1355 100 106.6 213 >0.999 
 K562 TOP2B MPOi-II 100 94.8 19.4 >0.999 
 
F 
Cell 
line 
TARDIS 
Assay 
Pre-
treatment 
Mitoxantrone
/ µM 
%+ve 
control SEM Sig (P-value) 
 K562 TOP2A None  0.5 71.3 2.9   
 K562 TOP2A PF1355 0.5 69.9 1.6 >0.999 
 K562 TOP2A MPOi-II 0.5 79.07 8.1 >0.999 
 K562 TOP2A None  1 100 10.7   
 K562 TOP2A PF1355 1 105.8 7.5 >0.999 
 K562 TOP2A MPOi-II 1 109.3 17.3 >0.999 
 K562 TOP2B None  0.5 55.9 11.2   
 K562 TOP2B PF1355 0.5 53.9 7.8 >0.999 
 K562 TOP2B MPOi-II 0.5 57.6 5.4 >0.999 
 K562 TOP2B None  1 100 25.3   
 K562 TOP2B PF1355 1 110.5 27.2 >0.999 
 K562 TOP2B MPOi-II 1 105.3 25.1 >0.999 
 
Figure 4.26. PF1355 and MPOi-II do not affect etoposide (A&B) or mitoxantrone (C&D) 
stabilised TOP2-DNA complexes in non-MPO expressing cells. K562 cells were pre-treated with 
MPO inhibitors PF1355 (10µM 4hr) or MPOi-II (5µM 4hr) or neither before the adding etoposide (10µM 
or 100µM) or mitoxantrone (0.5µM or 1µM) for 1 hr or a vehicle control. TOP2 poison stabilised TOP2-
DNA complexes were quantified by TARDIS for TOP2A (A) and TOP2B (B). Data are expressed 
relative to the mean of 100µM etoposide (A&B) or 1µM mitoxantrone (C&D) for non-treated K562 cells 
(grey bars) ±S.E.M. Statistical analysis was performed by the one-way ANOVA with post hoc Tukey’s 
multiple comparison test. (E-F) Supporting tables to show the percentage values expressed relative 
the mean value obtained for 100µM etoposide (E) or 1µM mitoxantrone (F) in non-pretreated NB4 
cells and significance values compare non-pretreated NB4 cells to inhibitor treated cells for each 
specified drug dose. 
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C Cell 
line Assay 
Pre-
treatment 
Etoposide/ 
µM 
%+ve 
control SEM Sig (P-value) 
 K562 γH2Ax None  10 55.3 4.3   
 K562 γH2Ax PF1355 10 54.1 2.3 >0.999 
 K562 γH2Ax MPOi-II 10 57.4 10.2 >0.999 
 K562 γH2Ax None  100 100 2.1   
 K562 γH2Ax PF1355 100 80.3 15.4 >0.999 
 K562 γH2Ax MPOi-II 100 95.3 14.6 >0.999 
 
D 
Cell 
line Assay 
Pre-
treatment 
Mitoxantrone/ 
µM 
%+ve 
control SEM Sig (P-value) 
 K562 γH2Ax None  0.5 73.2 3.7   
 K562 γH2Ax PF1355 0.5 82.4 2.2 >0.999 
 K562 γH2Ax MPOi-II 0.5 76 3.7 >0.999 
 K562 γH2Ax None  1 100 5.9   
 K562 γH2Ax PF1355 1 94.2 4.6 >0.999 
 K562 γH2Ax MPOi-II 1 101.6 5.9 >0.999 
 
Figure 4.27. Direct MPO inhibitors do not effect TOP2 poison induced H2Ax phosphorylation in 
non-MPO expressing cells. K562 were pre-treated with either PF1355 (10µM 4hr) or MPOi-II (5µM 
4hr) or neither followed by the treatment with etoposide (10µM or 100µM) (A) or mitoxantrone (0.5µM 
or 1µM) (B) for 1hr or a vehicle control and processed for the detection the of H2Ax phosphorylation. 
Data are expressed relative to the mean of 100µM etoposide (A) or 1µM mitoxantrone (B) ±S.E.M in 
non-pretreated cells. Statistical analysis was performed by the one-way ANOVA with post hoc Tukey’s 
multiple comparison test.  (C-D) Supporting tables to show the percentage values expressed relative 
the mean value obtained for 100µM etoposide (E) or 1µM mitoxantrone (F) in non-pretreated NB4 
cells and significance values compare non-pretreated NB4 cells to inhibitor treated cells for each 
specified drug dose. 
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4.4 Discussion 
 
In this study, the role of myeloperoxidase in enhancing etoposide and mitoxantrone- 
mediated DNA damage was investigated using three different cell-based systems. 
The first system employed SA to inhibit MPO activity in the MPO expressing cell-line 
NB4. In the second system, K562 cells that do not express MPO were engineered to 
express MPO. Thirdly, new chemical inhibitors of MPO were used to reduce MPO 
activity in NB4 cells to further confirm the results generated using SA and in the MPO 
expressing K562 cell line. Two key assays were used, one to quantify TOP2-DNA 
complex levels (TARDIS assay) and one to measure the formation of DSB (γH2Ax 
assay) following exposure to etoposide or mitoxantrone in NB4 or K562 cells. 
Myeloperoxidase can mediate the one or two-electron oxidation of etoposide to 
generate etoposide quinone via a phenoxyl-radical intermediate (Gantchev and 
Hunting, 1998). Previous studies have shown that etoposide quinone is a more 
effective TOP2 poison compared to etoposide, with greater potency towards the 
TOP2B isoform in vitro (Jacob et al., 2011; Smith et al., 2014b; Gibson et al., 2016). 
In the cell line based work described here, the presence of active MPO increased the 
level of etoposide-stabilised complexes for both TOP2A and TOP2B (Figure.4.7A-B) 
and the inhibition of MPO resulted in a greater decrease in TOP2B complexes 
compared to TOP2A (Figure. 4.5A-D and Figure.4.23A-B). These results suggest the 
effect of MPO-dependent enhancement in etoposide-stabilised complexes formed in 
cellulo is due the production of etoposide quinone. To our knowledge, this is first time 
that the effect of MPO on etoposide-stabilised complexes has been investigated at a 
TOP2 isoform specific level. The results generated from the γH2Ax assay 
complemented the TARDIS data, showing MPO contributes to etoposide mediated 
γH2Ax formation in cells, an indication of the level of DSB in cells. In the presence of 
MPO, etoposide induced γH2Ax formation is likely to be due the contribution of DSB 
induced by etoposide, etoposide phenoxyl radical and etoposide quinone which 
stabilise the TOP2-DNA complexes that are subsequently processed to DSB using 
proteolytic and nucleolytic pathways. In addition, the methyl radical produced from 
the oxidation of etoposide to the phenoxyl radical, can directly lead to DNA strand 
breaks (Haim et al., 1986; Augusto et al., 1990).  
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While the results with etoposide can be explained by the MPO mediated 
biotransformation of etoposide to etoposide quinone, the situation is less clear for 
mitoxantrone. MPO mediates the oxidation of mitoxantrone to a naphthoquinoxaline 
metabolite, which is the intermediate species generated in the reaction (Panousis et 
al., 1994; Panousis et al., 1997). Naphthoquinoxaline can react covalently with DNA 
both in cell-free systems and in cells. The end reaction product of the MPO mediated 
reaction has not been determined which is partly due to instability of the unknown 
compound. Additionally, MPO can oxidise amino acids to produce reactive 
aldehydes, including formaldehyde. Mitoxantrone can be activated by formaldehyde 
to generate DNA adducts which can covalently adduct to the N2 exocyclic amino 
group of guanine (Anderson et al., 1997; Hazen et al., 1998; Parker et al., 2004) (see 
section 1.3.2). However, it is unclear whether these mitoxantrone metabolites interact 
directly with TOP2. The data generated in this study shows the inhibition of MPO in 
NB4 cells significantly reduces mitoxantrone stabilised TOP2A and TOP2B 
complexes (Figure.4.11, 4.12 and 4.23C-D). Whereas exogenous expression of MPO 
in K562 cells resulted in a two-fold increase in mitoxantrone stabilised TOP2A and 
TOP2B complexes (Figure.4.14). Suggesting MPO mediates the biotransformation of 
mitoxantrone to metabolites that poison the catalytic cycle of TOP2, although the 
mechanism may be as result of DNA adducts or repair intermediates that can also 
result in TOP2 poisoning and the results presented here do not distinguish between 
these possibilities (Kingma et al., 1995; Sabourin and Osheroff, 2000).  
The use of the recently developed chemically distinct MPO inhibitors; PF1355 (Phase 
I clinical trials) and MPOi-II have further supported the conclusions drawn using SA 
and induction of exogenous expression of MPO into K562 cells. Pre-treatment with 
PF1355 or MPOi-II in NB4 cells resulted in a significant reduction in both TOP2-DNA 
complex stabilisation and γH2Ax formation upon exposure to etoposide or 
mitoxantrone (Figure 4.23A-D, 4.24A-B and 4.25A-B). This shows the potential of 
such compounds to be tailored into primary chemotherapy regimes to reduce genetic 
damage in myeloid progenitors.  
The effect of MPO enhancement in TOP2 poison mediated DNA damage reported 
above, is likely due the presence of MPO in the nucleus (Murao et al., 1988) as 
metabolites produced from the oxidation of etoposide and mitoxantrone are prone to 
be conjugated with glutathione (Blanz et al., 1991; Mewes et al., 1993; Kagan et al., 
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1999; Zheng et al., 2006). The effects of glutathione on TOP2 poison mediated 
damage are discussed in chapter 5.  
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Chapter 5. The role of glutathione in TOP2 poison mediated DNA 
damage 
5.1 Introduction 
 
The peroxidase-mediated oxidation of etoposide or mitoxantrone leads to metabolites 
that contain high electrophilic centers (reactive quinone and quinone-diimine 
moieties) these can effectively react with thiol containing peptides/proteins and 
adduct DNA (Kolodziejczyk et al., 1988; Blanz et al., 1991; Gantchev and Hunting, 
1997; Fan et al., 2006; Vlasova et al., 2011). However, in cells the effect of these 
reactive metabolites can be effectively dampened down by conjugation with reduced 
glutathione, thereby reducing intracellular damage including DNA damage (Mewes et 
al., 1993; Kagan et al., 1994; Gantchev and Hunting, 1997). Glutathione (L-γ-
glutamyl-L-cysteinyl-glycine) is a major intracellular non-protein thiol present in cells 
at milli-molar concentrations serving to protect cells from oxidative damage and to 
detoxify xenobiotics (Chatterjee, 2013) (see section 1.4). Conjugation with 
glutathione occurs via the active thiol group (in the form of a cysteine residue), this 
reaction either occurs spontaneously or is catalysed by glutathione-S-transferase. 
The MPO-mediated oxidation of etoposide yields etoposide quinone (Fan et al., 
2006; Zheng et al., 2006)  (Figure 5.1). Etoposide quinone may either intercalate into 
the TOP2-DNA binary complex (TOP2 poison) or interact with N-terminal clamp of 
TOP2 by adducting sulfhydryl residues and block the entry of DNA (TOP2 covalent 
poison) (Jacob et al., 2011; Jacob et al., 2013; Smith et al., 2014b; Gibson et al., 
2016) (see section 1.3.1). Due to the presence of the 3’ and 4’ carbonyl groups on 
the E-ring, etoposide quinone can potentially react with any protein that contains a 
free sulfhydryl group modifying protein function. To overcome this, glutathione can 
conjugate with etoposide quinone producing etoposide-OH-6’-SG and/or etoposide-
OH-2’-SG reducing the carbonyl groups of the E-ring to hydroxyls (Fan et al., 2006; 
Zheng et al., 2006) (Figure 5.1).  
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Figure 5.1. Conjugation of reduced glutathione with etoposide quinone. Etoposide can undergo a 
sequential two-electron oxidation yielding reactive etoposide quinone, however in cells etoposide 
quinone can be rendered ineffective by the conjugation with reduced glutathione. The reaction with 
glutathione reduces etoposide quinone to etoposide-OH-6’-SG and/or etoposide-OH-2’-SG. (The 2’ 
and 6’ numbering of the E-ring shown in this figure were used from Zheng, 2006). 
 
The oxidation of mitoxantrone to a naphthoquinoxaline metabolite proceeds via the 
generation of a reactive quinone-diimine that is able to covalently modify DNA and 
proteins (Figure 5.2) (Kolodziejczyk et al., 1988; Reszka et al., 1989; Blanz et al., 
1991). Whilst mitoxantrone and naphthoquinoxaline do not seem to react with 
glutathione, the quinone-diimine intermediate effectively conjugates with glutathione 
and prevents the formation of the naphthoquinoxaline metabolite (Blanz et al., 1991; 
Mewes et al., 1993). However the structure of the glutathione- quinone-diimine have 
not been confirmed. 
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Figure 5.2. Conjugation of glutathione with mitoxantrone-quinone-diimine. The peroxidase-
mediated biotransformation of mitoxantrone proceeds via a quinone-diimine intermediate, which 
further undergoes intramolecular cyclisation to generate the naphthoquinoxaline metabolite. 
Glutathione reacts with quinone-diimine via a nucleophilic 1,4 addition detoxifying the peroxidase 
mediated reaction (predicted structure obtained from Blanz et al., 1991).   
 
In the previous chapter, data generated showed the presence of active MPO 
increases TOP2 poison induced damage, this is suggested to be mediated via the 
MPO-mediated oxidation of etoposide or mitoxantrone.  If this were the case then the 
presence of glutathione in cells would limit the damage caused by MPO-mediated 
oxidation of TOP2 poisons. Therefore, in this chapter, the effects of depletion of 
glutathione on TOP2 poison induced TOP2-DNA covalent complex stabilisation and 
γH2Ax formation were analysed in MPO positive cells.  
5.2 Aims: 
 
• To investigate the effect of glutathione depletion and MPO inhibition on the 
level of etoposide or mitoxantrone-induced TOP2-DNA covalent complex and 
γH2Ax formation.  
• To test for the level of TOP2-DNA covalent complex stabilisation and γH2Ax 
formation induced by the etoposide metabolites; etoposide catechol or 
etoposide quinone in NB4 cells (structures shown in Figure 5.1). 
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• To compare the stability of etoposide or etoposide quinone stabilised TOP2-
DNA covalent complexes after depletion of glutathione in NB4 cells.  
5.3. Results 
5.3.1 Glutathione depletion increases etoposide-mediated TOP2 DNA damage. 
 
Etoposide quinone can be reduced by the conjugation with glutathione rendering 
etoposide quinone inactive (Figure 5.1). As etoposide quinone is the product of the 
MPO-mediated oxidation of etoposide, it follows that in the presence of glutathione 
the effects of high MPO expression may be limited. To investigate the effect of 
glutathione on the level of etoposide induced damage in MPO positive cells (NB4 
cells), cellular glutathione levels were reduced using buthionine sulfoximine (BSO). 
BSO inhibits glutathione synthesis by irreversibly inhibiting glutamate cysteine ligase 
(γ-glutamylcysteine synthetase) (Griffith and Meister, 1979; Biterova and Barycki, 
2010). Incubation with 150µM BSO for 4.5hr in NB4 cells reduced the levels of total 
glutathione by 74.3% ± 8.4, and levels of reduced glutathione by 79.3% ± 8.57 
compared to untreated cells (see section 3.3.9 and 2.12). In addition, 150µM BSO 
did not affect TOP2 activity in vitro (conducted by C.A. Austin published in (Atwal et 
al., 2017). Following the depletion of glutathione, NB4 cells were treated with 10µM 
or 100µM etoposide for 1hr whilst retaining BSO in the cell medium during the time of 
drug incubation. Cells were then processed to quantify the level of etoposide-
stabilised TOP2A and TOP2B-DNA covalent complexes using the TARDIS assay 
(see section 2.13 and 4.3.1).  
BSO-treated NB4 cells displayed greater levels of stabilised TOP2A- and TOP2B-
DNA complexes with 10µM etoposide (44% and 63% more, respectively) (Figure  
5.3.A-C). With 100µM etoposide, BSO treatment increased the level of TOP2B-DNA 
complexes by 32% but no increase was observed for TOP2A (P=0.460). Next, the 
effect of MPO inhibition combined with the depletion of glutathione on etoposide 
induced TOP2-DNA complex stabilisation was investigated. To test this, NB4 cells 
were firstly treated with SA (200µM for 48hr) to reduce mature MPO protein synthesis 
(Ch3.3.5), followed by the incubation with BSO (150µM for 4.5hr) to deplete 
glutathione. As shown in Figures 5.3.A-B the reduction in MPO activity and 
glutathione levels significantly decreases the level of etoposide stabilised TOP2A- 
and TOP2B-DNA covalent complexes (Figure. 5.3.A-B). With 10µM etoposide the 
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level of stabilised TOP2A complexes reduced by 31% (P=0.031) in SA+BSO pre-
treated cells and for TOP2B the reduction was 34% (P=0.024) compared to non-pre-
treated NB4 cells (10µM etoposide, black bars) (Figure. 5.3.A-B). For 100µM 
etoposide, TOP2A complexes reduce by 25% (P=0.024) whereas no reduction in 
TOP2B complexes (P=0.900) is observed with 100µM etoposide compared to non-
pre-treated NB4 cells (Figure. 5.3.A-B). Notably, the level of stabilised complexes 
observed with the combined treatment of SA and BSO were not significantly different 
to that observed with SA pre-treatment at 10µM (P=0.714) and 100µM (P>0.999) 
etoposide for TOP2A and at 10µM etoposide (P>0.999) for TOP2B (Figure. 5.3.A-B). 
The data generated shows the observed increase in etoposide-stabilised TOP2-DNA 
complexes in gluatathione-depleted cells is dependent on active MPO protein 
expression  
In addition, the effect of glutathione on etoposide induced γH2Ax formation (a marker 
for DSB) was analysed using quantitative immunofluorescence (see section 2.11 and 
4.3.4). γH2Ax foci appear within 20 minutes upon etoposide treatment (Sunter et al., 
2010). This indicates the processing of drug-stabilised TOP2-DNA complexes to 
DSBs, a process that involves the proteolytic and/or nucleolytic removal of TOP2 
from DNA and conversion of the DNA strand break to a DSB (Nitiss, 2009a; Lee et 
al., 2012a; Povirk, 2012; Lee et al., 2016). 
NB4 cells were treated with BSO (150µM, 4.5hr) followed by the incubation with 
10µM or 100µM etoposide. Cells were then fixed onto slides, permeabilised and 
probed for the level of γH2Ax formation. BSO treated cells exhibited significantly 
higher levels of γH2Ax signal after etoposide addition (Figure 5.4). At 10µM 
etoposide, BSO treated cells had a 54% (P<0.001) increase in γH2Ax formation, a 
level which was no longer significantly different from 100µM etoposide treatment 
(P=0.494) (Figure 5.4). At 100µM etoposide an even greater increase of 70% 
(P<0.001) in γH2Ax formation was observed in BSO treated cells (Figure 5.4). BSO 
alone (0µM) did not increase the basal level of γH2Ax compared to non-BSO treated 
cells (p=0.761) (Figure 5.4). In addition to the depletion of glutathione, cells were also 
pre-treated with SA to inhibit MPO. The combination of MPO inhibition and 
glutathione depletion reduced the level of etoposide-induced γH2Ax formation at 
100µM etoposide (41%) but not with 10µM etoposide treatment (P=0.964) compared 
to non-pretreated NB4 cells (Figure 5.4). However as observed in the TARDIS assay, 
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BSO did not affect the level of γH2Ax formation in SA treated cells (Figure 5.3. and 
5.4). These results indicate the observed increase in etoposide γH2Ax formation 
following the depletion of glutathione is due to MPO-mediated oxidation of etoposide 
to reactive metabolites that poison TOP2. 
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C           
Cell 
line 
TARDIS 
Assay 
Pre-
treatment 
Etoposide/
µM 
%+ve 
control SEM 
Sig (P-
value) 
% 
decrease 
with SA 
% 
increase 
with 
BSO 
% 
decrease 
with 
SA+BSO 
NB4 TOP2A None  10 50.8 5.6         
NB4 TOP2A SA 10 21.5 2.2 0.019 57.1     
NB4 TOP2A BSO 10 90.6 6.1 <0.001   43.9   
NB4 TOP2A SA+BSO 10 35.3 6.4 0.031      30.5 
NB4 TOP2A None  100 100.0 3.6         
NB4 TOP2A SA 100 75.4 4.1 0.004 24.6     
NB4 TOP2A BSO 100 116.2 8.2 0.460   -   
NB4 TOP2A SA+BSO 100 74.7 3.4 0.024     25.3 
NB4 TOP2B None  10 34.4 2.1         
NB4 TOP2B SA 10 20.7 4.0 0.011 40     
NB4 TOP2B BSO 10 92.4 4.0 <0.001   62.8   
NB4 TOP2B SA+BSO 10 22.8 3.4 0.024     33.7 
NB4 TOP2B None  100 100.0 3.3         
NB4 TOP2B SA 100 56.1 8.4 <0.001 43.9     
NB4 TOP2B BSO 100 146.3 10.0 <0.001   31.6   
NB4 TOP2B SA+BSO 100 89.8 6.2 0.900     - 
 
Figure 5.3. Glutathione depletion increases etoposide stabilised TOP2-DNA complexes. NB4 
cells were pretreated with SA (200µM, 48hr) or BSO (150µM, 4.5hr) or with both or with neither, 
followed by the incubation with etoposide (10µM or 100µM) or a vehicle control (0.02% DMSO). 
Etoposide stabilised TOP2-DNA complexes were quantified for TOP2A (A) or TOP2B (B). Data are 
expressed relative to the mean value for non-pretreated NB4 cells (black bars) incubated with 100µM 
etoposide ± S.E.M. *P<0.05; **P<0.01;***P<0.001. Percentage values are expressed relative to 
100µM etoposide. (C) Supporting table shows the percentage of TOP2-DNA complexes relative to the 
positive control (Non-pretreated NB4 cells with 100µM etoposide) and the significance values for 
comparison of each pretreatment with non-pretreated NB4 cells after treatment with etoposide. 
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B          
Cell 
line Assay 
Pre-
treatment 
Etoposide
/µM 
%+ve 
control SEM 
Sig (P-
value) 
% 
decrease 
with SA 
% 
increase 
with 
BSO 
% 
decrease 
with 
SA+BSO 
NB4 γH2Ax None  10 52 6.6         
NB4 γH2Ax SA 10 39.7 2.2 0.993 23.7     
NB4 γH2Ax BSO 10 112.6 8.6 <0.001   53.8   
NB4 γH2Ax SA+BSO 10 37.7 4.5 0.964     - 
NB4 γH2Ax None  100 100 4.5         
NB4 γH2Ax SA 100 65 3.8 0.032 35     
NB4 γH2Ax BSO 100 170.1 20.1 <0.001   70.1   
NB4 γH2Ax SA+BSO 100 58.8 5 0.048     41.2 
 
Figure 5.4. Glutathione depletion significantly increases etoposide induced global H2Ax 
phosphorylation.  NB4 cells were pre-treated with SA (200µM, 48hr) or BSO (150µM, 4.5hr) or with 
both or with neither, followed by the incubation with etoposide (10µM or 100µM) or a vehicle control 
(0.02% DMSO) and analysed for the level of γH2Ax phosphorylation. Data are expressed relative to 
the mean value obtained for non-pretreated NB4 cells incubated with 100µM etoposide ± S.E.M. 
*P<0.05; **P<0.01;***P<0.001. Percentage values are expressed relative to 100µM etoposide. (B) 
Supporting table shows the percentage of γH2Ax phosphorylation relative to the positive control (Non-
pretreated NB4 cells with 100µM etoposide) and the significance values for comparison of each 
pretreatment with non-pretreated NB4 cells after treatment with etoposide. 
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5.3.2 Glutathione depletion enhances mitoxantrone induced TOP2 mediated 
DNA damage. 
 
MPO-mediated oxidation of mitoxantrone yields a highly electrophilic mitoxantrone 
quinone-diimine intermediate that can be readily detoxified by glutathione (Figure 
5.2) (Blanz et al., 1991). There are no known published studies which have analysed 
the role of quinone-diimine intermediate or the naphthoquinoxaline in TOP2 
poisoning or DSB formation. The TARDIS assay was used to determine the effect of 
glutathione depletion on the level of mitoxantrone-stabilised TOP2-DNA complexes. 
Glutathione levels were reduced using BSO (150µM, 4.5hr) in NB4 cells, followed by 
the incubation with 1µM mitoxantrone for 1hr. BSO treated NB4 cells had significantly 
higher levels of TOP2A- and TOP2B-DNA complexes induced by 1µM mitoxantrone 
(29% and 38% more, respectively) (Figure 5.5.A-B). Additionally, the effects of MPO 
inhibition in combination with the depletion of glutathione were analysed. To inhibit 
MPO NB4 cells were treated with 200µM SA for 48hr. Pretreatment with SA reduced 
the level of mitoxantrone stabilised TOP2A- and TOP2B-DNA complexes by 52% 
(P=0.002) and 45% (P=0.001) respectively (Figure 5.5A-B). Significantly, the addition 
of BSO in SA pretreated cells had no affect on the level mitoxantrone induced TOP2 
complexes (Figure 5.5A-B).  NB4 cells pretreated with SA and BSO had a similar 
level of stabilised TOP2A- (P=0.418) and TOP2B- (P=0.983) DNA covalent 
complexes compared to cells treated with SA. This implies the increase seen with the 
depletion of glutathione is dependent on MPO-mediated oxidation of mitoxantrone to 
metabolites that may directly or indirectly poison TOP2.  
A similar trend to that observed in the TARDIS assay was observed with the level of 
mitoxantrone-induced γH2Ax formation, a marker for the level of DBS within a cell. 
Depletion of glutathione increased the level of mitoxantrone γH2Ax formation by 47%  
(P<0.001) (Figure 5.6), indicating that in the presence of glutathione a significant 
proportion of mitoxantrone or its metabolites are prevented from inducing DSBs. In 
the absence of MPO activity using, SA, the level of mitoxantrone induced γH2Ax 
signal reduced by 44%. The addition of BSO to SA pretreated cells did not increase 
the level of mitoxantrone-induced γH2Ax formation (36% reduction compared to non-
pretreated cells) (Figure 5.6). This suggests the increase in γH2Ax formation 
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observed in glutathione depleted cells is due to MPO-mediated biotransformation of 
mitoxantrone.    
 
 C          
Cell 
line 
TARDIS 
Assay 
Pre-
treatment 
Mitoxantrone 
/µM 
%+ve 
control SEM 
Sig (P-
value) 
% 
decrease 
with SA 
% 
increase 
with BSO 
% decrease 
with 
SA+BSO 
NB4 TOP2A None  1 100.0 9.1         
NB4 TOP2A SA 1 48.0 4.8 0.002 52     
NB4 TOP2A BSO 1 140.4 11.9 0.017   28.8   
NB4 TOP2A SA+BSO 1 62.7 7.2 0.016     37.3 
NB4 TOP2B None  1 100.0 14.7         
NB4 TOP2B SA 1 55.5 9.9 0.001 44.5     
NB4 TOP2B BSO 1 161.5 22.5 0.039   38   
NB4 TOP2B SA+BSO 1 47.5 10.4 0.004     52.5 
 
Figure 5.5. Glutathione depletion increases mitoxantrone mediated TOP2-DNA complex 
stabilisation. NB4 cells were pretreated with SA (200µM, 48hr), BSO (150µM, 4.5hr) or both or with 
neither, followed by 1hr incubation with 1µM mitoxantrone. Mitoxantrone stabilised TOP2-DNA 
complexes were quantified by the TARDIS assay using antibodies specific to (A) TOP2A (4556) or (B) 
TOP2B (4555). (C) Supporting table shows the percentage of relative to non-pretreated NB4 cells with 
1µM mitoxantrone and the significance values for comparison of each pretreatment with non-
pretreated NB4 cells after treatment with etoposide. Data are expressed relative to the mean value 
obtained for non-pretreated NB4 cells (black bar) at 1µM mitoxantrone ± S.E.M. *P<0.05; 
**P<0.01;***P<0.001. Percentage values are expressed relative to 1µM mitoxantrone. 
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 B          
Cell 
line Assay 
Pre-
treatment Mitoxantrone 
/µM 
%+ve 
control SEM 
Sig (P-
value) 
% 
decrease 
with SA 
% 
increase 
with BSO 
% 
decrease 
with 
SA+BSO 
NB4 γH2Ax None  1 100 5.9         
NB4 γH2Ax SA 1 55.7 3.4 <0.001 44.3     
NB4 γH2Ax BSO 1 147.1 8 <0.001   47.1   
NB4 γH2Ax SA+BSO 1 64.1 4.4 0.001     35.9 
 
Figure 5.6. Depletion of glutathione elevates mitoxantrone induced H2Ax phosphorylation. NB4 
cells were pretreated with SA (200µM, 48hr), BSO (150µM, 4.5hr) or both or with neither, followed by 
1hr incubation with 1µM mitoxantrone or a vehicle control (0.02% dH2O). Mitoxantrone induced γH2Ax 
formation was quantified using immunofluorescence. Data are expressed relative to the mean value 
obtained for non-pretreated NB4 cells (black bars) with 1µM mitoxantrone ± S.E.M. **P<0.01; 
***P<0.001, percentage values are expressed relative to 1µM mitoxantrone (C). 
 
5.3.3 Etoposide E-ring metabolites. 
 
The main products of the peroxidase associated oxidation of etoposide at its E-ring 
are the CYP450 catalysed metabolite, etoposide catechol (O-demethylated at 3’ 
position of E-ring) and the MPO-mediated oxidation product, etoposide quinone 
(Figure 5.1). Etoposide catechol can be further oxidised by MPO to etoposide 
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quinone (van Maanen et al., 1988b; Jacob et al., 2013). Etoposide quinone is defined 
by the presence of the 3’ and 4’ carbonyl groups on the E-ring and is dark red in 
colour whereas both etoposide and etoposide catechol are white (solid state) (Fan et 
al., 2006). Both etoposide catechol and quinone are more effective at poisoning 
TOP2 in vitro DNA cleavage assays than etoposide (Jacob et al., 2011; Smith et al., 
2014b; Gibson et al., 2016). In this study, the TOP2 poisoning ability of 100µM 
etoposide catechol or etoposide quinone was compared to 100µM etoposide using 
the TARDIS assay in NB4 cells.  
As shown in Figure 5.7 the level of stabilised TOP2A- and TOP2B-DNA complexes 
induced by etoposide catechol were similar to etoposide (P=0.860 and P=0.822 
respectively) (Figure 5.7.A-B). Whereas etoposide quinone induced 30% fewer 
TOP2A- and 46% less TOP2B-DNA complexes, compared to etoposide (Figure  
5.7.A-B). These results are different to in vitro data, as both etoposide catechol and 
quinone are more effective in poisoning TOP2 compared to etoposide in vitro (Jacob 
et al., 2011; Jacob et al., 2013; Smith et al., 2014b). However, the lower TOP2 
poisoning ability could be due to reduced cellular and nuclear uptake of the two 
metabolites and/or conjugation with glutathione, which may reduce the amount of 
drug that reaches the nucleus.  
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C 
Cell 
line 
TARDIS 
Assay 
Drug 
/100µM 
%+ve 
control SEM 
Sig (P-
value) 
% difference from 
Etoposide  
 NB4 TOP2A Etoposide 100.0 8.5     
 
NB4 
TOP2A Etoposide 
catechol 95.3 3.8 0.860 4.7 
 
NB4 
TOP2A Etoposide 
quinone 70.2 5.9 0.020 29.8 
 NB4 TOP2B Etoposide 100.0 8.5     
 
NB4 TOP2B 
Etoposide 
catechol 95.3 3.8 0.822 4.7 
 
NB4 TOP2B 
Etoposide 
quinone 54.2 2.4 <0.001 45.8 
 
Figure 5.7. TOP2 poisoning by etoposide metabolites, in cellulo. NB4 cells were treated with 
100µM etoposide or its metabolites (etoposide catechol or quinone, synthesised by Angelica Mariani, 
France) for 1hr. Drug stabilised TOP2-DNA complexes were quantified for TOP2A (A) or TOP2B (B). 
Data are expressed relative to the mean value obtained for NB4 cells incubated with 100µM etoposide 
± S.E.M. (C) Percentage values and significance values are expressed relative to 100µM etoposide. 
 
Next, the etoposide metabolites were tested for γH2Ax formation with 100µM drug for 
1hr. Both etoposide catechol (P=0.324) and etoposide quinone (P=0.629) induce 
similar levels of γH2Ax formation to etoposide (Figure 5.8.A-B). The results obtained 
for etoposide quinone in the γH2Ax assay do not correlate with the data obtained 
from the TARDIS assay. This suggests either that (i) etoposide quinone stabilised 
TOP2-DNA covalent complexes are processed to DSB quicker compared to 
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etoposide stabilised complexes or (ii) etoposide quinone may induce γH2Ax 
formation via a route in addition to poisoning TOP2.  
 
 
     B Cell line Assay Drug /100µM %+ve control SEM 
Sig (P-
value) 
 NB4 γH2Ax Etoposide 100 13.1   
 NB4 γH2Ax Etoposide catechol 76.7 8.3 0.324 
 NB4 γH2Ax Etoposide quinone 85.9 9.3 0.629 
 
Figure 5.8. Etoposide metabolites induce a similar level of γH2Ax phosphorylation. NB4 cells 
were treated with 100µM etoposide or its metabolites (etoposide catechol or quinone, synthesised by 
Angelica Mariani, France) or a vehicle control for 1hr. The level of drug-induced γH2Ax formation was 
detected using quantitative immunofluorescence. Data are expressed relative to the mean value for 
NB4 cells incubated with 100µM etoposide ± S.E.M. Percentage values are expressed relative to 
100µM etoposide. (C) Percentage values and significance values are expressed relative to 100µM 
etoposide. 
 
Etoposide catechol is an inherently unstable compound and once exposed to air can 
quickly oxidise to a red compound, indicating the oxidation to etoposide quinone or a 
semi-quinone species, therefore it is difficult to conclude whether the data obtained 
with etoposide catechol is due to the compound itself. Due to this instability of 
etoposide catechol, no further experiments were conducted with this compound. The 
data shown using etoposide catechol and quinone in Figures 5.7 and 5.8 were 
obtained from a different source (synthesised by Angelica Mariani, France) to the 
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results shown for etoposide quinone in Figures 5.9 and onwards (purchased from 
Cayman Chemicals, Cambridge, UK).  
Etoposide quinone forms adducts with glutathione, this conjugation prevents DNA or 
cellular damage (Fan et al., 2006). Therefore, experiments were conducted to 
analyse whether depletion of glutathione using BSO (150µM for 4.5hr) altered the 
level of etoposide quinone induced TOP2-DNA complexes (using the TARDIS assay) 
and DSB formation (using γH2Ax quantification) in NB4 cells. In each experiment 
etoposide was included as a positive control and the mean of medians obtained from 
integrated fluorescence for 100µM etoposide was used to normalise data from 
multiple biological replicates (see section 2.14).  
Treatment with 10µM etoposide quinone induces substantially lower levels of 
stabilised TOP2A- (P=0.002) and TOP2B-DNA (P=0.013) complexes compared to 
10µM etoposide (83% and 55% less respectively) (Figure 5.9.A-C). Treatment with 
BSO in NB4 cells significantly elevated the levels of TOP2A-DNA complexes induced 
with 10µM and 100µM etoposide quinone (79% and 49% more, respectively) (Figure 
5.9.A). Notably, at 100µM etoposide quinone BSO treated cells have 55% more 
stabilised TOP2A complexes compared to 100µM etoposide in non-BSO treated cells 
(P=0.002) (Figure 5.9.A and C). However, no increase in etoposide quinone (10µM or 
100µM) stabilised TOP2B complexes were observed in BSO treated cells (P=0.718 
and P=0.371 respectively) (Figure 5.9.B).  
Similarly, the effects of glutathione depletion were analysed for the level of γH2Ax 
formation with 10µM or 100µM etoposide quinone in NB4 cells. Etoposide quinone as 
observed previously, induces a similar level of γH2Ax formation to etoposide at 
100µM (Figure 5.10). However, at 10µM etoposide quinone has 42% less γH2Ax 
formation (P=0.042) compared to 10µM etoposide (Figure 5.10. A). Upon treatment 
with BSO a 57% (P<0.001) increase in γH2Ax formation was observed with 10µM 
etoposide quinone, this exceeds the γH2Ax signal observed with 10µM etoposide 
(P=0.034) (Figure 5.10.A and B). However, BSO did not affect γH2Ax formation at 
100µM etoposide quinone (P=0.993) (Figure 5.10). 
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  C         
Cell 
line 
TARDIS 
Assay 
Pre-
treatment 
Etoposide
/µM 
Etoposide 
quinone/µM 
%+ve 
control SEM 
Sig (P-
value) 
% increase 
with BSO 
NB4 TOP2A None  10 .! 62.2 6.3     
NB4 TOP2A BSO 10 .! 125.0 0.6 0.011 50 
NB4 TOP2A None  .! 10 10.6 0.5 !!   
NB4 TOP2A BSO .! 10 50.0 2.9 0.005 78.8 
NB4 TOP2A None  100 .! 100.0 5.8     
NB4 TOP2A BSO 100 .! 124.7 21.4 0.963 - 
NB4 TOP2A None  .! 100 112.1 9.1     
NB4 TOP2A BSO .! 100 219.6 7.5 0.001 49 
NB4 TOP2B None  10 .! 28.6 8.8     
NB4 TOP2B BSO 10 .! 80.1 3.8 0.001 64.3 
NB4 TOP2B None  .! 10 13.0 2.1     
NB4 TOP2B BSO .! 10 24.7 3.7 0.718 - 
NB4 TOP2B None  100 .! 100.0 8.9     
NB4 TOP2B BSO 100 .! 192.5 26.4 <0.001 48 
NB4 TOP2B None  .! 100 53.2 5.6     
NB4 TOP2B BSO .! 100 92.1 24 0.371 - 
 
Figure 5.9. Glutathione depletion increases etoposide quinone stabilised TOP2A-DNA 
complexes. NB4 cells were pre-treated with 150µM BSO for 4.5hr followed by 1hr incubation with 
10µM or 100µM etoposide or etoposide quinone or a vehicle control (0.02% DMSO). TOP2-DNA 
complexes were quantified using antibodies specific to TOP2A (A) or TOP2B (B). Data are expressed 
relative to the mean value for NB4 cells incubated with 100µM etoposide ± S.E.M. *P<0.05; 
**P<0.01;***P<0.001. (C) Percentage values are expressed relative to 100µM etoposide in non-BSO 
treated cells and significance values used difference between non-BSO treated and BSO treated cells 
for the specified drug. (Etoposide quinone synthesised by Cayman Chemicals, Michigan) 
 
  
 
174 
 
 
Figure 5.10. Glutathione depletion increases the level of etoposide quinone induced global 
H2Ax phosphorylation at 10µM. NB4 cells were pre-treated with BSO (150µM, 4,5hr) followed by the 
incubation with 10µM or 100µM etoposide or etoposide quinone and analysed for the level of H2Ax 
phosphorylation. Data are expressed relative to the mean value for NB4 cells incubated with 100µM 
etoposide ± S.E.M. ***P<0.001. (B) Percentage values are expressed relative to 100µM etoposide in 
non-BSO treated cells and significance values used difference between non-BSO treated and BSO 
treated cells for the specified drug. (Etoposide quinone synthesised from Cayman Chemicals, 
Michigan).  
 
The data generated shows the depletion of glutathione significantly increases TOP2A 
poisoning induced at 10µM and 100µM etoposide quinone treatment but did not 
affect TOP2B poisoning. For DSB induction the depletion of glutathione increases 
γH2Ax formation at 10µM etoposide quinone but not with 100µM treatment. 
   B         
Cell 
line Assay 
Pre-
treatment 
Etoposide/
µM 
Etoposide 
quinone/µM 
%+ve 
control SEM 
Sig (P-
value) 
% increase 
with BSO 
NB4 γH2Ax None  10 .! 60.0 3.3     
NB4 γH2Ax BSO 10 .! 106.1 12.1 <0.001 43.4 
NB4 γH2Ax None  .! 10 34.8 3.0 !!   
NB4 γH2Ax BSO .! 10 80.2 5.2 <0.001 56.6 
NB4 γH2Ax None  100 .! 100.0 0.7     
NB4 γH2Ax BSO 100 .! 180.0 17.2 <0.001 40 
NB4 γH2Ax None  .! 100 92.1 5.7     
NB4 γH2Ax BSO .! 100 87.1 2.4 0.993 - 
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5.3.4 Longevity of etoposide or etoposide quinone stabilised TOP2-DNA 
complexes-TARDIS reversal assay.  
 
The TARDIS assays data shown above (5.3.1 to 5.3.3) and in chapter 4 were utilised 
to quantify the level of drug-stabilised TOP2-DNA covalent complexes after cells are 
exposed to a TOP2 poison for 1 hour. Immediately after the 1 hour drug incubation 
period, cells are processed for the detection of stabilised TOP2-DNA complexes. The 
TARDIS assay can be modified at the stage of drug incubation to analyse the 
longevity of drug-stabilised TOP2-DNA complexes at different time-points after drug 
removal, allowing the determination of the half-life of drug-stabilised TOP2-DNA 
complexes (Willmore et al., 1998). This assay is therefore referred to as the TARDIS 
reversal assay. To conduct these experiments, the desired TOP2 poison was 
incubated in cells for 1 hour followed by the removal of drug from the cell medium. 
Cells were then placed in fresh drug-free medium and incubated at 37oC. At specific 
time-points after drug removal, the TARDIS assay was conducted using the standard 
protocol (for further details see sections 2.13.1 to 2.13.7). Previous studies 
conducted in the Austin lab have shown 50% of etoposide-stabilised TOP2A-DNA 
complexes reverse within 30-40min. Whereas, for TOP2B the reversal time was 15-
20min with almost complete complex reversal achieved within 120mins after drug 
removal. These previous studies were conducted in MEFs (Errington et al., 2004), 
CCRF-CEMs (human leukaemia cell line) (Willmore et al., 1998) and K562 cells 
(Errington et al., 2004; Lee et al., 2016).   
The TARDIS reversal assay was conducted to measure the rate of reversal of 
etoposide stabilised TOP2-DNA covalent complexes in the presence or absence 
(using BSO) of glutathione in NB4 cells. NB4 cells treated with or without BSO 
(150µM, 4.5hr) were incubated with 100µM etoposide for 1 hour. The level of 
etoposide stabilised TOP2A- and TOP2B-DNA complexes were investigated at 0, 
30min, 60min and 120min time-points after drug removal. Figures 5.11.A-B 
represents the level of integrated fluorescence obtained per nucleus for a single 
biological replicate. The integrated fluorescence values represent the level of 
stabilised TOP2-DNA covalent complexes for each individual nucleus. Data from an 
additional two biological replicates were combined using the median value (red line)  
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to produce the data shown in Figures 5.11.C-D. Firstly, the results in the absence of 
BSO will be discussed. For TOP2A 72% of etoposide-stabilised complexes resolved 
within 30min after drug removal (Figure 5.11.A,C and E). At 60min, the average level 
of integrated fluorescence was comparable to the basal level of TOP2A-DNA 
complexes within the cell (0min no drug, P=0.469) (Figure 5.11.A and C). For 
TOP2B, a 56% reduction in etoposide-stabilised complexes was achieved after 
30min of drug removal and as seen with TOP2A, 60min after etoposide removal the 
level of TOP2B complexes were comparable to the basal level of TOP2B-DNA 
complexes (P=0.500) (Figure 5.11.B and D). Taken together these results show 
etoposide stabilised TOP2-DNA complexes have a half-life of less than 30min in NB4 
cells. 
The addition of BSO to reduce glutathione levels induced a small increase in the 
level of etoposide-stabilised TOP2B-DNA (P=0.017) complexes remaining after drug 
removal (Figure 5.11.B&D). However, there was less evidence that depletion of 
glutathione affected the level of stabilised TOP2A-DNA complexes after etoposide 
removal (P=0.181) (Figure 5.11.A&C). These results suggest that glutathione plays a 
small role in increasing the longevity of stabilised etoposide TOP2B-DNA complexes 
(Figures 5.11.A-D). 
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Figure 5.11. Depletion of glutathione increases the level of etoposide stabilised TOP2B-DNA 
complexes (P=0.017) but not TOP2A-DNA complexes (P=0.181) that remain after drug removal. 
NB4 cells were pre-treated with BSO (150µM, 4.5hr) followed by treatment with 100µM etoposide or a 
vehicle control for 1hr. Following this, etoposide containing medium was removed from cells and cells 
were replaced in fresh non-drug medium (BSO was re-added in cells which had prior BSO treatment). 
Level of etoposide stabilised TOP2-DNA complexes remaining after drug removal were quantified at 
the specified time-points for TOP2A (A) or TOP2B (B) n=1, a minimum of 600 cells analysed per 
treatment. Means of median (red line) were calculated from an additional two experiments. Data are 
expressed relative to the mean value obtained with 100µM etoposide for non-pretreated NB4 cells or 
NB4 cells treated with 100µM etoposide in BSO treated cells at the 0min time-point ± S.E.M for 
TOP2A (C) and TOP2B (D). (E) Supporting table on next page, shows the percentage values relative 
to either 100µM etoposide in non-pretreated NB4 cells or NB4 cells treated with 100µM etoposide in 
BSO treated cells. Statistical analysis was conducted using the two-way ANOVA. 
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    E 
Cell line TARDIS  Assay Pre-treatment 
Time after 
drug 
removal  
%+ve 
control 
(100µM 
non-BSO 
treated) 
%+ve 100µM 
BSO treated 
 NB4 TOP2A None  0 100   
 NB4 TOP2A BSO 0  100 
 NB4 TOP2A None  30 28.2   
 NB4 TOP2A BSO 30  33 
 NB4 TOP2A None  60 13.9   
 NB4 TOP2A BSO 60  23.6 
 NB4 TOP2A None  120 4.5   
 NB4 TOP2A BSO 120  7.2 
 NB4 TOP2B None  0 100   
 NB4 TOP2B BSO 0  100 
 NB4 TOP2B None  30 44.3   
 NB4 TOP2B BSO 30  30.4 
 NB4 TOP2B None  60 22.6   
 NB4 TOP2B BSO 60  18.7 
 NB4 TOP2B None  120 25.7   
 NB4 TOP2B BSO 120   39.7 
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Studies have reported that etoposide quinone behaves as a covalent TOP2 poison 
(Smith et al., 2014b) therefore, in principle etoposide quinone-stabilised TOP2-DNA 
complexes could persist for longer than those formed with etoposide, which is an 
interfacial TOP2 poison. To test this, NB4 cells were treated with 100µM etoposide 
quinone for 1hr followed by drug removal and analysed for TOP2-DNA covalent 
complex disappearance for up to 120min after drug removal using the TARDIS 
assay. Results obtained show that like etoposide, 70% of the TOP2A-DNA 
complexes (Figure 5.12.A&C) and 50% of TOP2B-DNA complexes induced by 
etoposide quinone reverse within 30min of drug removal (Figure 5.12.B&D). However 
in the presence of BSO, to deplete glutathione, the level of etoposide quinone 
TOP2A (P=0.019) and TOP2B-DNA (P=0.031) complexes persist for longer in cells 
at all time-points tested. This can also be seen in the scatterplot data shown in 
Figures 5.12A-B, that show in the presence of BSO there are a higher proportion of 
cells compared to non-BSO treated cells which display high level of stabilised 
complexes after 30min and 60min following drug removal for both TOP2A and 
TOP2B.  
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E Cell line 
TARDIS  
Assay 
Pre-
treatment 
Time after 
drug 
removal  
%+ve control %+ve 100µM BSO treated 
 NB4 TOP2A None  0 100   
 NB4 TOP2A BSO 0   100 
 NB4 TOP2A None  30 23.6   
 NB4 TOP2A BSO 30   28.8 
 NB4 TOP2A None  60 13.7   
 NB4 TOP2A BSO 60   12.3 
 NB4 TOP2A None  120 5.2   
 NB4 TOP2A BSO 120   5.3 
 NB4 TOP2B None  0 100   
 NB4 TOP2B BSO 0   100 
 NB4 TOP2B None  30 53   
 NB4 TOP2B BSO 30   63.6 
 NB4 TOP2B None  60 53.8   
 NB4 TOP2B BSO 60   38.8 
 NB4 TOP2B None  120 47.6   
 NB4 TOP2B BSO 120   39.7 
 
 
 
Figure 5.12. Glutathione depletion increases the level of stabilised etoposide quinone 
stabilised TOP2A- (P=0.019) and TOP2B- (P=0.031) DNA complexes remaining after drug 
removal. NB4 cells were treated with 100µM etoposide quinone or a vehicle control for 1hr. Etoposide 
quinone was subsequently removed from the cell culture medium and cells were replaced in fresh 
non-drug medium (BSO was re-added in cells which has prior BSO treatment). TOP2-DNA complexes 
remaining after drug removal were quantified using the TARDIS assay for TOP2A (A) and TOP2B (B) 
n=1, a minimum of 500 cells analysed per treatment. Means of median (red line) were calculated from 
an additional four experiments. Data are expressed relative to the mean value obtained with 100µM 
etoposide for untreated NB4 cells at the 0min time-point ± S.E.M for TOP2A (C) and TOP2B (D). (E) 
Supporting table shows the percentage values relative to either 100µM etoposide quinone in non-
pretreated NB4 cells or NB4 cells treated with 100µM etoposide quinone in BSO treated cells. 
Statistical analysis was conducted using the two-way ANOVA. 
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5.4 Discussion  
 
Etoposide and mitoxantrone metabolites containing reactive quinone and quinone-
diimine groups can be detoxified by glutathione. The MPO-mediated oxidation of 
etoposide generates etoposide quinone via a semi-quinone species, both of these 
quinone containing compounds are susceptible to glutathione mediated inactivation. 
HL60 cell lysates (MPO positive cell line) treated with etoposide revealed the 
formation of etoposide quinone conjugated with glutathione (Figure 5.1) (Fan et al., 
2006). Similarly, MPO mediated oxidation of mitoxantrone results in the formation of 
the naphthoquinoxaline metabolite via a reactive quinone-diimine, which is also liable 
to detoxification by glutathione (Blanz et al., 1991) (Figure 5.2). Therefore, the effect 
of high MPO expression on TOP2 poison-mediated DNA damage in cells may be 
limited by glutathione. To investigate this, NB4 cells were treated with BSO to inhibit 
glutathione synthesis. Glutathione depleted cells displayed significantly increased 
levels of etoposide and mitoxantrone stabilised TOP2-DNA covalent complexes and 
γH2Ax formation. In glutathione depleted cells 10µM etoposide treatment resulted in 
TOP2A- and TOP2B-DNA complexes that did not significantly differ to 100µM 
etoposide treatment in non-glutathione depleted cells (P=0.919 and P=0.978 
respectively) (Figure 5.3 A-B). A similar effect was observed with 10µM etoposide for 
γH2Ax formation (Figure 5.4.A). For mitoxantrone, glutathione depletion also 
increased the level of TOP2A and TOP2B-DNA covalent complexes and γH2Ax 
formation (Figure 5.5 and 5.6). 
Interestingly, the result observed with the depletion of glutathione was dependent on 
MPO, as treatment with SA (to inhibit MPO activity) decreased the level of etoposide 
or mitoxantrone mediated damage as measured using the TARDIS assay  
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and γH2Ax detection assay.  
Notably the level of damage observed in SA + BSO treated cells were comparable to 
that observed in SA treated cells, suggesting that BSO had no affect in cells which do 
not contain MPO activity. The effect seen in SA pre-treated NB4 cells represents the 
TOP2 poisoning activity of un-metabolised (by MPO) etoposide or mitoxantrone. 
These results indicate the TARDIS and γH2Ax signal in glutathione depleted cells are 
due to the presence of MPO mediated oxidation of etoposide and mitoxantrone to 
metabolites that poison TOP2 and induce DSB in cells. This was further confirmed by 
the addition of exogenous etoposide quinone (MPO metabolite), which both poisoned 
TOP2 and induced γH2Ax formation, which increased upon glutathione depletion 
(Figure 5.9 and 5.10).  
It was hypothesised that as etoposide quinone is able to covalently poison TOP2, the 
stabilised TOP2-DNA complexes induced by etoposide quinone may have a greater 
half-life compared to etoposide (Smith et al., 2014b). Etoposide quinone and 
etoposide stabilised complexes were shown to reverse at similar rates in NB4 cells 
(Figure 5.11-5.12), this result is in line with in vitro published data (Gibson et al., 
2016). Interestingly, the depletion of glutathione delayed TOP2A and TOP2B-DNA 
complex reversal after etoposide quinone was removed from the drug medium 
(Figure 5.12A-D). The same was true for the etoposide stabilised TOP2B complexes 
(Figure 5.11A-D). This suggests the stabilised complexes observed with etoposide 
quinone may be a mixture of complexes stabilised by the interfacial poisoning 
mechanism and the covalent poisoning route (see section 1.3.1). TOP2A- or TOP2B-
DNA complexes, stabilised by covalent poisoning are predicted to be longer-lived 
due to the interaction with the protein-DNA complex being stronger compared to drug 
intercalation into the binary complex. 
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The substantial increase observed in TOP2 poison mediated damage upon depletion 
of glutathione is clinically important as patients on high-intensity chemotherapy  
regimes have reduced levels of glutathione (Charushila and Subodhini, 2013; Kadam 
and Abhang, 2015). Therefore the affect seen is BSO-treated cells can reflect the 
potential genetic damage caused during cytotoxic TOP2 poison therapy in MPO 
positive cells.  
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Chapter 6. Effect of MPO inhibition on anthracycline mediated DNA 
damage and the role of anthracyclines and mitoxantrone as 
catalytic TOP2 inhibitors 
6.1 Introduction 
6.1.1 Anthracyclines 
  
The anthracyclines, doxorubicin and epirubicin (Figure.6.1) are widely used in cancer 
therapy and unlike etoposide are reported to utilise multiple mechanisms for 
cytotoxicity including, TOP2 poisoning (Capranico et al., 1990a; Capranico et al., 
1990b), intercalation with DNA (Agudelo et al., 2014), lipid peroxidation (Winterbourn 
et al., 1985; Hrelia et al., 2002), formation of DNA adducts (Swift et al., 2006; 
Coldwell et al., 2008), free radical formation (Sinha et al., 1989; Benchekroun et al., 
1993) and apoptotic death via p53 (Magnelli et al., 1995). However, it is debatable 
whether at the doses given to patients (maximum cumulative dose 450mg/m2 of 
doxorubicin and 0.9-1g/m2 of epirubicin, NICE Feb 2017 guidelines) and in the 
presence of glutathione if all these mechanisms of anthracycline-mediated 
cytotoxicity would take place (Gewirtz, 1999b; Minotti et al., 2004).  
 
Figure.6.1 Structures of doxorubicin and epirubicin.  
 
  
Studies have been conducted to evaluate the role of peroxidases (MPO and 
lactoperoxidase) on the oxidation of doxorubicin. Since epirubicin differs only by the 
position of a hydroxyl group at C-4’ in dauosamine (sugar moiety) (axial-to-equatorial 
epimerization), in principle the mechanism of doxorubicin action would apply to 
epirubicin (Figure.6.2). MPO can mediate the oxidation of hydroquinone moiety (ring 
C) to a semi-quinone species (Figure.6.2). This semi-quinone species may further 
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disproportionate into the parent compound and to a di-quinone species (strong 
electrophile). Glutathione can conjugate with the semi-quinone species reducing the 
formation of anthracycline-di-quinone (Reszka et al., 2004). The di-quinone species 
is potentially cytotoxic to cells however, studies have suggested that this species 
degrades into two inactive metabolites termed 3-methoxyphthalic acid and 3-
methoxysalicylic acid (Reszka et al., 2005; Wagner et al., 2007), this potentially could 
be a protective measure for cells. 
 
 
Figure.6.2 Structures of anthracycline semi-quinone and di-quinone species. Su denotes the 
sugar molecule (dauosamine) for doxorubicin or epirubicin. Peroxidases (MPO, LPO) can mediate the 
oxidation of hydroquinone moiety (ring C) to form a semi-quinone species. The semi-quinone may 
disproportionate rapidly to the parent compound and to a di-quinone species. Structures of 
anthracycline semi-quinone and di-quinone obtained from Reszka et al., 2001. 
 
 
Another mechanism of the biotransformation of doxorubicin and epirubicin is the 
formation of formaldehyde adducts; doxoform and epiform that can adduct DNA 
(Fenick et al., 1997; Taatjes et al., 1998) (Figure.6.3). The formation of these 
conjugates may be dependent on MPO and glutathione. The reason for suggesting 
this is that MPO can lead to the production of formaldehyde via the oxidation of 
amino acids (Hazen et al., 1998) whereas glutathione can adduct with formaldehyde 
reducing the level of intracellular free formaldehyde (Bateman et al., 2007). In this 
chapter, the effects of active MPO and reduced glutathione on doxorubicin and 
epirubicin stabilised TOP2-DNA covalent complexes and formation of DSB have 
been evaluated.   
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Figure.6.3 Structures of anthracycline-formaldehyde conjugates. Doxoform and epiform consist of 
two parent molecules joined to each other via three methylene groups. At neutral pH these 
anthracycline-formaldehyde conjugates exist in equilibrium with a mixture of the monomeric and 
dimeric anthracycline-formaldehyde conjugates without release of the formaldehyde. Both doxoform 
and epiform can react with DNA to form DNA adducts. Structures of formaldehyde conjugates 
obtained from Fenwick et al., 1997 and Taatjes et al., 1998.  
 
6.1.2 TOP2 Catalytic inhibitors 
 
Catalytic inhibitors (such as novobiocin, merbarone, bisdioxopiperazines, e.g. ICRF-
193, ICRF-187) are distinct from TOP2 poisons in that they do not lead to the 
accumulation of TOP2-DNA covalent complexes but inhibit at other stages of the 
TOP2 catalytic cycle (Larsen et al., 2003) (for TOP2 catalytic cycle see section 
1.1.3). For example, the bisdioxopiperazines derivatives trap TOP2 in a closed clamp 
state and inhibit ATP hydrolysis, whereas novobiocin blocks binding of ATP to TOP2 
(Sekiguchi et al., 1996; Jensen et al., 2000). In comparison to TOP2 poisons, 
catalytic inhibitors are generally less cytotoxic and can be used to reduce 
anthracycline-induced damage or increase the sensitivity to TOP2 poisons. 
Dexrazoxane (ICRF-187) is sometimes used as a cardioprotective or to prevent 
tissue necrosis in doxorubicin therapy (Swain et al., 1997; Kane et al., 2008; Asselin 
et al., 2016). On the other hand, suramin and novobiocin can be used to increase the 
efficacy of doxorubicin and etoposide (Lorico et al., 1992; Benini et al., 2001; Zhang 
et al., 2001). However, a given compound does not need to directly interact with the 
TOP2 protein for it to be considered as a catalytic inhibitor. Examples include the 
anthracyclines, aclarubicin and idarubicin which inhibit TOP2 poison induced TOP2-
DNA complex stabilisation.  Studies have suggested that aclarubicin or idarubicin 
behave as catalytic TOP2 inhibitors by intercalating into DNA, which prevents TOP2 
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from binding to DNA (Jensen et al., 1990; Sehested and Jensen, 1996; Willmore et 
al., 2002).   
6.2 Aims 
 
• To investigate the effect of MPO inhibition and glutathione depletion on 
anthracycline (doxorubicin and epirubicin) induced DNA damage using the 
TARDIS and γH2Ax quantitative immunofluorescence assays.  
• To establish whether anthracyclines, mitoxantrone or etoposide quinone 
behave as TOP2 catalytic inhibitors using the TARDIS inhibitor assay. 
6.3. Results 
6.3.1 Stabilisation of TOP2-DNA covalent complexes by doxorubicin or 
epirubicin.  
 
The TARDIS assay was employed to quantify the level of doxorubicin or epirubicin 
stabilised TOP2A- or TOP2B-DNA covalent complexes in NB4 cells. The TARDIS 
assay allows the quantification of TOP2 protein covalently bound to DNA, after the 
removal of non-covalently bound proteins and cellular constituents from nuclear DNA 
by SDS-salt extraction (method described in 2.13). Previous studies conducted by 
the Austin lab have shown treatment with 0.1µM to 10µM doxorubicin in K562 cells 
induced low levels of complex stabilisation for both TOP2A and for TOP2B; the level 
of anthracycline induced complexes were not significantly different to the basal level 
of TOP2B-DNA covalent complexes (Willmore et al., 2002). To test whether the same 
is applicable in NB4 cells, cells were treated with 0.1µM, 1µM or 10µM doxorubicin or 
epirubicin for 1hour. Following this, cells were processed to quantify the level of drug-
stabilised TOP2-DNA covalent complexes using the TARDIS assay.  
The TARDIS assay data obtained for doxorubicin and epirubicin show that both 
drugs have a similar trend in TOP2A and TOP2B-DNA complex stabilisation to each 
other (Figure.6.4.A-D). The data shown in Figures 6.4.A-D are represented as 
scattergrams, each scatter-point depicts the level of integrated fluorescence obtained 
per nucleus and the red line represents the median value of integrated fluorescence 
obtained in the cell population. For each treatment a minimum of 300 nuclei were 
analysed. 
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Figure 6.4. Dose response of doxorubicin or epirubicin mediated TOP2A or TOP2B-DNA 
complex stabilisation. NB4 cells were treated with 0.1µM to 10µM of doxorubicin (A&B) or epirubicin 
(C & D) for 1 hour. Drug-stabilised TOP2-DNA covalent complexes were quantified by the TARDIS 
assay using antibodies specific to either TOP2A (A & C) or TOP2B (B & D). Data are represented as 
scattergrams, each point corresponds to the integrated fluorescence obtained for a single nucleus, the 
median value (red line) of integrated fluorescence obtained for the whole population (n=1).  
 
Doxorubicin produced a dose-dependent increase in TOP2A-DNA covalent 
complexes (Figure. 6.4.A). However for TOP2B, doxorubicin treatment did not induce 
a noticeable increase in the median fluorescence signal above the control level (0µM 
doxorubicin) in NB4 cells (Figure.6.4.B). With 0.1µM doxorubicin, there were a small 
proportion of cells, with stabilised TOP2B-DNA complexes which were above the 
basal level of TOP2B complexes, compared to 1µM or 10µM doxorubicin (Figure. 
6.4.B), a result which is consistent with previous published data (Willmore et al., 
2002). A similar trend for TOP2 poisoning was observed for epirubicin treated NB4 
cells (Figure.6.4.C-D). As for doxorubicin, treatment with epirubicin induces a dose-
dependent increase in TOP2A complexes but not for TOP2B complexes (Figure. 
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6.4.C-D). These results indicate both doxorubicin and epirubicin poison TOP2A, but 
at very low level under the conditions tested. 
Next, the level of doxorubicin and epirubicin stabilised TOP2-DNA complexes were 
tested at various time-points after drug treatment. To investigate this, a time-course 
experiment was conducted, NB4 cells were treated with 10µM doxorubicin or 
epirubicin. Following this, cells were processed to quantify for the level of drug-
stabilised TOP2A or TOP2B-DNA complexes at 15min, 30min, 60min and 120min of 
drug treatment. Results shown in Figures 6.5.A-B were obtained from a single 
biological replicate to conduct analyses, data from an additional two biological 
replicates were combined using the median value (red line) obtained for each 
treatment. The mean of the medians obtained with 10µM doxorubicin with 60min 
treatment was used to normalise data from multiple biological replicates (see section 
2.14) (Figure.6.5C-D). 
Doxorubicin treated cells show a similar level of TOP2A-DNA complex stabilization at 
each time-point investigated, due to the low level of signal obtained there are a lot of 
fluctuations in the data, which is represented by the large standard error 
(Figure.6.5A&C). At any given time-point after doxorubicin treatment the level of 
doxorubicin stabilised TOP2A-DNA complexes were not significantly above the basal 
level of TOP2A-DNA complexes observed in non-drug treated cells (0min) 
(Figure.6.5C). However, there was an observed increase in the proportion of cells 
with increased integrated fluorescence from 15min to 60min of doxorubicin 
incubation (Figure.6.5.A). This heterogeneity in TOP2-DNA complex stabilisation 
across the cell population was also observed in etoposide and in mitoxantrone 
treated cells (chapter 4; Figures 4.3 and 4.4). For TOP2B, the level of complex 
stabilisation observed in doxorubicin treated cells was comparable to the basal level 
of TOP2B complex stabilisation (0mins) at all time-points tested (Figure.6.5B&D).  
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Figure 6.5. Time course for doxorubicin mediated TOP2A or TOP2B-DNA complex stabilisation. 
NB4 cells were treated with 10µM doxorubicin and levels of TOP2A- (A) or TOP2B- (B) DNA stabilised 
complexes were quantified at the specified time-points using the TARDIS assay (a minimum of 700 
cells analysed per treatment). Data obtained from A and B was combined with an additional two 
experiments using the median values obtained (red line) and represented as histograms for TOP2A 
(C) and TOP2B (D) (n=3). Data are expressed relative to the mean of the median values obtained for 
1hr treatment with 10µM doxorubicin ±S.E.M.   
 
There is a noticeable difference between the integrated fluorescence values obtained 
in the non-drug treated cells (0µM/0mins) between Figures 6.4 and 6.5. This is due to 
the differences in background subtraction and the camera exposure value chosen in 
each experiment. For Figure 6.4, 100µM etoposide was used to set the exposure 
value of each channel (FITC and DAPI) in the experiment whereas for Figures 6.5 
and 6.6, 10µM doxorubicin or epirubicin were used to set exposure values. As 100µM 
etoposide gives, a high intensity integrated fluorescence signal compared to 
doxorubicin or epirubicin the exposure value for each channel was lower for data in 
Figure 6.4. 
  
 
192 
A time-course TARDIS experiment was conducted using 10µM epirubicin in NB4 
cells and the level of TOP2A- or TOP2B-DNA covalent complexes were investigated 
at 15min, 30min, 60min and 120min after drug exposure. A time-dependent increase 
in TOP2A-DNA complex stabilisation was observed with epirubicin, with maximum 
complex stabilisation obtained at 60min of drug exposure (80% above basal levels) 
(Figure.6.6.C). Additionally, the level of epirubicin stabilised TOP2A-DNA complexes 
were significantly above the basal level of TOP2A complexes at 30min (P=0.019), 
60min (P<0.001) and 120mins (P=0.004). This is different to data obtained using 
10µM doxorubicin (Figure 6.5C). For TOP2B, epirubicin treatment did not result in 
TOP2B signal significantly above basal levels at any of the time-points tested 
(Figure.6.6.B&D). This is similar to the response obtained with doxorubicin 
(Figure.6.5.B&D). Additionally, it was observed that epirubicin treatment resulted in 
less variation between replicate experiments compared to doxorubicin, which is 
represented by the lower standard error in the data obtained using epirubicin 
compared to doxorubicin (Figure.6.5C-D and Figure. 6.6C-D). For this reason further 
TARDIS experiments were conducted using epirubicin and not doxorubicin.  
The TARDIS data shown above and in the previous chapters were obtained using 
isoform specific TOP2 antibodies, raised to the C-terminal domain of either TOP2A or 
TOP2B (see Table 2.2 for antibody details). The C-terminal region is most diverse 
between the two isoforms and the site where modifications such as phosphorylation 
and SUMOylation occur, which potentially block antibody binding (Wells et al., 1995b; 
Ishida et al., 1996; Yoshida et al., 2016). If modifications to the C-terminus occurred 
after anthracycline treatment (but not after etoposide treatment) then this could 
possibly explain the lower TARDIS signal observed with anthracyclines using anti-C-
terminal antibodies 4566 (TOP2A) and 4555 (TOP2B). To examine this possibility an 
antibody raised to N-terminal region of TOP2 was used in the TARDIS assay 
(antibodies details listed in Table 2.2). However, due to high sequence homology 
between TOP2A and TOP2B in the N-terminal region (site of catalytic centers), this 
antibody does not distinguish between the isoforms of TOP2.  
To conduct this TARDIS experiment, NB4 cells were treated with 10µM doxorubicin 
or epirubicin for 1hour. In addition, cells were separately treated with 20µM 
mitoxantrone or etoposide (10µM or 100µM). Figure 6.7. shows both doxorubicin and 
epirubicin induce TOP2-DNA complex stabilisation which is similar to that obtained in 
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non-drug treated cells (P=0.846 and P=0.999 respectively). Whereas both 
mitoxantrone and 10µM etoposide induce TOP2-DNA complexe levels that are 
significantly above the basal level of TOP2-DNA complexes (P=0.0171 and P=0.001 
respectively). This data generated using the N-terminal TOP2 antibody was obtained 
under conditions where both doxorubicin and epirubicin induced low levels of TOP2-
DNA complex stabilisation using TOP2-CTD antibodies 4566 (TOP2A) and 4555 
(TOP2B) (see table 2.2. for antibody details). Therefore, it is unlikely that the low 
level of TOP2-DNA complexes induced by anthracyclines observed in the TARDIS 
assay is due to post-translational modifications at the C-terminus of TOP2. 
 
Figure 6.6. Time course for epirubicin mediated TOP2A or TOP2B-DNA complex stabilisation. 
NB4 cells were treated with 10µM epirubicin and probed for the level of TOP2A- (A) or TOP2B- (B) 
DNA covalent complexes at the specified timepoints (a minimum of 700 cells analysed per treatment). 
Data from additional two biological replicates were combined using the mean of median values (shown 
as a red line in A&B) and represented as histograms. Data are expressed relative to the mean value 
obtained with 10µM epirubicin at 1hr from three separate experiments ±S.E.M.  
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Figure 6.7. Probing for the level TOP2-DNA covalent complex stabilisation using TOP2 
antibody raised to N-terminal domain of bovine TOP2. Cells were treated with the specified TOP2 
poisons for 1 hour and probed for the level of drug-stabilised TOP2 complexes by the TARDIS assay 
using an antibody (4882) raised to the N-terminal (140kDa) of bovine TOP2. Data are expressed 
relative to 100µM etoposide ±S.E.M.  
6.3.2. Inhibition of MPO reduces the level of epirubicin-stabilised TOP2A-DNA 
complexes. 
 
MPO has been implicated in the oxidation of anthracyclines, the precise 
consequence of this oxidation is unclear. In this chapter, the role of MPO on 
epirubicin induced TOP2-DNA covalent complex stabilisation was investigated. To 
inhibit MPO activity, NB4 cells were pre-treated with 200µM SA for 48hr (see section 
3.3.5) followed by the incubation with 10µM epirubicin for 1 hour. Pretreatment with 
SA reduced the levels of epirubicin stabilised TOP2A-DNA complexes by 40% 
(P=0.006), but as observed previously, epirubicin did not induce TOP2B-DNA 
complex stabilisation above basal levels (Figure 6.8A-B).   
Glutathione can conjugate with the peroxidase-mediated oxidation metabolites of 
anthracyclines and therefore the presence of glutathione may reduce the level of 
TOP2 poisoning in cells. To investigate this, glutathione levels were reduced in NB4 
cells using 150µM BSO for 4.5hr (see section 3.3.9). Following this, cells were 
incubated with 10µM epirubicin for 1hour and tested for the level of TOP2A-DNA or 
TOP2B-DNA complex stabilisation using the TARDIS assay. BSO treatment had no 
effect on epirubicin stabilised TOP2A- or TOP2B-DNA complexes (P=0.820 and 
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P=0.330 respectively) (Figure 6.8.A-B). For TOP2A the pre-treatment with SA and 
BSO resulted in a 29% decrease in epirubicin stabilised complexes compared to non-
pretreated cells (Figure 6.8.A). Notably the level of epirubicin induced TOP2A-DNA 
complexes in SA+BSO pretreated cells were comparable to those obtained in SA 
pretreated cells (P= 0.150) (Figure 6.8.A). Taken together the data generated shows 
MPO activity contributes to epirubicin induced TOP2A-DNA complex stabilisation but 
the depletion of glutathione does not affect epirubicin TOP2 poisoning ability. The 
results obtained for glutathione are in-line with in vitro experiments conducted using 
doxorubicin, which showed depletion of glutathione (using BSO) does not affect the 
level TOP2-DNA complex stabilisation induced by doxorubicin (Bonner et al., 1992). 
 
C 
Cell 
line 
TARDIS 
Assay 
Pre-
treatment 
Epirubicin/
µM 
%+ve 
control SEM  
Sig (P-
value)  
% 
reduction 
by SA 
% reduction 
by 
SA+BSO 
 NB4 TOP2A None  10 100 1.7 
  
  
 NB4 TOP2A SA 10 59.6 4.3 0.006 40.4   
 NB4 TOP2A BSO 10 110.1 14.9 0.82 
 
  
 NB4 TOP2A SA+BSO 10 70.9 6.5 0.070 
 
29.1 
 NB4 TOP2B None  10 100 2.7       
 NB4 TOP2B SA 10 109.5 31 0.990 
 
  
 NB4 TOP2B BSO 10 50.4 22.7 0.330 
 
  
 NB4 TOP2B SA+BSO 10 43.7 14.9 0.230     
 
Figure 6.8. Inhibition of MPO reduces epirubicin stabilised TOP2A-DNA covalent complexes. 
NB4 cells were pre-treated with 200µM SA for 48hr or 150µM BSO for 4.5 hours, or with both or with 
neither followed by 1hr incubation with 10µM epirubicin. Cells were processed and analysed for the 
level of epirubicin stabilised TOP2-DNA covalent complexes for TOP2A (A) or TOP2B (B). Data are 
expressed relative to the mean value obtained with 10µM epirubicin in non-pre-treated cells (black 
bar). (C) Percentage values showing the mean level of TOP2-DNA complex stabilisation compared to 
10µM epirubicin in non-pretreated cells. Statistical analysis was performed by the one-way ANOVA 
with post hoc Tukey’s multiple comparison test.  * P <0.05; ** P <0.01. 
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6.3.3. γH2Ax formation in doxorubicin or epirubicin treated NB4 cells. 
 
Doxorubicin and epirubicin elicit the formation of γH2Ax foci, which indicates 
production of DSBs within a cell (Kurz et al., 2004; Monteiro et al., 2013). The 
induction of γH2Ax foci upon treatment with doxorubicin or epirubicin is partly 
dependent on TOP2A (Yan et al., 2009) but additional mechanisms such as redox 
cycling may also contribute to γH2Ax formation. To measure the level of DSB 
induced by doxorubicin or epirubicin, NB4 cells were treated with a range of 
concentrations of either doxorubicin or epirubicin for 1hour. Following this, the drug 
was removed from the cell medium and cells were fixed onto slides, permeabilised 
and probed for the level of γH2Ax formation using quantitative immunofluorescence 
(method described 2.11). For each treatment a minimum of 700 cells were analysed 
and data are represented as scattergrams. Each data-point represents the level of 
integrated fluorescence obtained per cell, which is indicative of the level of γH2Ax 
formation in each cell. 
Data presented in Figure 6.9.A-B, show both doxorubicin and epirubicin elicit a dose-
dependent increase in γH2Ax formation (Figure.6.9A-B). A low level of γH2Ax was 
observed in the non-drug treated NB4 cells, this basal level of γH2Ax formation is 
presumably caused during normal cellular processes (McManus and Hendzel, 2005; 
An et al., 2010). The intensity of integrated fluorescence is distributed 
heterogeneously in the cell population, a response which is similar to that observed 
in the TARDIS assay (Figure.6.4). Due to this heterogeneity across the cell 
population, the median value (red line) of integrated fluorescence was used to 
combine replicate experiments to present data as histograms shown in Figure 6.9.C-
D. 
For doxorubicin, a dose of 10µM doxorubicin was required to achieve γH2Ax 
formation above the basal level (0µM) (P>0.001) (Figure.6.9C). In epirubicin treated 
cells, the response to treatment is dose dependent but between 10µM and 20µM, 
there was no observed change in integrated fluorescence. However, in contrast to 
doxorubicin, 1µM epirubicin treatment (P=0.027) is sufficient to produce a response 
above basal levels (Figure. 6.9D). This suggests that epirubicin is more potent than 
doxorubicin at inducing DSB within cells. 
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Figure 6.9. Dose response of doxorubicin or epirubicin- induced γH2Ax formation. NB4 cells 
were treated with the specified concentrations of doxorubicin (A) or epirubicin (B) for 1 hour and 
probed for the level of γH2Ax formation using quantitative immunofluorescence (A & B) n=1. In figures 
A and B, each point on the scattergram represents the level of integrated fluorescence (i.e. level of 
γH2Ax signal) obtained per cell. Data from a further three experiments were combined using the mean 
of the medians (median value shown as a red line in A & B) to generate the histograms shown in C & 
D. Data are expressed relative to 10µM of doxorubicin (C) or 10µM epirubicin (D) ±S.E.M (n=4). 
6.3.4. The effect of MPO inhibition and glutathione depletion on doxorubicin 
and epirubicin induced γH2Ax formation. 
 
As described in section 6.3.2, inhibition of MPO activity significantly reduced the level 
of epirubicin induced TOP2A-DNA covalent complexes in NB4 cells (Figure.6.8A). 
Therefore, I investigated whether inhibition of MPO also affected the level of γH2Ax 
formation after treatment with 10µM epirubicin or doxorubicin. To inhibit MPO, cells 
were pretreated with 200µM SA for 48hr followed by incubation with 10µM 
doxorubicin or epirubicin. Pretreatment with SA significantly reduced the level of both 
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doxorubicin (Figure.6.10A) and epirubicin (Figure.6.10.B) induced γH2Ax formation 
(reduction by 36% and 28% respectively) (Figure.6.10.C). As SA pre-treatment 
reduced the level of epirubicin stabilised TOP2A-DNA covalent complexes by 40% 
this suggests the formation of DSB in epirubicin treated cells may at least be partly 
due to the processing of stabilised TOP2A-DNA covalent complexes to DSB. For 
doxorubicin, a TARDIS signal above basal TOP2-DNA complex stabilisation was not 
obtained, despite the robust γH2Ax phosphorylation using the same drug 
concentration. This may suggest that doxorubicin induces predominantly DSB via a 
different mechanism to poisoning TOP2.  
Both doxorubicin and epirubicin undergo redox cycling within cells, it is plausible that 
reduced glutathione may reduce the action of both the anthracyclines and therefore, 
reduce the level of DSB in cells upon exposure to doxorubicin or epirubicin. NB4 cells 
were pre-treated with 150µM BSO for 4.5hr to deplete cells of total and reduced 
glutathione. BSO treated cells had 28% more doxorubicin-induced γH2Ax formation 
(P=0.044) compared to non-BSO pre-treated cells (Figure.6.10A). Similarly, BSO 
treatment induced a 28% increase in epirubicin induced γH2Ax formation (P=0.001) 
(Figure.6.10.B). To investigate if the affect observed in glutathione-depleted cells is 
due to MPO, NB4 cells were first pre-treated with SA followed by treatment with BSO. 
In SA+BSO pre-treated cells, incubation with either doxorubicin or epirubicin reduced 
the level of γH2Ax formation to a level that was no longer significantly different to SA 
treated cells (P=0.239 and P=0.524 respectively) (Figure.6.10.A-B). This indicates 
the elevated levels of doxorubicin or epirubicin induced γH2Ax formation in 
glutathione depleted cells is dependent upon MPO mediated oxidation of doxorubicin 
and epirubicin to semi-quinone and di-quinone species.  
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   C          
Cell 
line Assay 
Pre-
treatment 
Doxorubicin/
µM 
%+ve 
control SEM  
Sig (P-
value)  
% 
reductio
n by SA 
% 
increase 
by BSO 
% 
reduction 
by 
SA+BSO 
NB4 γH2Ax None  10 100 8.4 
   
  
NB4 γH2Ax SA 10 63.8 2.8 0.094 36.2 
 
  
NB4 γH2Ax BSO 10 120.1 10.1 0.044 
 
28.4   
NB4 γH2Ax SA+BSO 10 56.5 5.1 0.019     43.5 
  D 
         
Cell 
line Assay 
Pre-
treatment 
Epirubicin/ 
µM 
%+ve 
control SEM  
Sig (P-
value)  
% 
reductio
n by SA 
% 
increase 
by BSO 
% 
reduction 
by 
SA+BSO 
NB4 γH2Ax None  10 100 2.8 
   
  
NB4 γH2Ax SA 10 72 5.8 0.013 28 
 
  
NB4 γH2Ax BSO 10 138 4.5 0.001 
 
27.5   
NB4 γH2Ax SA+BSO 10 65.1 8.5 0.002     35 
 
Figure 6.10. The effect of inhibiting MPO and depleting glutathione on the level of doxorubicin 
(A) and epirubicin (B) induced γH2Ax formation. NB4 cells were pre-treated with SA (200µM, 48hr) 
or BSO (150µM, 4.5hr) or with both or with neither followed by the treatment with 10µM doxorubicin 
(A) or epirubicin (B) for 1 hour. Cells were then processed to quantify the level of γH2Ax 
phosphorylation using immunofluorescence. Data are expressed relative to 10µM doxorubicin (A) or 
10µM epirubicin (B) ±S.E.M. (C-D) Percentage values are shown relative to the mean of 10µM 
doxorubicin (C) or 10µM epirubicin in non-pretreated cells. Statistical analysis was performed by the 
one-way ANOVA with post hoc Tukey’s multiple comparison test.   * P <0.05; ** P <0.01; ***P<0.001. 
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6.3.5 Catalytic inhibition of TOP2 by anthracyclines and mitoxantrone 
 
The anthracyclines, aclarubicin and idarubicin behave as catalytic inhibitors of TOP2 
and reduce TOP2 poison induced TOP2-DNA covalent complex stabilisation. The 
route of catalytic inhibition by aclarubicin or idarubicin is thought to be via DNA 
intercalation preventing the binding of TOP2 (Ferrazzi et al., 1991; Jensen and 
Sehested, 1997). Therefore it was investigated whether the anthracyclines; 
doxorubicin and epirubicin and the anthracenedione, mitoxantrone behave as 
catalytic inhibitors of TOP2 as these drugs can intercalate into DNA. To conduct 
these experiments the TARDIS assay was modified at the stage of drug incubation to 
explore whether a particular compound behaves as a TOP2 catalytic inhibitor. This 
will be referred to as the TARDIS inhibitor assay (method described in 2.13.1 to 
2.13.8). In this assay the proposed catalytic inhibitor is added to the cells for 1 hour. 
Following this, a known TOP2 poison (etoposide) is added to cells for an additional 1 
hour. During the incubation with etoposide the catalytic inhibitor remains in the cell 
culture medium. If the compound catalytically inhibits TOP2, then the level of 
etoposide stabilised TOP2-DNA covalent complexes will be reduced compared to the 
etoposide alone positive control.  
NB4 cells were incubated separately with the proposed catalytic inhibitors 
(doxorubicin, epirubicin or mitoxantrone) for 1 hour followed by the incubation with 
10µM or 100µM etoposide. The dose chosen for mitoxantrone was 20µM as at this 
concentration mitoxantrone reduced levels of TOP2A and TOP2B-DNA complex 
stabilisation compared to 1µM mitoxantrone treatment (see section 4.3.1). In 
addition, 100µM ICRF-193, an established catalytic inhibitor of TOP2 was used as 
positive control. Previous studies conducted in the Austin lab showed that 100µM 
ICRF-193 inhibited etoposide induced TOP2A and TOP2B-DNA covalent complex 
stabilisation in MEFs (Errington, 2001) .  
Figure 6.11A-D shows the pre-treatment with the ICRF-193 or proposed catalytic 
inhibitor doxorubicin, epirubicin or mitoxantrone substantially reduces the level of 
etoposide stabilised TOP2A- and TOP2B-DNA covalent complexes across the whole 
cell population, this is true for both 10µM and 100µM etoposide. Notably the TOP2B 
signal obtained with 10µM etoposide in the presence of catalytic inhibitors is 
comparable to the basal level of TOP2B-DNA complex stabilisation observed in non-
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drug treated cells (0µM). (Figure.6.11.B). Data from a five additional biological 
replicates were combined using the median values (red line-Figure. 6.11.A-C) to 
produce data for statistical analysis and is shown in Figure 6.12.   
 
Figure 6.11. Inhibition of etoposide-stabilised TOP2A (A and C) and TOP2B (B and D) DNA 
covalent complexes by anthracyclines or mitoxantrone. NB4 cells were pre-incubated with either 
10µM of doxorubicin or epirubicin or 20µM mitoxantrone or 100µM ICRF-193 (positive control) for 1 hr. 
Following this, cells were treated with 10µM (Ju et al.) or 100µM (C-D) etoposide or a vehicle control 
(0.02% DMSO) for 1hr. Etoposide stabilised complexes were quantified for TOP2A (A and C) or 
TOP2B (B and D) using TARDIS assay. Data are expressed as scattergrams obtained from a single 
biological replicate, where the red line represents medium line of integrated fluorescence (a minimum 
of 600 cell analysed per treatment). 
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Pre-treatment with 10µM doxorubicin resulted in 40% (P<0.001) reduction in TOP2A-
DNA complexes induced by 100µM etoposide, this signal obtained was no longer 
different to that observed with 10µM etoposide for non-pretreated cells (P=0.750) 
(Figure.6.12.A). However, at 10µM etoposide a reduction of 70% (P<0.001) in 
TOP2A-DNA complexes was observed with the prior treatment with doxorubicin 
(Figure.6.12.A). For TOP2B, pre-treatment with doxorubicin resulted in 38% 
(P<0.001) and 47% (P<0.001) reduction in etoposide stabilised TOP2B-DNA 
complexes at 10µM and 100µM etoposide respectively (Figure.6.12.B). Notably with 
doxorubicin treatment, the levels of TOP2B complexes induced with 10µM etoposide 
were comparable to the level of basal TOP2B-DNA complexes observed in non-drug 
treated cells (P=0.226) (Figure.6.12.B).   
The addition of epirubicin prior to treatment with etoposide, reduced the levels of 
etoposide stabilised TOP2A complexes by 60% with 10µM etoposide (P<0.001) and 
49% with 100µM etoposide (P<0.001) (Figure.6.12.A and C). The level of TOP2A-
DNA complexes induced with 100µM etoposide in 10µM epirubicin pre-treated cells 
was comparable to the level of TOP2A complexes observed with 10µM etoposide in 
non-pretreated cells (P=0.997) (Figure.6.12A). The same was true for TOP2B, prior 
treatment with 10µM epirubicin reduced the level of TOP2B-DNA complexes with 
100µM etoposide, to a level which was no longer significantly different to 10µM 
etoposide treatment in non-pretreated cells (P=0.323) (Figure.6.12.B). Similarly, to 
doxorubicin pre-treatment, the pre-treatment with epirubicin reduced the levels of 
etoposide (10µM) stabilised TOP2B complexes to a level that was no longer 
significantly different to the basal level of TOP2B-DNA complexes (P=0.960) 
(Figure.6.12B).  
The suggestion made in chapter 4 (4.3.1) that mitoxantrone could behave as a TOP2 
poison at lower doses (0.1µM-10µM) and as a TOP2 catalytic inhibitor at higher 
doses is supported by the data obtained in Figures 6.11 to 6.12A-C.  Pretreatment 
with 20µM mitoxantrone resulted in a significant reduction in etoposide complex 
stabilisation for both TOP2A and TOP2B at both 10µM (70% and 44%) and 100µM 
(61% and 63%) etoposide (Figure.6.12A-C). Interestingly, pretreatment with 
mitoxantrone resulted in a level of etoposide stabilised TOP2A complexes with 10µM 
etoposide being lower than those obtained with 20µM mitoxantrone alone for TOP2A 
(P<0.001). Additionally, TOP2A-DNA complexes obtained with the pre-incubation of 
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mitoxantrone at 100µM etoposide were significantly lower than the level of complex 
stabilisation obtained with 10µM etoposide in non-pretreated cells (23% lower, 
P=0.030) (Figure.6.12.A).  
As ICRF-193 is a catalytic inhibitor of TOP2, it is not anticipated that ICRF-193 alone 
will poison TOP2, however it was observed that 100µM ICRF-193 induced a small 
increase in integrated fluorescence values, consistent with a low level of TOP2A 
poisoning (P<0.001); this has been previously reported in vitro (Jensen et al., 2000; 
Huang et al., 2001). The degree of TOP2A poisoning obtained with 100µM ICRF-193 
is comparable to 10µM epirubicin (P=0.941). Pre-treatment with ICRF-193 resulted in 
reduced levels of etoposide complex stabilisation for both TOP2A and TOP2B at both 
10µM (67% and 55%) and 100µM (34% and 64%) etoposide (Figure.6.12A-C). NB4 
cells contain MPO, and as anthracyclines and mitoxantrone are affected by MPO 
activity, it was thought that the effects observed for catalytic inhibition in NB4 cells 
may affected by the action of MPO. To test this a replicate experiment was 
performed in K562 cells, which are negative for MPO expression. As shown in Figure 
6.13A-B doxorubicin, epirubicin and mitoxantrone behave as catalytic inhibitors in 
K562 cells. Notably the affect seen in K562 cells is more pronounced with 100µM 
etoposide treatment compared to NB4 cells for TOP2B (Figure.6.13.B-C and 6.14.B-
C). At 100µM etoposide the pre-treatment with the proposed catalytic inhibitors 
resulted in a level of TOP2B complex stabilisation being lower than that obtained with 
10µM etoposide (Figure.6.14.B). As a result, pretreatment with doxorubicin or 
epirubicin resulted in the TOP2B-DNA complex level obtained with 100µM etoposide 
being 59% (P=0.012) and 48% (P=0.044) lower than the signal obtained with 10µM 
etoposide for non-pretreated cells (Figure.6.14.B). Pre-treatment with 20µM 
mitoxantrone at 100µM etoposide also resulted in a 59% (P=0.012) reduction of 
TOP2B-DNA complexes compared to 10µM etoposide (Figure.6.14.B-C).  
In contrast, using each proposed catalytic inhibitor or ICRF-193 the level of reduction 
obtained after treatment with 100µM etoposide for TOP2A was greater in NB4 cells 
(Figure.6.12.A) than K562 cells (Figure.6.14.A). As a result, mitoxantrone pre-
treatment in NB4 cells resulted in 63% (P<0.001) reduction in TOP2A-DNA complex 
stabilisation at 100µM etoposide whereas in K562 cells the level of reduction was 
38% (P=0.014) (Figure.6.14.A and C). Similarly, for doxorubicin pre-treatment in NB4 
cells, the level of TOP2A-DNA complexes at 100µM reduced by 47% (P<0.001) 
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(Figure 6.12.A and C) and for K562 cells the reduction was 20% (P=0.002) 
(Figure.6.14.A and C). 
Taken together the data obtained show that doxorubicin, epirubicin and mitoxantrone 
behave as catalytic inhibitors of TOP2 and reduce TOP2 poison action, which is 
independent on the expression of active MPO. 
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    C 
Cell 
line 
TARDIS 
Assay Pre-treatment 
Etoposide 
/µM 
%+ve 
control SEM  
Sig (P-
value)  
% reduction by 
pre-treatment 
 NB4 TOP2A None  10 51.4 3.4 
 
  
 NB4 TOP2A 10µM Doxorubicin  10 15.5 0.2 <0.001 70 
 NB4 TOP2A 10µM Epirubicin  10 20.7 1.7 <0.001 60 
 NB4 TOP2A 20µM Mitoxantrone   10 15.6 0.8 <0.001 70 
 NB4 TOP2A 100µM ICRF-193 10 17.2 4 <0.001 66.5 
 NB4 TOP2A None  100 100 3.1 
 
  
 NB4 TOP2A 10µM Doxorubicin  100 60.5 4.7 <0.001 39.5 
 NB4 TOP2A 10µM Epirubicin  100 51.4 8 <0.001 48.6 
 NB4 TOP2A 20µM Mitoxantrone   100 39.1 2.8 <0.001 60.9 
 NB4 TOP2A 100µM ICRF-193 100 66.2 7.8 <0.001 33.8 
 NB4 TOP2B None  10 34.7 3.2 
 
  
 NB4 TOP2B 10µM Doxorubicin  10 21.5 2.9 <0.001 38 
 NB4 TOP2B 10µM Epirubicin  10 12.7 1.3 <0.001 63.4 
 NB4 TOP2B 20µM Mitoxantrone   10 19.3 6 0.05 44.4 
 NB4 TOP2B 100µM ICRF-193 10 15.8 2.1 0.004 54.5 
 NB4 TOP2B None  100 100 3 
 
  
 NB4 TOP2B 10µM Doxorubicin  100 53.3 2.3 <0.001 46.7 
 NB4 TOP2B 10µM Epirubicin  100 40.8 5.7 <0.001 59.2 
 NB4 TOP2B 20µM Mitoxantrone   100 37.5 2.7 <0.001 62.8 
 NB4 TOP2B 100µM ICRF-193 100 36.3 2.9 <0.001 63.7 
 
Figure 6.12. Inhibition of etoposide-stabilised TOP2A (A) and TOP2B (B) DNA covalent 
complexes by anthracyclines or mitoxantrone. NB4 cells were pre-incubated with either 10µM of 
doxorubicin or epirubicin or 20µM mitoxantrone or 100µM ICRF-193 (positive control) for 1 hr. 
Following this, cells were treated with 10µM or 100µM etoposide or a vehicle control (0.02% DMSO) 
for 1hr. Etoposide stabilised complexes were quantified for TOP2A (A) or TOP2B (B) by TARDIS 
assay. Data are expressed relative to 100µM etoposide in non-pre-treated cells ±S.E.M. (C) 
Percentage values are relative to the mean value obtained with 100µM etoposide in non-pretreated 
cells. Statistical analysis was performed by the one-way ANOVA with post hoc Tukey’s multiple 
comparison test.   * P <0.05; ** P <0.01; ***P<0.001 
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Figure 6.13. Inhibition of etoposide-stabilised TOP2A (A and C) and TOP2B (B and D) DNA 
covalent complexes by anthracyclines or mitoxantrone in K562 cells. K562 cells were pre-
incubated with either 10µM of antracyclines (doxorubicin or epirubicin) or 20µM mitoxantrone or 
100µM ICRF-193 (positive control) for 1 hr followed by the addition of 10µM (Ju et al.) or 100µM (C-D) 
etoposide and probed for the level of etoposide stabilised TOP2A (A and C) or TOP2B (B and D) 
complexes using the TARDIS assay. Data are represented as scattergrams where each point 
represents the integrated fluorescence (i.e TOP2-DNA complex stabilisation) obtained in each 
individual nuclei (a minimum of 600 cells analysed per treatment). 
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   C 
Cell 
line 
TARDIS 
Assay Pre-treatment 
Etoposide 
/µM 
%+ve 
control SEM  
Sig (P-
value)  
% reduction 
by pre-
treatment 
 K562 TOP2A None  10 46.2 2.7 
!
  
 K562 TOP2A 10µM Doxorubicin  10 15 0.8 <0.001 67.5 
 K562 TOP2A 10µM Epirubicin  10 12.9 1.1 <0.001 72.1 
 K562 TOP2A 20µM Mitoxantrone   10 32 2.2 0.003 30.7 
 K562 TOP2A 100µM ICRF-193 10 28.2 1.5 <0.001 39 
 K562 TOP2A None  100 100 3.3 !!   
 K562 TOP2A 10µM Doxorubicin  100 80.2 1.7 0.002 19.8 
 K562 TOP2A 10µM Epirubicin  100 69.4 21.2 0.259 30.6 
 K562 TOP2A 20µM Mitoxantrone   100 61.8 18.5 0.014 38.2 
 K562 TOP2A 100µM ICRF-193 100 83.6 4.6 0.047 16.4 
 K562 TOP2B None  10 68 7.8 
!
  
 K562 TOP2B 10µM Doxorubicin  10 11.9 1.5 <0.001 82.5 
 K562 TOP2B 10µM Epirubicin  10 25.6 1.6 <0.001 62.4 
 K562 TOP2B 20µM Mitoxantrone   10 6.1 1.1 0.012 91 
 K562 TOP2B 100µM ICRF-193 10 18.1 2.8 <0.001 73.3 
 K562 TOP2B None  100 100 6.9     
 K562 TOP2B 10µM Doxorubicin  100 27.7 9.3 <0.001 72.3 
 K562 TOP2B 10µM Epirubicin  100 35.7 3 <0.001 64.3 
 K562 TOP2B 20µM Mitoxantrone   100 27.8 1 <0.001 72.2 
 K562 TOP2B 100µM ICRF-193 100 48.7 5 <0.001 51.3 
Figure 6.14. Inhibition of etoposide-stabilised TOP2A (A) and TOP2B (B) DNA covalent 
complexes by anthracyclines or mitoxantrone in K562 cells. K562 cells were pre-incubated with 
either 10µM of antracyclines or 20µM mitoxantrone or 100µM ICRF-193 (positive control) for 1 hr, 
followed by addition of 10µM or 100µM etoposide and probed for the level of etoposide stabilised 
TOP2A (A) or TOP2B (B) complexes. (C) Percentage values are shown relative to the mean value 
obtained with 100µM etoposide in non-pretreated cells. Data are expressed relative to 100µM 
etoposide (non-pretreated) ±S.E.M. Statistical analysis was performed by the one-way ANOVA with 
post hoc Tukey’s multiple comparison test.   * P <0.05; ** P <0.01; ***P<0.001 
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From the data obtained using the TARDIS inhibitor assay, I hypothesised that in the 
presence of catalytic inhibitors the level of etoposide induced γH2Ax formation would 
be reduced. To test this, NB4 cells were pre-incubated with either 10µM doxorubicin 
or epirubicin, or 20µM mitoxantrone for 1 hour followed by the addition of 10µM or 
100µM etoposide for an additional 1 hour. ICRF-193 (100µM) was used as positive 
control in this experiment. NB4 cells were processed to analyse for the level of 
γH2Ax formation using quantitative immunofluorescence. 
For doxorubicin and epirubicin the results differ (Figure.6.15A-B & 6.16). Pre-
treatment with 10µM doxorubicin did not significantly alter the level of γH2Ax 
formation at 10µM (P=0.950) or 100µM (P=0.600) etoposide, suggesting the addition 
of doxorubicin does not significantly reduce etoposide DSB formation in cells 
(Figure.6.16). Treatment with 10µM epirubicin alone results in 20% greater γH2Ax 
formation compared to 10µM doxorubicin (Figure.6.16). Upon treatment with 10µM or 
100µM etoposide the γH2Ax formation induced is comparable to response obtained 
with epirubicin alone (P=0.821 and P=0.993 respectively) (Figure.6.16). This 
suggests that etoposide does not induce additional DSB breaks in cells treated with 
epirubicin due to reduction in etoposide induced TOP2-DNA complex stabilisation. 
Treatment with 100µM ICRF-193 alone in NB4 cells did not result in γH2Ax 
formation. Prior treatment with ICRF-193 did reduce the level of etoposide induced 
γH2Ax formation at 10µM and 100µM etoposide (67% and 39% less respectively) 
(Figure.6.16). 
Prior treatment with 20µM mitoxantrone resulted in the greatest inhibition of 
etoposide induced γH2Ax formation (Figure.6.15 and Figure.6.16). With 10µM 
etoposide, the pre-treatment with mitoxantrone reduced the level of γH2Ax formation 
by 79% (P<0.001). Interestingly a greater reduction of 89% was observed with 
mitoxantrone pre-treatment at 100µM etoposide, this signal was comparable to that 
obtained with 10µM etoposide in mitoxantrone pretreated cells (P=0.502) 
(Figure.6.16.A-B). Interestingly, at both doses of etoposide the pretreatment with 
mitoxantrone resulted in the level of γH2Ax signal being comparable to basal levels 
(Figure.6.16.A). 
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Figure 6.15. Effect on etoposide-induced γH2Ax by pretreatment anthracyclines or 
mitoxantrone in NB4 cells. NB4 cells were pre-incubated with either doxorubicin, epirubicin or 
mitoxantrone or ICRF-193 (positive control) for 1 hr. Following this, cells were treated with with 10µM 
(A) or 100µM (B) etoposide or a vehicle control (0.02% DMSO) for 1hr and probed for the level of 
γH2Ax formation using quantitative immunofluorescence. 
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B 
Cell 
line Assay Pre-treatment 
Etoposide 
/µM 
%+ve 
control SEM  
Sig (P-
value)  
% reduction 
by pre-
treatment 
 NB4 γH2Ax None  10 62.4 7.7 
 
  
 NB4 γH2Ax 10µM Doxorubicin  10 72.7 8.8 0.950  
 NB4 γH2Ax 10µM Epirubicin  10 64 1.7 >0.999 
  NB4 γH2Ax 20µM Mitoxantrone   10 13.2 1.7 <0.001 78.8 
 NB4 γH2Ax 100µM ICRF-193 10 20.5 2.2 <0.001 67.1 
 NB4 γH2Ax None  100 100 3     
 NB4 γH2Ax 10µM Doxorubicin  100 118.2 7.1 0.600  
 NB4 γH2Ax 10µM Epirubicin  100 64.7 4.7 0.020 35.3 
 NB4 γH2Ax 20µM Mitoxantrone   100 10.9 3.2 <0.001 89.1 
 NB4 γH2Ax 100µM ICRF-193 100 60.9 11 0.007 39.1 
 
Figure 6.16. Effect on etoposide-induced γH2Ax by pre-treatment anthracyclines or 
mitoxantrone in NB4 cells. NB4 cells were pre-incubated with either doxorubicin, epirubicin or 
mitoxantrone or ICRF-193 (positive control) for 1 hr. Following this, cells were treated with with 10µM 
or 100µM etoposide or a vehicle control (0.02% DMSO) for 1hr and probed for the level of γH2Ax 
formation using quantitative immunofluorescence. Data are expressed relative to 100µM etoposide 
±S.E.M. (B) Supporting data table shows the percentage values relative to the mean value obtained 
with 100µM etoposide in non-pretreated cells. Statistical analysis was performed by the one-way 
ANOVA with post hoc Tukey’s multiple comparison test.   * P <0.05; ** P <0.01; ***P<0.001. 
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6.3.6. Role of etoposide quinone as a TOP2 covalent inhibitor. 
 
In vitro studies have reported that etoposide quinone both poisons TOP2 and inhibits 
DNA binding to TOP2 (Smith et al., 2014b; Gibson et al., 2016). Etoposide quinone is 
an MPO catalysed metabolite of etoposide. Etoposide quinone is defined by the 
presence of carbonyl groups at the 3’ and 4’ positions of the E-ring.  In the previous 
chapter (see section 5.3.3 to 5.3.4) the role of etoposide quinone as a TOP2 poison 
was investigated and data showed that etoposide quinone poisons both TOP2A and 
TOP2B in perhaps a similar mechanism to etoposide. In this chapter the role of 
etoposide quinone as a catalytic inhibitor was investigated using the TARDIS inhibitor 
assay (see section 6.3.5 and 2.13). For this 10µM etoposide quinone was incubated 
in NB4 cells for 1 hour prior to addition with 10µM or 100µM etoposide. The dose of 
10µM etoposide quinone was chosen, as at this dose there was low level of TOP2 
poisoning observed (5.3.3). 
As seen in Figure 6.17A, 10µM etoposide quinone does not induce TOP2A-DNA 
complexes which are significantly above the basal level of TOP2A complexes 
observed in non-drug treated cells (P=0.992). However, the pre-treatment with 
etoposide quinone significantly reduces the level of etoposide (10µM) stabilised 
TOP2A complexes by 32% (P=0.038), but no significant affect was observed at 
100µM etoposide (P=0.056) (Figure.6.17.A and C). For TOP2B, etoposide quinone 
did not reduce the level of TOP2 poisoning induced by either 10µM or 100µM 
etoposide (Figure.6.17.B). Indeed, at 100µM etoposide the pre-treatment of 
etoposide quinone resulted in greater TOP2B-DNA complex stabilisation of 38% 
(P=0.005) (Figure.6.17.B and C). This suggests that etoposide quinone behaves as a 
catalytic inhibitor of TOP2A but not for TOP2B. 100µM etoposide treatment seems to 
out-compete the catalytic inhibitor capacity of 10µM etoposide quinone.  
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  C 
Cell 
line Assay Pre-treatment 
Etoposide 
/µM 
%+ve 
control SEM  
Sig (P-
value)  
% 
reduction 
by pre-
treatment 
 NB4 TOP2A-CC None  10 59 6.2 
 
  
 NB4 TOP2A-CC 10µM Etoposide quinone 10 40.2 2 0.038 31.8 
 NB4 TOP2A-CC None  100 100 15.4 
 
  
 NB4 TOP2A-CC 10µM Etoposide quinone 100 135.2 3.5 0.056   
 NB4 TOP2B-CC None  10 68.8 6.2     
 NB4 TOP2B-CC 10µM Etoposide quinone 10 68.7 7.2 >0.999   
 NB4 TOP2B-CC None  100 100 6.4 
 
  
 NB4 TOP2B-CC 10µM Etoposide quinone 100 160.5 6.9 0.005   
 
Figure 6.17. Effect of etoposide quinone pretreatment on the level of etoposide stabilised 
TOP2A (A) and TOP2B (B) covalent complexes in NB4 cells. Cells were pre-treated with 10µM 
etoposide quinone (Cayman Chemicals) for 1 hour followed by the incubation with 10µM or 100µM 
etoposide. Cells were then processed for the level of etoposide stabilised TOP2A or TOP2B using the 
TARDIS assay. Data are expressed relative to the mean value obtained with 100µM etoposide for pre-
treated NB4 cells (black bars) ±S.E.M. (C) Percentage values are shown relative to mean value 
obtained for 100µM etoposide in non-pretreated cells. Statistical analysis was performed using the 
Student’s t-test.   * P <0.05; ** P <0.01.. 
 
6.4 Discussion 
 
The anthracyclines doxorubicin and epirubicin are known to have potentially multiple 
mechanisms for cytotoxicity. However, it is unknown whether under the doses 
administered in chemotherapy regimes doxorubicin or epirubicin are able to 
accumulate in cells to have multiple routes of damage causing DNA DSB. As shown 
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in this chapter, both doxorubicin and epirubicin cause a dose dependent increase in 
DNA DSB formation as assayed by the quantification of γH2Ax formation 
(Figure.6.9A-D). Additionally active MPO expression and depletion of glutathione 
enhanced the level of γH2Ax formation in doxorubicin or epirubicin treated cells 
(Figure.6.10A-B). Notably the elevation in γH2Ax formation in glutathione-depleted 
cells was dependent on active MPO expression. This supports the idea that MPO 
mediates the formation of doxorubicin or epirubicin semi-quinone species that further 
disproportionates to a di-quinone species leading to DNA DSB formation (Reszka et 
al., 2005). In the presence of glutathione, the semi-quinone and di-quinone species 
could conjugate with glutathione leading to their detoxification. In addition, as MPO 
can catalyse the production of formaldehyde, the formation of doxoform and epiform 
could contribute to the γH2Ax formation observed in NB4 cells. If doxoform or 
epiform were produced in cells then DNA damage would be caused by the formation 
of DNA cross-links via a combination of covalent bonding (by formaldehyde), DNA 
intercalation and hydrogen bonding (by the anthracycline) (Fenick et al., 1997).  
Both doxorubicin and epirubicin displayed low potency towards TOP2 poisoning 
(Figure.6.4 to 6.6.) yet displayed effective TOP2 catalytic inhibitor functionality by 
inhibiting etoposide induced TOP2A- and TOP2B-DNA complex stabilisation 
(Figure.6.11-6.14). Additionally mitoxantrone pre-treatment also effectively inhibited 
etoposide TOP2A and TOP2B complex formation. It is not clear how doxorubicin, 
epirubicin or mitoxantrone behave as TOP2 catalytic inhibitors. Studies have 
suggested that anthracycline based TOP2 catalytic inhibition act by DNA intercalation 
which blocks TOP2 binding to DNA (Sorensen et al., 1992; Sehested and Jensen, 
1996). Mitoxantrone can be activated by peroxidases or formaldehyde to form DNA 
adducts which may also block TOP2 binding (Panousis et al., 1994; Panousis et al., 
1997; Parker et al., 1999; Parker et al., 2000; Parker et al., 2001). Additionally as 
mitoxantrone is able to condense nuclei acids, this may also block TOP2 binding to 
DNA (Kapuscinski and Darzynkiewicz, 1986; Hajihassan and Rabbani-Chadegani, 
2009). However, as both the anthracyclines and mitoxantrone are able to poison 
TOP2 it is possible that these drugs interact with TOP2 and inhibit the enzyme 
directly. As etoposide quinone is reported to inhibit TOP2 due to presence of ortho-
quinone on the E-ring (Lindsey et al., 2005; Bender and Osheroff, 2007; Jacob et al., 
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2011), it could be feasible that the anthracyclines and mitoxantrone use their quinone 
moieties to adduct TOP2.  
Whilst doxorubicin, epirubicin and mitoxantrone followed the same trend in the 
reduction of etoposide induced TOP2-DNA complex stabilisation, the trend in 
inhibition of etoposide induced γH2Ax formation was different for each drug 
(Figure.6.15-6.16). Prior treatment with doxorubicin did not affect etoposide induced 
γH2Ax formation whereas epirubicin treatment inhibited the γH2Ax formation by 
etoposide. Mitoxantrone pre-treatment reduced the level of etoposide induced γH2Ax 
formation to basal levels (0µM) and was the most effective inhibitor of etoposide 
induced DSB formation. Clinically this is important as mitoxantrone, epirubicin and 
doxorubicin are separately used in chemotherapy regimes involving etoposide. For 
example in chemotherapy regimes termed, MEC, PACE, VIDE and IEV involve 
etoposide (represented by E or V) used in combination therapy with mitoxantrone 
(represented by M), doxorubicin (represented by A or D) or epirubicin (represented 
by E in IEV). The data shown in this chapter suggests that using etoposide in 
conjugation with anthracyclines or mitoxantrone will reduce etoposide activity in cells.  
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Chapter 7. Discussion  
7.1 The effect of myeloperoxidase expression on TOP2 poison-mediated DNA 
damage. 
 
Topoisomerase II (TOP2) poisons are effective cytotoxic agents used to treat a wide 
range of neoplasms including solid cancers and haematological malignancies. 
However, TOP2 poison therapy is associated with a small but increasing risk of 
developing therapy related acute myeloid leukaemia, characterised by recurrent 
balanced chromosome translocations commonly involving the MLL (KMT2A) gene at 
11q23 or t(15,17)(PML-RARA), t(8,21)(RUNX1-RUNX1T1/ETO), or 
inv(16)(p13;q22)(CBFB-MYH11),  and are generally associated with a poor prognosis 
compared to de novo AML (Leone et al., 2010; Kayser et al., 2011; Cowell and 
Austin, 2012).  
The development of therapy related leukaemia is a rare but life threating complication 
side effect from primary therapy. Although mechanisms leading to t-AML have not 
been fully elucidated, measures to protect hematopoietic progenitors from genotoxic 
damage caused during primary therapy would be of clinical benefit. Whereas the 
development of t-AML reflects genotoxic damage caused by TOP2 poisons, another 
side effect of TOP2 poison therapy is myelosuppression (bone marrow suppression), 
defined by the reduction in blood cell activity due to decreased production in blood 
cells.  
Myeloperoxidase (MPO) is expressed in myeloid progenitor cells and is capable of 
catalysing the oxidation of TOP2 poisons including etoposide, mitoxantrone and 
anthracyclines to metabolites with altered DNA damaging properties and potentially 
genotoxic in nature. Therefore, the presence of MPO could increase myeloid cell 
susceptibility to TOP2 poison induced genetic and/or cytotoxic damage. This 
hypothesis is supported by data reported in this thesis which shows inhibition of MPO 
using succinylacetone (SA) significantly reduces the level of TOP2 poison induced 
TOP2-DNA damage (tested using etoposide, mitoxantrone, epirubicin) and γH2Ax 
formation (tested using etoposide, mitoxantrone, doxorubicin or epirubicin) in NB4 
cells.  
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To further, confirm the data generated using SA in NB4 cells, two small molecule 
direct inhibitors of MPO were used; PF1355 (Phase I clinical trials completed) and 
MPOi-II. Results generated with both inhibitors showed specific inhibition of MPO 
greatly reduced the level of TOP2 poison induced DNA damage for both etoposide 
and mitoxantrone. Similarly, induction of exogenous expression of MPO into K562 
cells (non-MPO expressers) significantly increased the level of etoposide- or 
mitoxantrone induced TOP2 mediated damage. An example of this is one K562MPO 
cell line that only exhibited 18% MPO activity compared to NB4 cells displayed up to 
50% more stabilised TOP2-DNA complexes compared to parental cell lines (Table 
4.1 and Figure 4.7.A-C). This result highlights that MPO expressed at moderate 
levels can significantly enhance TOP2 poison mediated damage. 
The TOP2 poisons, etoposide and mitoxantrone effectively target both isoforms of 
TOP2, stabilising TOP2A- and TOP2B-DNA covalent complexes that could be 
detected and quantified using the TARDIS assay. However, under the conditions 
tested epirubicin did not induce detectable TOP2B-DNA complexes. For etoposide 
and mitoxantrone, suppression of MPO activity resulted in a greater reduction in the 
level of drug stabilised TOP2B-DNA complexes compared to TOP2A. Interesting at 
lower doses of etoposide or mitoxantrone the inhibition of MPO resulted in the level 
of drug stabilised TOP2B-DNA complexes that was comparable to the level of 
complexes observed in non-drug treated cells. This result is of interest as recent 
evidence points a greater role for TOP2B in TOP2 poison mediated carcinogenesis 
and in the induction of DNA breaks at regions in genes involved in t-AML (Azarova et 
al., 2007; Haffner et al., 2010; Cowell et al., 2012; Smith et al., 2014a). 
Another factor that may increase patient susceptibility to t-AML or myelosuppression 
is the level glutathione present within cells. Studies have reported that following high-
level chemotherapy regimens patients have reduced plasma glutathione (Charushila 
and Subodhini, 2013; Kadam and Abhang, 2015). Low glutathione results in a 
reduction in the body’s capability to detoxify reactive oxide species and xenobiotics. 
Glutathione can protect cells from the MPO catalysed production of TOP2 poison 
metabolites by formation of glutathione conjugates that are subsequently excreted 
from the body (Blanz et al., 1991; Mewes et al., 1993; Zheng et al., 2006). As 
observed in NB4 cells the depletion of glutathione using buthionine sulfoximine 
(BSO) greatly elevated the level of etoposide, mitoxantrone, doxorubicin and 
  
 
217 
epirubicin induced γH2Ax formation and TOP2-DNA complex stabilisation (etoposide 
and mitoxantrone only). However, the elevated response to glutathione depletion was 
only observed in NB4 cells with MPO activity. Glutathione depletion did not affect the 
level of TOP2 poisoning or γH2Ax formation in cells with suppression of MPO 
activity. This suggests glutathione acts to reduce the damage caused by MPO 
catalysed metabolites of TOP2 poisons. 
The role of MPO and neutrophils in inflammatory disorders is of clinical interest and 
has led to the development of novel specific MPO inhibitors. In the work reported 
here, two such inhibitors PF1355 and MPOi-II were shown to effectively reduce 
etoposide and mitoxantrone induced TOP2-DNA complexes and γH2Ax formation. 
Therefore, it is feasible that compounds like PF1355 and MPOi-II could be tailored 
into primary chemotherapy regimens to reduce damage caused to myeloid 
progenitors, to decrease the occurrence of t-AML and myelosuppression. The use of 
glutathione supplements (ClinicalTrials.gov ID NCT01044277) could additionally 
protect myeloid cells from damage caused by MPO catalysed metabolites of TOP2 
poisons.  
7.2 The role of doxorubicin, epirubicin and mitoxantrone as catalytic inhibitors 
of TOP2. 
 
In the latter section of this thesis, the effects of anthracyclines (doxorubicin and 
epirubicin) and mitoxantrone (anthracenedione) as TOP2 catalytic inhibitors were 
investigated. When testing the effects of MPO inhibition on TOP2 poison stabilised 
TOP2-DNA complexes, there were difficulties in observing a signal for TOP2-DNA 
stabilised complexes for doxorubicin and epirubicin and at higher concentrations of 
mitoxantrone. A similar observation was previously observed using mouse embryonic 
fibroblast cell line using doxorubicin and in vitro studies showed at high antracyclines 
concentrations the level of TOP2 mediated cleavage of plasmid DNA was inhibited 
(Tewey et al., 1984; Capranico et al., 1990a; Capranico et al., 1990b; Willmore et al., 
2002). This led to the hypothesis that doxorubicin, epirubicin and mitoxantrone may 
behave as catalytic inhibitors of TOP2. A TOP2 catalytic inhibitor is defined as a 
compound that can interfere with TOP2’s catalytic cycle to prevent the formation of 
TOP2-DNA covalent complexes (Sehested and Jensen, 1996). To test whether a 
proposed drug behaves as a catalytic inhibitor, cells were incubated with the drug in 
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question for one hour prior to the addition of etoposide and detection for the level 
TOP2-DNA complexes using the TARDIS assay. If the drug behaves as a TOP2 
catalytic inhibitor, then the immunofluorescence TARDIS signal is reduced compared 
to the signal obtained with etoposide alone, due to reduced formation of TOP2-DNA 
covalent complexes. 
Doxorubicin, epirubicin and mitoxantrone inhibited etoposide’s TOP2 poisoning 
activity and γH2Ax formation and this did not require the action of MPO. This effect is 
likely due to the ability of anthracyclines and mitoxantrone to intercalate between 
DNA base pairs, which prevent TOP2 binding to DNA. 
There are no strong consensus sequences for TOP2 mediated cleavage, although 
preferred in vitro DNA cleavage sites have been described, and there is some 
preference for A/T sites (Capranico and Binaschi, 1998). In addition, TOP2 does 
show preference for DNA structures and preferentially binds to helix-helix 
juxtapositions (Zechiedrich and Osheroff, 1990; West and Austin, 1999). Doxorubicin 
and epirubicin display a preference for binding to A/T nucleotides resulting in DNA 
adducts (Capranico et al., 1990a; Capranico et al., 1990b). This action of 
anthracyclines may create local structures within the DNA molecule that disfavour the 
binding of TOP2. Additionally as doxorubicin, epirubicin and mitoxantrone contain a 
hydroquinone moiety within their structures, they could potentially bind to free thiol or 
amine residues on TOP2 and inhibit TOP2 directly, a mechanism similar to that 
observed for etoposide quinone (MPO catalysed metabolite) (Gibson et al., 2016). 
Therefore, adding etoposide into cells with anthracycline or anthracenedione agents 
reduces etoposide action and this could potentially result in more ‘free’ etoposide to 
undergo oxidative activation by peroxidases such as MPO. This result is of interest 
as etoposide is regularly used in combination with anthracyclines or mitoxantrone for 
treatment in refractory AML, myeloma, plasma cell leukaemia, Ewing’s sarcoma and 
refractory non-Hodgkin/Hodgkin lymphoma. 
Future work 
 
The data generated show that MPO expression enhances TOP2 poison mediated 
damage and the inhibition MPO activity using three chemically distinct inhibitors can 
reduce excessive TOP2 poison mediated DNA damage. This study could be 
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extended to analyse the effects of MPO expression on TOP2 poison mediated 
cytotoxicity in myeloid cells to assess whether MPO expression could be a 
contributor to TOP2 poison induced myelosuppression.  The same approach could 
be used to assess whether using anthracyclines or mitoxantrone in combination with 
etoposide effects level of cell death. Additionally, it would be interesting to investigate 
if MPO affects the level of TOP2 poison mediated breaks within breakpoint regions in 
genes implicated in t-AML either in cell lines or in primary bone marrow cells. This 
study has the potential to be extended into primary hematopoietic cells, to determine 
if MPO expression contributes to TOP2-mediated DNA damage. Notably the protein 
expression of MPO is readily detectable in primary CD34+ bone marrow blood 
progenitor cells (Atwal et al., 2017) and there is potential that the hypothesis tested 
here may also hold true in cells where a leukaemic stem cell is likely to arise from. 
Therefore, this hypothesis could be tested in an ex vivo system, experimentally using 
the methods described in chapters 3, 4 and 5.  
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Appendices 
 
Figure i. Mass spectroscopy data for etoposide quinone 
Figure ii. Mass spectroscopy data for etoposide catechol  
Figure iii. Elemental Composition Report for etoposide quinone and etoposide 
catechol  
Figure iv. Insert cDNA sequence for MPO in expression vector RC216029.  
 
 
Figure i. Mass spectroscopy data for etoposide quinone, synthesised by Angelica Mariani, France 
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Figure ii. Mass spectroscopy data for etoposide catechol, synthesised by Angelica Mariani, France. 
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Figure iii. Elemental composition report for etoposide quinone (upper panel) and etoposide catechol 
(lower panel), synthesised by Angelica Mariani. 
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Orange=Cloning site Blue=ORF Green=Tag(s) 
 
1 TTTTGTAATA CGACTCACTA TAGGGCGGCC GGGAATTCGT CGACTGGATC  
      51 CGGTACCGAG GAGATCTGCC GCCGCGATCG CCATGGGGGT TCCCTTCTTC  
     101 TCTTCTCTCA GATGCATGGT GGACTTAGGA CCTTGCTGGG CTGGGGGTCT  
     151 CACTGCAGAG ATGAAGCTGC TTCTGGCCCT AGCAGGGCTC CTGGCCATTC  
     201 TGGCCACGCC CCAGCCCTCT GAAGGTGCTG CTCCAGCTGT CCTGGGGGAG  
     251 GTGGACACCT CGTTGGTGCT GAGCTCCATG GAGGAGGCCA AGCAGCTGGT  
     301 GGACAAGGCC TACAAGGAGC GGCGGGAAAG CATCAAGCAG CGGCTTCGCA  
     351 GCGGCTCAGC CAGCCCCATG GAACTCCTAT CCTACTTCAA GCAGCCGGTG  
     401 GCAGCCACCA GGACGGCGGT GAGGGCCGCT GACTACCTGC ACGTGGCTCT  
     451 AGACCTGCTG GAGAGGAAGC TGCGGTCCCT GTGGCGAAGG CCATTCAATG  
     501 TCACTGATGT GCTGACGCCC GCCCAGCTGA ATGTGTTGTC CAAGTCAAGC  
     551 GGCTGCGCCT ACCAGGACGT GGGGGTGACT TGCCCGGAGC AGGACAAATA  
     601 CCGCACCATC ACCGGGATGT GCAACAACAG ACGCAGCCCC ACGCTGGGGG  
     651 CCTCCAACCG TGCCTTTGTG CGCTGGCTGC CGGCGGAGTA TGAGGACGGC  
     701 TTCTCTCTTC CCTACGGCTG GACGCCCGGG GTCAAGCGCA ACGGCTTCCC  
     751 GGTGGCTCTG GCTCGCGCGG TCTCCAACGA GATCGTGCGC TTCCCCACTG  
     801 ATCAGCTGAC TCCGGACCAG GAGCGCTCAC TCATGTTCAT GCAATGGGGC  
     851 CAGCTGTTGG ACCACGACCT CGACTTCACC CCTGAGCCGG CCGCCCGGGC  
     901 CTCCTTCGTC ACTGGCGTCA ACTGCGAGAC CAGCTGCGTT CAGCAGCCGC  
     951 CCTGCTTCCC GCTCAAGATC CCGCCCAATG ACCCCCGCAT CAAGAACCAA  
    1001 GCCGACTGCA TCCCGTTCTT CCGCTCCTGC CCGGCTTGCC CCGGGAGCAA  
    1051 CATCACCATC CGCAACCAGA TCAACGCGCT CACTTCCTTC GTGGACGCCA  
    1101 GCATGGTGTA CGGCAGCGAG GAGCCCCTGG CCAGGAACCT GCGCAACATG  
    1151 TCCAACCAGC TGGGGCTGCT GGCCGTCAAC CAGCGCTTCC AAGACAACGG  
    1201 CCGGGCCCTG CTGCCCTTTG ACAACCTGCA CGATGACCCC TGTCTCCTCA  
    1251 CCAACCGCTC AGCGCGCATC CCCTGCTTCC TGGCAGGGGA CACCCGTTCC  
    1301 AGTGAGATGC CCGAGCTCAC CTCCATGCAC ACCCTCTTAC TTCGGGAGCA  
    1351 CAACCGGCTG GCCACAGAGC TCAAGAGCCT GAACCCTAGG TGGGATGGGG  
    1401 AGAGGCTCTA CCAGGAAGCC CGGAAGATCG TGGGGGCCAT GGTCCAGATC  
    1451 ATCACTTACC GGGACTACCT GCCCCTGGTG CTGGGGCCAA CGGCCATGAG  
    1501 GAAGTACCTG CCCACGTACC GTTCCTACAA TGACTCAGTG GACCCACGCA  
    1551 TCGCCAACGT CTTCACCAAT GCCTTCCGCT ACGGCCACAC CCTCATCCAA  
    1601 CCCTTCATGT TCCGCCTGGA CAATCGGTAC CAGCCCATGG AACCCAACCC  
    1651 CCGTGTCCCC CTCAGCAGGG TCTTTTTTGC CTCCTGGAGG GTCGTGCTGG  
    1701 AAGGTGGCAT TGACCCCATC CTCCGGGGCC TCATGGCCAC CCCTGCCAAG  
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    1751 CTGAATCGTC AGAACCAAAT TGCAGTGGAT GAGATCCGGG AGCGATTGTT  
    1801 TGAGCAGGTC ATGAGGATTG GGCTGGACCT GCCTGCTCTG AACATGCAGC  
    1851 GCAGCAGGGA CCACGGCCTC CCAGGATACA ATGCCTGGAG GCGCTTCTGT  
    1901 GGGCTCCCGC AGCCTGAAAC TGTGGGCCAG CTGGGCACGG TGCTGAGGAA  
    1951 CCTGAAATTG GCGAGGAAAC TGATGGAGCA GTATGGCACG CCCAACAACA  
    2001 TCGACATCTG GATGGGCGGC GTGTCCGAGC CTCTGAAGCG CAAAGGCCGC  
    2051 GTGGGCCCAC TCCTCGCCTG CATCATCGGT ACCCAGTTCA GGAAGCTCCG  
    2101 GGATGGTGAT CGGTTTTGGT GGGAGAACGA GGGTGTGTTC AGCATGCAGC  
    2151 AGCGACAGGC CCTGGCCCAG ATCTCATTGC CCCGGATCAT CTGCGACAAC  
    2201 ACAGGCATCA CCACCGTGTC TAAGAACAAC ATCTTCATGT CCAACTCATA  
    2251 TCCCCGGGAC TTTGTCAACT GCAGTACACT TCCTGCATTG AACCTGGCTT  
    2301 CCTGGAGGGA AGCCTCCACG CGTACGCGGC CGCTCGAGCA GAAACTCATC  
    2351 TCAGAAGAGG ATCTGGCAGC AAATGATATC CTGGATTACA AGGATGACGA  
    2401 CGATAAGGTT TAA  
 
Figure iv. Insert cDNA sequence for MPO in expression vector RC216029.  
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